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FGAM synthetase, or PurL, catalyzes the fourth step of the de novo purine 
biosynthetic pathway where N-formylglycinamide ribonucleotide (FGAR), ATP, and 
glutamine yield N-formylglycinamidine ribonucleotide (FGAM), ADP, Pi, and 
glutamate.  Two forms of PurL have been observed: one large, found in Gram-negative 
bacteria and eukaryotes; and the other, small, found in Gram-positive bacteria and 
archaea.  Large PurL is a single gene product that is functional as a monomer whereas 
small PurL forms a αβ2γ heterotetramer with two other gene products:  PurS and PurQ, 
which are analogous to the N-terminal and glutaminase domains of large PurL, 
respectively.  Regardless of quaternary structure, all FGAM synthetases are thought to 
use ATP to O-phosphorylate the FGAR formamide, which is then attacked by ammonia 
to give FGAM. 
 
The acetic acid bacterium Acetobacter aceti, and closely related α-proteobacteria, 
differ from other Gram-negatives in that they contain purSQL genes.  The structural 
genes for the PurSQL complex (AaFS) are clustered into an apparent operon, which also 
contains an open reading frame (orf) that we designate orf Y and two genes (bolA and 
grxD) that have key roles in the assembly of iron-sulfur clusters.  OrfY has a narrow 
species distribution: it is found in most acetic acid bacteria and several closely related 
Gram-negative bacteria.  OrfY possesses four conserved cysteines and an N-terminal 
export sequence typical of periplasmic or exported proteins.  Given this unusual set of 




grxD operon, we speculate that OrfY might be an additional subunit for PurSQL, perhaps 
required for function in the acidic cytoplasm of acetic acid bacteria; a participant in iron-
sulfur cluster assembly, which is essential for the production of the first purine pathway 
enzyme PurF and therefore purine biosynthesis; or as a regulatory factor.  As a first step 
in understanding the role of OrfY, we sought to establish the functional form of the A. 
aceti enzyme to determine if orf Y encodes a heretofore unknown fourth subunit of the 
small PurL complex.  This study focused on construct generation of various purine 
biosynthetic genes, purification of the proteins they encode, and preliminary work on 
gene complementation, the operon, and growth of A. aceti in minimal media. 
 
 Functional complementation studies in an Escherichia coli ∆purL strain have 
shown that active AaFS is likely composed of PurS, PurQ, and PurL, although the 
stoichiometry of the subunits is still unknown, thus indicating that OrfY is likely not a 
subunit of the AaFS complex.  The presence of orfY in the gene cluster affected 
recombinant PurQ expression and caused a delay in growth in the E.coli ∆purL 
strain.  Recombinant OrfY was successfully purified from E. coli and mass spectrometry 






CHAPTER 1. CONSTRUCT GENERATION AND PURIFICATION OF AAFS 
SUBUNITS 
1.1 Introduction 
 FGAM synthase (FS) catalyzes the fourth step of the de novo purine biosynthesis 
pathway, which makes purine bases from phosphoribosyl pyrophosphate (PRPP) through 
a series of enzyme-catalyzed steps [1].  FS converts formyglycinamide ribonucleotide 
(FGAR), ATP, and L-glutamine, to formylglycinamidine ribonucleotide (FGAM), ADP, 
Pi, and L-glutamate [1, 2]).  Figure 1.1 shows a simplified de novo purine biosynthesis 
pathway, with an emphasis on the FS-catalyzed FGAR conversion to FGAM step. 
 
 
Figure 1.1 The FGAR to FGAM reaction catalyzed by FS.   
The glutaminase domain hydrolyzes L-glutamine to L-glutamate and ammonia, the latter 
which travels to the FGAM synthetase domain via a channel linking the two active sites.  
Nucleophilic attack of ammonia onto the carbonyl carbon of the O-phosphorylated 




















 FS exists in two forms: the first, a 1300 amino acid-long polypeptide, or “large 
PurL”, is found in Gram-negative bacteria (i.e. Escherichia coli, EcFS) and eukaryotes; 
and the second, “small PurL”, of about 700 amino acids, is found in Gram-positive 
bacteria (i.e. Bacillus subtilis, BsFS) and archaea [1]. 
  Multi-subunit FS studies have demonstrated that PurS and PurQ correspond to 
the N-terminal and glutaminase domains of large PurL, respectively [3-6].  The 
stoichiometric ratio of the BsFS components was determined to be 2 PurS : 1 PurQ : 1 
PurL [7].  Crystal structures have also been solved for Gram-negative Salmonella 
typhimurium large PurL (StFS) and Gram-positive Thermotoga maritima small PurL 
(TmFS, Figure 1.2 [1]). Putative ammonia channels linking the glutaminase and FGAM 
synthetase active sites have been located in the StFS and TmFS crystal structures [5, 6].  
This channel is critical to avoid protonation of ammonia to yield ammonium as 
demonstrated by the 50-fold activity increase seen with L-glutamine-dependent FGAM 
synthesis [7, 8].  Proper channeling of ammonia is likely a result of correct protein 
folding or FS complex assembly for maximum FS activity. 
 
 
Figure 1.2 Crystal structures of large PurL and small PurL. 
Large PurL of Gram-negative S. typhimurium (left) and small PurL of the PurSQL 
complex of Gram-positive T. maritima (right) [1].  The two forms of FS have visible 
structural similarities.  PurQ corresponds to the glutaminase domain of large PurL; PurS 
is a dimer (right, in red and yellow) and corresponds to the N-terminal domain of large 
PurL.  Ligands in the FGAM synthetase and PurL active sites is ADP; in the glutaminase 








 EcFS has been reported to require chaperone assistance for proper folding [9]; 
however, since the internal cavity of the well-studied chaperone GroEL-ES is apt to fit a 
~70 kDa protein [10], many proteins require multiple rounds of folding [11].  A multi-
subunit version of FS complex, composed of smaller and more easily folded proteins, 
may be an alternative and a selective advantage to make FS for organisms living in harsh 
environments (i.e. heat, salinity, acid).  The dependence of small PurL on a chaperone 
system has not been reported.  The Gram-negative Acetobacter aceti, best known for 
acetic acid production, is unusual due to its ability to survive with an acidic cytoplasm 
where the pH can range from 3.5 to 6 [12].  We hypothesize that acidophiles, like the 
Gram-negative Acetobacter aceti, have developed specialized mechanisms to prevent 
cytoplasmic acidification and/or conduct acid metabolism to keep their proteins folded 
and functional.  Various cytoplasmic A. aceti proteins have been demonstrated to be acid-
stable (and coincidentally thermo-stable) [13-16], where their stability is likely intrinsic 
to the primary structure of the proteins themselves.  These proteins are 
thermodynamically and kinetically resistant to unfolding, which should lessen the burden 
on chaperones and on the cell. 
 AaFS is hypothesized to contain a multi-subunit FS, as suggested by gene cluster 
alignments with BsFS (Figure 1.3). 
Figure 1.3 FS gene cluster alignment. 
Includes select Gram-negative α-proteobacteria: A. aceti, Gram-negative E. coli, and 
Gram-positive B. subtilis.  To date, acetic acid bacteria are the only Gram-negative 
bacteria that may contain PurS, PurQ, PurL, and even OrfY in some.  




 A multi-subunit AaFS is unexpected since A. aceti is Gram-negative; however 
closely related α-proteobacteria (Figure 3) also show the same gene cluster structure.  
Additionally, A. aceti and closely related acidophilic acetic acid bacteria also contain a 
previously uncharacterized open reading frame, orfY, located between purS and purQ 
(Figure 1.3).  
  This chapter focuses on construct design and purification of the tagged AaFS genes. 
 
 
1.2 Materials and Methods 
Materials 
All materials were from Sigma Aldrich or Fisher Scientific and of the highest purity 
unless otherwise noted.  Vent DNA polymerase, OneTaq polymerase, all restriction 
endonucleases, T4 DNA ligase, and T4 polynucleotide kinase were from New England 
Biolabs.  Phusion Hot Start polymerase was from Finnzymes.  GoTaq polymerase and 
deoxynucleotides (dATP, dGTP, dCTP, and dTTP) were from Promega.  Mutagenesis 
was performed using QuikChange Mutagenesis kits from Stratagene (Pfu Polymerase).  
Oligodeoxynucleotides (ODNs) were from Integrated DNA Technologies (Table 1).  
Plasmid Miniprep kits were from either Sigma, Fermentas Life Sciences, or Qiagen.   
QIAquick PCR Purification kit was from Qiagen.  Chemically competent DH5α cells 
were from Invitrogen.  Vectors pET23a, pET23d, pET28a, pCDF-Duet, and pET-Duet 
were from Novagen.  Centrifugation steps were performed on a tabletop Eppendorf 
5415D centrifuge.  PCR reactions were performed in a Bio-Rad MyCycler Thermal 
Cycler or a MJ Research Inc. Programmable Thermal Cycler PTC-100.  H6purS and 
H6orfY in pUC57 (pJK518) were synthesized by GenScript.  A. aceti 1023 was isolated 




Table 1.1 Oligodeoxynucleotides used in construction of plasmids and sequencing. 










































General cloning procedure.  Each recombinant gene was amplified by PCR with gene-
specific primers (Table 1) Acetobacter aceti 1023 genomic DNA or plasmid DNA as 
specified below.  E. coli strain DH5α was used for cloning and plasmid maintenance.  All 
constructs were screened by restriction mapping or colony PCR (Chapter 6).  All 
numbered plasmids were verified by DNA sequencing at the Genomics Core Facility 
DNA Sequencing Low Throughput Laboratory at Purdue University, using primers for 
both directions.  
Table 1.2 Plasmids used in this chaptera. 
pJK Vector Description Source 
518 pUC57 purS-H6orfY GenScript 
520 pUC57 purS-H6orfY TJK 
522 pET28a H6purS-H6orfY TJK 
529 pET23a PCR B Mutant R430L (purL 2nd half) This study 
530 pET23d orfYH6 This study 
531 pET23d orfY This study 
532 pET28a H6purQ (silA63) This study 
533 pET23d purS This study 
534 pET23a purQ (Q10C and R13L)-PCR A2 This study 
535 pET23a purQ (silA63)-purL(G209D) This study 
537 pET23a purL(G209D) This study 
539 pET23a purL This study 
543 pCDF-Duet purS and purL This study 
544 pCDF-Duet purS This study 
546 pET-Duet orfY This study 
548 pET-Duet orfY and purQ This study 
549 pCDF-Duet purL This study 
555 pET23a purQ This study 
567 pCDF-Duet orfY This study 
571 pUC57 purS-H6orfY-purQ-purL(G209D) This study 
574 pUC57 purS-H6orfY-purQ-purL This study 
575 pET23a purLH6 This study 
576 pUC57 purS-orfY-purQ(part) This study 
577 pUC57 purS-purQ(part) This study 
595 pUC57 purS-orfY-purQ-purL(part/G209D) This study 
596 pUC57 purS-purQ-purL(part/G209D) This study 
598 pET23a purS-orfY-purQ-purL This study 




Table 1.2 (continued) Plasmids used in this chaptera. 
599 pET23a purS-orfY-purQ-purLH6 This study 
605 pET23a purS-purQ-purL This study 
606 pET23a purS-purQ-purLH6 This study 
610 pET23a purQ-purL This study 
611 pET23a purQ-purLH6 This study 
612 pET23a purS-orfYΔS70-K123-purQ-purL This study 
613 pET23a purS-orfYΔS70-K123-purQ-purLH6 This study 
618 pET28a H6purS-purQ-purLH6 This study 
619 pET28a H6purS-orfY-purQ-purL This study 
620 pET28a H6purS This study 
622 pET28a H6purL This study 
623 pET23a orfY-purQ-purL This study 
624 pET23a orfY-purQ-purLH6 This study 
625 pET28a H6purS-purQ-purLH6 This study 
aHyphens indicate overlapping genes (as in the native A. aceti sequence). 
 
Synthetic purS-H6orfY construct plasmid pJK518 (TJK).  Synthetic purS (silent D15 and 
L66 mutations), H6orfY (silent T40, G67, and H114 mutations) , and the first 45 bases of 
purQ were synthesized by GenScript.  The plasmid encodes for PurS, H6OrfY, and the 
first 11 amino acids of PurQ. 
 
Synthetic purS-H6orfY construct plasmid pJK520 (TJK).  pJK518 was digested with 
NdeI to remove a 218 bp fragment and ligated to yield from pJK520.  The plasmid 
encodes for PurS, H6OrfY, and the first 11 amino acids of PurQ. 
 
Synthetic H6purS-H6orfY construct plasmid pJK522 (TJK).  pJK520 was digested with 
NdeI and HindIII and ligated into the NdeI and HindIII restriction sites of the destination 
vector pET28a to yield pJK522 .  The plasmid encodes for H6PurS, H6OrfY, and the first 
11 amino acids of PurQ. 
 
a.  Cloning of orfY 
Construction of single orfYH6 construct plasmid pJK530.  A 0.4 kb product containing 
orfY was amplified from template pJK522, using ODNs 2117 and 2120 with an annealing 
temperature of 60°C and melting, annealing, and extension times of 20 s, 30 s, and 30 s 




PCR purification kit, digested with NcoI and HindIII, and ligated into the NcoI and 
HindIII sites of the destination vector pET23d to yield pJK530.  The plasmid encodes for 
OrfYH6. 
 
Construction of single orfY construct plasmid pJK531.  A 0.4 kb product containing orfY 
was amplified from template pJK522, using ODNs 2117 and 2118 with an annealing 
temperature of 60°C and melting, annealing, and extension times of 20 s, 30 s, and 30 s 
for 25 cycles using Vent DNA Polymerase.  The product was purified using a Qiagen 
PCR purification kit, digested with NcoI and HindIII, and ligated into the NcoI and 
HindIII sites of the destination vector pET23d to yield pJK530.  The plasmid encodes for 
OrfY.  
 
Construction of single orfY construct plasmid pJK567.  pJK531 was digested with NcoI 
and HindIII and ligated into the NcoI and HindIII restriction sites of the destination 
vector pCDF-Duet to yield pJK567.  The plasmid encodes for OrfY. 
 
b.  Cloning of purS 
Construction of single purS construct plasmid pJK533.  A 0.2 kb product containing purS 
was amplified from template pJK522, using ODNs 2115 and 2116 with an annealing 
temperature of 60°C and melting, annealing, and extension times of 20 s, 30 s, and 30 s 
for 25 cycles using Vent DNA Polymerase.  The product was purified using a Qiagen 
PCR purification kit, digested with NcoI and HindIII, and ligated into the NcoI and 
HindIII sites of the destination vector pET23d to yield pJK533.  The plasmid encodes for 
PurS.  
   
Construction of single H6purS construct plasmid pJK620.  A 0.2 kb product containing 
purS was amplified from template pJK533, using ODNs 2091 and 2116 with an 
annealing temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, 
and 30 s for 25 cycles using OneTaq Polymerase.  The product was purified using a 
Qiagen PCR purification kit, digested with NdeI and HindIII, and ligated into the NdeI 
and HindIII sites of the destination vector pET28a to yield pJK620.  The plasmid encodes 




c.  Cloning of purL 
Construction of intermediate construct plasmid pJK529.  A 1.5 kb product containing the 
C-terminus of purL was amplified from A. aceti strain 1023 genomic DNA, using ODNs 
2104 and 2092 (Figure 4) with an annealing temperature of 60°C and melting, annealing, 
and extension times of 20 s, 30 s, and 1 min 30 s for 25 cycles using Vent DNA 
Polymerase.  The product was purified using a Qiagen PCR purification kit, digested with 
HindIII and XhoI, and ligated into the HindIII and XhoI restriction sites of the destination 
vector pET23a to yield pJK529.  The plasmid encodes for the last 488 amino acids of 
PurL with a mutation R430L. 
 
 
Figure 1.4 Schematic for building pJK529, pJK534, and pJK535. 
Left, PCRs A and B; and right, PCRs QA2, A2, and B, relative to purQ and purL (genes 
not to scale) with ODNs used to obtain the PCR products. 
 
 
The cloning strategy used to build the purL construct is summarized in Figure 5, on the 
next page. 
 
Construction of intermediate construct plasmid pJK534.  A 1.4 kb product containing 
purQ and the N-terminus of purL (PCR A in Figure 4) was amplified from A. aceti strain 
1023 genomic DNA, using ODNs 2121 and 2105 with an annealing temperature of 60°C 
and melting, annealing, and extension times of 20 s, 30 s, and 1 min 30 s for 25 cycles 
using Vent DNA Polymerase.  PCR A was purified using a Qiagen PCR purification kit, 
digested with NdeI and HindIII, and ligated into the NdeI and HindIII restriction sites of 
the destination vector pET23a to yield pJK534.  The plasmid encodes for PurQ G10C and 
















Figure 1.5 Summary of the construction of pJK539.   
PCR B (yellow) was ligated into plasmid pJK534, which contains PCR QA2 (green) , to 
yield plasmid pJK535.  A linker (ODNs 2132 and 2133, tan) was then ligated into 
plasmid pJK535 after the excision of purQ (orange), to yield plasmid pJK537.  PCR A2 
(red) was ligated into plasmid pJK537 to repair the G209D mutation in purL (purple).  
Plasmids not to scale. 
 
 
Construction of intermediate construct plasmid pJK535.  A 1.5 kb product containing the 
C-terminus of purL (PCR B in Figure 4) was amplified from A. aceti strain 1023 genomic 
DNA, using ODNs 2104 and 2092 with an annealing temperature of 60°C and melting, 
annealing, and extension times of 20 s, 30 s, and 1 min 30 s for 25 cycles using Vent 
DNA Polymerase.  PCR B was purified using a Qiagen PCR purification kit, digested 
with HindIII and XhoI, and ligated into the HindIII and XhoI restriction sites of the 
destination vector pJK534.  The plasmid encodes for PurQ silent A63 mutation (random 

























































Construction of intermediate construct plasmid pJK537.  ODNs 2132 and 2133 were 
phosphorylated, annealed, and ligated at a 1:10 molar ratio of vector : linker into the NdeI 
and EcoRI sites of destination vector pJK537.  The plasmid encodes for PurL G209D. 
 
Construction of single purL construct plasmid pJK539.  A 0.7 kb product (PCR A2) 
containing the N-terminus of purL was amplified from A. aceti strain 1023 genomic DNA, 
using ODNs 2123 and 2105 with an annealing temperature of 60°C and melting, 
annealing, and extension times of 20 s, 30 s, and 1 min 30 s for 25 cycles using Vent 
DNA Polymerase.  PCR A2 was purified using a Qiagen PCR purification kit, digested 
with EcoRI and HindIII, and ligated into the EcoRI and HindIII restriction sites of the 
destination vector pJK537.  The plasmid encodes for PurL. 
 
Construction of single purL construct plasmid pJK549.  pJK539 was digested with NdeI 
and XhoI and ligated into the NdeI and XhoI restriction sites of the destination vector 
pCDF-Duet to yield pJK549.  The plasmid encodes for PurL. 
 
Construction of single purL construct plasmid pJK575.  A 2.2 kb product was amplified 
from template pJK539, using ODNs 2104 and 2074 with an annealing temperature of 
60°C and melting, annealing, and extension times of 20 s, 30 s, and 2 min 30 s for 25 
cycles using Vent DNA Polymerase.  The product was purified using a Qiagen PCR 
purification kit, digested with NdeI and XhoI, and ligated into the NdeI and XhoI 
restriction sites of the destination vector pET23a.  The plasmid encodes for PurLH6. 
 
Construction of single H6purL construct plasmid pJK622.  pJK539 was digested with 
NdeI and XhoI and ligated into the NdeI and XhoI restriction sites of the destination 
vector pET28a to yield pJK622.  The plasmid encodes for H6PurL. 
 
d. Cloning of purQ 
Construction of single H6purQ construct plasmid pJK532.  pJK535 was digested with 
NdeI and EcoRI and ligated into the NdeI and EcoRI restriction sites of the destination 





Construction of single purQ construct plasmid pJK555.  pJK532 was digested with NdeI 
and XhoI and ligated into the NdeI and XhoI restriction sites of the destination vector 
pET23a to yield pJK555.  The plasmid encodes for PurQ. 
 
e. Construction of double gene constructs 
Construction of single purS construct plasmid pJK544.  pJK533 was digested with NcoI 
and HindIII and ligated into the NcoI and HindIII restriction sites of the destination 
vector pCDF-Duet to yield pJK544.  The plasmid encodes for PurS (with an additional 
Ala2 residue to accomodate the NcoI site).  
 
Construction of double purS and purL construct plasmid pJK543.  pJK539 was digested 
with NdeI and XhoI and ligated into the NdeI and XhoI restriction sites of the destination 
vector pJK544 to yield pJK543.  The plasmid encodes for PurS (with an additional Ala2 
residue to accomodate the NcoI site) and PurL. 
 
Construction of single orfY construct plasmid pJK546.  pJK531 was digested with NcoI 
and HindIII and ligated into the NcoI and HindIII restriction sites of the destination 
vector pET-Duet to yield pJK546.  The plasmid encodes for OrfY (with an additional 
Ala2 residue to accomodate the NcoI site. 
 
Construction of double orfY and purQ construct plasmid pJK548.  pJK532 was digested 
with NdeI and XhoI and ligated into the NdeI and XhoI restriction sites of the destination 
vector pJK546 to yield pJK548.  The plasmid encodes for OrfY((with an additional Ala2 
residue to accomodate the NcoI site) and PurQ. 
 
f.  Cloning the overlapping 2-gene, 3-gene, and 4-gene constructs 
The cloning strategies to build the AaFS 4-gene and 3-gene constructs are summarized in 





Figure 1.6 Summary of the construction of the AaFS 4-gene cluster.   
PCR A (blue) was ligated into plasmid pJK576, which contains purS (yellow), orfY 
(pink), and part of purQ (orange), to yield plasmid pJK595.  A PCR product spanning 
from the restriction sites NdeI through HindIII was obtained using ODNs 2091 and 2105 
from template pJK595.  This PCR product was ligated into plasmid pJK539 to complete 
the purL gene (purple) to yield plasmid pJK598.  The same PCR product was also ligated 
into pJK575 to complete the purLH6 sequence to yield plasmid 599.   
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Figure 1.7 Summary of the construction of the AaFS 3-gene cluster. 
PCR A (blue) was ligated into plasmid pJK577, which contains purS (yellow), and part of 
purQ (orange), to yield plasmid pJK596.  A PCR product spanning from the restriction 
sites NdeI through HindIII was obtained using ODNs 2091 and 2105 from template 
pJK596.  This PCR product was ligated into plasmid pJK539 to complete the purL gene 
(purple) to yield plasmid pJK605.  The same PCR product was also ligated into pJK575 



















PCR, digest and ligate
















































Construction of intermediate purS-H6orfY-purQ-purL construct plasmid pJK571.  A 2.9 
kb product was amplified from template pJK535, using ODNs 2103 and 2092 with an 
annealing temperature of 60°C and melting, annealing, and extension times of 20 s, 30 s, 
and 2 min 30 s for 25 cycles using Vent DNA Polymerase.  The product was purified 
using a Qiagen PCR purification kit, digested with KpnI and XhoI, and ligated into the 
KpnI and XhoI restriction sites of the destination vector pJK520 to yield pJK571.  The 
plasmid encodes for PurS, H6OrfY, PurQ, and PurL G209D. 
 
Construction of intermediate purS-H6orfY-purQ-purL construct plasmid pJK574.   
pJK539 was digested with EcoRI and XhoI and ligated into the EcoRI and XhoI 
restriction sites of the destination vector pJK571 to yield pJK574.  The plasmid encodes 
for PurS, H6OrfY, PurQ, and PurL. 
 
Construction of intermediate purS-orfY-purQ construct plasmid pJK576.  ODNs 2193 
and 2194 were phosphorylated, annealed, and ligated at a 1:10 molar ratio of vector : 
linker into the NheI and SphI sites of destination vector pJK520 to yield pJK576.  The 
plasmid encodes for PurS, OrfY, and the first 11 amino acids of PurQ. 
 
Construction of intermediate purS-purQ construct plasmid pJK577.  ODNs 2195 and 
2196 were phosphorylated, annealed, and ligated at a 1:10 molar ratio of vector : linker 
into the NheI and SphI sites of destination vector pJK520 to yield pJK577.  The plasmid 
encodes for PurS and the first 11 amino acids of PurQ. 
 
Construction of purS-orfY-purQ-purL construct plasmid pJK595.  A 1.5 kb product was 
amplified from template pJK535, using ODNs 2103 and 2105 with an annealing 
temperature of 60°C and melting, annealing, and extension times of 20 s, 30 s, and 1 min 
30 s for 25 cycles using Vent DNA Polymerase.  The product was purified using a 
Qiagen PCR purification kit, digested with KpnI and XhoI, and ligated into the KpnI and 
XhoI restriction sites of the destination vector pJK576 to yield pJK595.  The plasmid 





Construction of purS-purQ-purL construct plasmid pJK596.  A 1.5 kb product was 
amplified from template pJK535, using ODNs 2103 and 2105 with an annealing 
temperature of 60°C and melting, annealing, and extension times of 20 s, 30 s, and 1 min 
30 s for 25 cycles using Vent DNA Polymerase.  The product was purified using a 
Qiagen PCR purification kit, digested with KpnI and XhoI, and ligated into the KpnI and 
XhoI restriction sites of the destination vector pJK577 to yield pJK596.  The plasmid 
encodes for PurS, PurQ, and the first 247 amino acids of PurL G209D. 
 
Construction of purS-orfY-purQ-purL construct plasmid pJK598.  A 2.0 kb product was 
amplified from template pJK595, using ODNs 2091 and 2105 with an annealing 
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 1 min 
30 s for 25 cycles using OneTaq polymerase.  The product was purified using a Qiagen 
PCR purification kit, digested with NdeI and EcoRI, and ligated into the NdeI and EcoRI 
restriction sites of the destination vector pJK539 to yield pJK598.  The plasmid encodes 
for PurS, OrfY, PurQ, and PurL.  
 
Construction of purS-orfY-purQ-purLH6 construct plasmid pJK599.  A 2.0 kb product 
was amplified from template pJK595, using ODNs 2091 and 2105 with an annealing 
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 1 min 
30 s for 25 cycles using OneTaq polymerase.  The product was purified using a Qiagen 
PCR purification kit, digested with NdeI and EcoRI, and ligated into the NdeI and EcoRI 
restriction sites of the destination vector pJK575 to yield pJK599.  The plasmid encodes 
for PurS, OrfY, PurQ, and PurLH6. 
 
Construction of purS-purQ-purL construct plasmid pJK605.  A 1.7 kb product was 
amplified from template pJK596, using ODNs 2091 and 2105 with an annealing 
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 1 min 
30 s for 25 cycles using OneTaq polymerase.  The product was purified using a Qiagen 
PCR purification kit, digested with NdeI and EcoRI, and ligated into the NdeI and EcoRI 
restriction sites of the destination vector pJK539 to yield pJK605.  The plasmid encodes 




Construction of purS-purQ-purLH6 construct plasmid pJK606.  A 1.7 kb product was 
amplified from template pJK596, using ODNs 2091 and 2105 with an annealing 
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 1 min 
30 s for 25 cycles using OneTaq polymerase.  The product was purified using a Qiagen 
PCR purification kit, digested with NdeI and EcoRI, and ligated into the NdeI and EcoRI 
restriction sites of the destination vector pJK575 to yield pJK606.  The plasmid encodes 
for PurS, PurQ, and PurLH6. 
 
Construction of purQ-purL construct plasmid pJK610.  ODNs 2247 and 2248 were 
phosphorylated, annealed, and ligated at a 1:10 molar ratio of vector : linker into the NdeI 
and KpnI sites of destination vector pJK605.  The plasmid encodes for PurQ and PurL. 
 
Construction of purQ-purLH6 construct plasmid pJK611.  ODNs 2247 and 2248 were 
phosphorylated, annealed, and ligated at a 1:10 molar ratio of vector : linker into the NdeI 
and KpnI sites of destination vector pJK606.  The plasmid encodes for PurQ and PurLH6. 
 
Construction of orfY-purQ-purL construct plasmid pJK612.  ODNs 2249 and 2250 were 
phosphorylated, annealed, and ligated at a 1:10 molar ratio of vector : linker into the 
BamHI and KpnI sites of destination vector pJK598.  The plasmid encodes for 
OrfY(ΔS70-K123), PurQ, and PurL. 
 
Construction of orfY-purQ-purLH6 construct plasmid pJK613.  ODNs 2249 and 2250 
were phosphorylated, annealed, and ligated at a 1:10 molar ratio of vector : linker into the 
BamHI and KpnI sites of destination vector pJK599.  The plasmid encodes for 
OrfY(ΔS70-K123), PurQ, and PurLH6. 
 
Construction of H6purS-orfY-purQ-purLH6 construct plasmid pJK618.  pJK599 was 
digested with NdeI and XhoI and ligated into the NdeI and XhoI restriction sites of the 
destination vector pET28a to yield pJK618.  The plasmid encodes for H6PurS, OrfY, 





Construction of H6purS-orfY-purQ-purL construct plasmid pJK619.  pJK598 was 
digested with NdeI and XhoI and ligated into the NdeI and XhoI restriction sites of the 
destination vector pET28a to yield pJK619.  The plasmid encodes for H6PurS, OrfY, 
PurQ, and PurL. 
 
Construction of orfY-purQ-purL construct plasmid pJK623.  A 1.3 kb product was 
amplified from template pJK598, using ODNs 2113 and 2076 with an annealing 
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 30 s 
for 25 cycles using Phusion polymerase.  The product was purified using a Qiagen PCR 
purification kit, digested with NdeI and EcoRI, and ligated into the NdeI and EcoRI 
restriction sites of the destination vector pJK539 to yield pJK623.  The plasmid encodes 
for OrfY, PurQ, and PurL. 
 
Construction of orfY-purQ-purLH6 construct plasmid pJK623.  A 1.3 kb product was 
amplified from template pJK598, using ODNs 2113 and 2076 with an annealing 
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 30 s 
for 25 cycles using Phusion polymerase.  The product was purified using a Qiagen PCR 
purification kit, digested with NdeI and EcoRI, and ligated into the NdeI and EcoRI 
restriction sites of the destination vector pJK575 to yield pJK624.  The plasmid encodes 
for OrfY, PurQ, and PurLH6. 
 
Construction of H6purS-purQ-purL construct plasmid pJK625.  A 1.2 kb product was 
amplified from template pJK605, using ODNs 2091 and 2076 with an annealing 
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 30 s 
for 25 cycles using Phusion polymerase.  The product was purified using a Qiagen PCR 
purification kit, digested with NdeI and EcoRI, and ligated into the NdeI and EcoRI 
restriction sites of the destination vector pJK622 to yield pJK625.  The plasmid encodes 





Protein expression and purification 
Underlined headers indicate the final purification method.  Antibiotics were used as 
follows:  Amp (ampicillin, 100 ug/mL); Kan (kanamycin, 70 ug/mL); and Stm 
(streptomycin, 50 ug/mL). 
 
a. OrfYH6 
OrfYH6 (pJK530) Prep 1.  A single colony of BL21(DE3) cells transformed with pJK530 
was used to inoculate a 50 mL LB-Amp starter culture and grown to saturation (37°C, 
200 rpm).  1 L of ZYM-5052-Amp medium [17] was inoculated 1:100 and grown 
overnight (37°C, 200 rpm).  Cells were harvested (5,000g, 15 min) and stored at -80°C 
until use.  All the following steps were performed at 4°C.  The cell pellet was 
resuspended in 50 mM Tris-HCl pH 8.0, 300 mM KCl (5 mL/g pellet) and disrupted by 
sonication using a Fisher Sonic Dismembrator at 20% output (3 cycles: 1 min on, 1 min 
off) on ice.  Cell debris was removed by centrifugation (30,000g, 30 min).  Streptomycin 
sulfate (10% w/v stock) was added to a final concentration of 1% w/v, incubated on ice 
for 10 min, then spun (30,000g, 10 min).  The soluble lysate was applied to a previously 
equilibrated and charged Ni-NTA column (1.5 cm x 2 cm, 3.5 mL) in the above buffer.  
The column was washed with 10 mM imidazole in the above buffer.  A linear imidazole 
gradient (10-500 mM in 50 mM Tris-HCl pH 8.0, 300 mM KCl) was used to elute the 
protein (35 mL x 35 mL).  Fractions containing pure protein by SDS-PAGE were pooled 
and the protein was concentrated using an Amicon Centricon YM-3 (7,000 rpm, 2 h).  
The protein was dialyzed overnight against 100 volumes (1 L) of 50 mM Tris-HCl pH 8.0, 
300 mM KCl using 7,000 MWCO Pierce Snakeskin dialysis tubing (no changes).  
Aggregates of the dialyzed protein (flaky precipitates) were removed by centrifugation in 
an Eppendorf 5415D microfuge (max speed, 10 min, at 4°C).  Protein quantitation was 
determined by the Bradford assay (Biorad).  33 mg of OrfYH6 was isolated with a final 
protein concentration of 7.5 mg/mL.  1 mg of OrfYH6 was buffer exchanged into i. 50 
mM Tris pH 8.0, ii. 50 mM Tris pH 9.0, iii. 50 mM CHES pH 9.0, or iv. 50 mM 
ammonium formate pH 4.0 to a final concentration of 2 mg/mL using an Amicon 




batch of protein was used for antibody generation (Cocalico Biologicals, Inc.), circular 
dichroism (Elwood Mullins, Data Report 2013-01-07), and ESI-MS (described below).   
 
OrfYH6 (pJK530) Preps 9-11.  BL21(DE3) carrying pJK530 in ZYM-5052-Amp 
medium [17] was grown overnight (30°C, 200 rpm).  Cells were harvested (5,000g, 15 
min) and used immediately or stored at -80°.  All the following steps were performed at 
4°C.  The cell pellet was resuspended in 50 mM Tris pH 8.0, 300 mM KCl (5 mL/g pellet) 
and disrupted by sonication (3 cycles, 1 min on, 1 min off) at 20-25% output using a 
Fisher Sonic Dismembrator.  Cell debris was removed by centrifugation (30,000g, 30 
min).  Streptomycin sulfate (10% w/v stock) was added to a final concentration of 1% 
and the lysate was cleared by centrifugation (30,000g for 10 min).  The cleared lysate 
was loaded onto a previously equilibrated (in 50 mM Tris pH 8.0, 300 mM KCl) and 
charged Ni-NTA column (1.5 cm x 2 cm, 3.5 mL) and the column was washed with 10 
column volumes of 10 mM imidazole in 50 mM Tris pH 8.0, 300 mM KCl buffer.  A 
linear imidazole gradient (10-500 mM in 50 mM Tris pH 8.0, 300 mM KCl) was used to 
elute the protein (15 mL x 15 mL).  Fractions containing pure protein by SDS-PAGE 
were pooled and the protein was concentrated using an an Amicon ultrafiltration 8050 
cell with a Millipore PL-5 membrane.  For prep 9, OrfYH6 was concentrated to 14.0 
mg/mL (49 mg total).  For prep 10, protein was concentrated to 7.5 mg/mL (15 mg total).  
For prep 11, OrfYH6 was concentrated to 18.9 mg/mL and then diluted down to ~ 4.5 
mg/mL to prevent precipitate formation (39 mg total).  No aggregates were observed thus 
far at the various concentrations.  These batches were used to set up crystal trays using 
the Emerald Wizard I and II solution kits (described below) and alkylation. 
 
Periplasmic isolation of OrfYH6 (pJK530) 
Prep 1.  Protocol adapted from [18].  BL21(DE3) carrying pJK530 in ZYM-5052-Amp 
medium [17] was grown overnight (30°C, 200 rpm).  Cells were harvested (5,000g, 15 
min) and used immediately or stored at -80°.  The cell pellet was resuspended in 400 mL 
of 30 mM Tris-HCl pH 8.0, 20% sucrose buffer (hypertonic solution), followed by the 
addition of EDTA pH 8.3 to 1 mM [final].  The solution was stirred slowly at room 




collected by centrifugation (10,000g, 10 min).  The supernatant was removed and the 
pellet was resuspended in ice cold 5 mM MgSO4 (hypotonic solution, unbuffered) and 
stirred slowly on ice for 10 min.  Cells were then spun down and the supernatant 
(periplasmic fraction) was transferred to a new tube.  The periplasmic fraction was loaded 
onto a pre-equilibrated (in 50 mM Tris-HCl pH 8.0, 300 mM KCl) and charged Ni-NTA 
column (1.5 cm x 1.5 cm, 2.7 mL).  The column was washed with 10 column volumes of 
10 mM imidazole in 50 mM Tris-HCl pH 8.0, 300 mM KCl buffer.  A linear imidazole 
gradient (10-400 mM in 50 mM Tris-HCl pH 8.0, 300 mM KCl) was used to elute the 
protein (15 mL x 15 mL). 
 
Prep 2.  Protocol adapted from [19].  The BL21(DE3)-pJK530 cell pellet was washed 
with 20 mL 30 mM Tris-HCl pH 8.0, 20% sucrose.  The cells were harvested (8,000g, 5 
min) and resuspended in 5 mL of the same buffer.  5 mL of 8 mM EDTA and 0.16 mg of 
lysozyme/mL were added to the cell resuspension and incubated on ice for 15 min.  Cells 
were pelleted (8,000g, 10 min) and the supernatant (periplasmic fraction) was collected.  
The pellet was resuspended in 2 mL 50 mM Tris pH 8.0, using a 10 mL syringe and 18-
gauge needle.  The cells were frozen and thawed 3 times in dry ice + ethanol and a 25°C 
water bath, respectively, as described previously [19].  Cell debris was removed (8,000g, 
10 min), and the supernatant (cytoplasmic fraction) was collected.  Ammonium sulfate 
precipitation was performed on the periplasmic fraction as described previously:  0-35% 
(208 g/L); 35-55% (128 g/L); and 55-85% (215 g/L).  The 35-55% cut was resuspended 
in a minimal amount of 50 mM Tris pH 8.0 buffer and loaded onto a pre-equilibrated and 
charged Ni-NTA column (1.5 cm x 1.5 cm, 2.7 mL).  The column was washed with 10 
column volumes of 10 mM imidazole buffer in 50 mM Tris pH 8.0.  A linear imidazole 
gradient (10-400 mM) was used to elute the protein (15 mL x 15 mL).  Fractions 
containing pure protein by SDS-PAGE were pooled and the protein was concentrated to 
0.04 mg/mL using an an Amicon ultrafiltration 8050 cell with a Millipore PL-5 
membrane.  
 
Prep 3.  Same protocol as prep 2 except the periplasmic fraction was directly loaded onto 




performed for 1 hr against 100 volumes (300 mL) of 50 mM Tris-HCl pH 8.0, 300 mM 
KCl using 7,000 MWCO Pierce Snakeskin dialysis tubing (no changes).  Post-dialysis 
precipitate was removed by centrifugation and the supernatant (unknown protein 
concentration) was loaded onto the recharged and pre-equilibrated Ni-NTA column.  The 
protein was eluted using 50 mM EDTA, 50 mM Tris pH 8.0, 100 mM KCl.  Fractions 
containing protein by A280 were pooled.  Ammonium sulfate fractionation was 
performed as a concentration step:  0-40% (242 g/L); 40-55% (63 g/L).  The 40-55% 
pellet was resuspended in a minimal amount of 50 mM Tris pH 8.0, 100 mM KCl buffer. 
 
Prep 6.  Protocol adapted from [20].  All the following steps were performed at 4°C.  In 
short, the BL21(DE3)-pJK530 cell pellet was resuspended in 100 mM Tris-acetate, 0.5 M 
sucrose, 5 mM EDTA (5 mL/g cell pellet).  40 uL of 2 mg/mL lysozyme (80 ug) and 500 
uL of ice cold water were added to the cell resuspension and incubated on ice for 5 min.  
MgSO4 was added to 5 mM final (7.5 uL of 1 M stock).  Spheroplasts were pelleted in a 
microcentrifuge (max speed, 2 min) and the supernatant (periplasmic fraction) was 
collected.  The pellet was washed with 1 mL 50 mM Tris-acetate pH 8.0, 0.25 M sucrose, 
10 mM MgSO4.  Spheroplasts were pelleted (max speed, 2 min) and the supernatant was 
discarded.  The pellet was resuspended in 1 mL 50 mM Tris-acetate pH 8.0, 300 mM KCl 
and lysed by sonication using a Misonix sonicator with microtip at 15W (Briggs lab, 
Program 3, 3 cycles of 5 s on, 5 s off, 5 s on).  The periplasmic fraction was dialyzed 
against 100 volumes of 50 mM Tris-HCl pH 8.0, 300 mM KCl (4 buffer exchanges, 30 
min, 100 mL) to remove the EDTA prior to loading 1.2 mL onto a Ni-NTA spin column.  
Spheroplast cellular debris was removed by centrifugation (max speed, 15 min).  Qiagen 
Ni-NTA spin columns were equilibrated with 400 mL of 50 mM Tris-HCl pH 8.0, 300 
mM KCl (800g, 2 min).  1.2 mL of dialyzed periplasmic solution and 700 uL of soluble 
spheroplast lysate were loaded onto the Ni-NTA spin columns (200g, 5 min).  The spin 
columns were washed with 700 uL 50 mM Tris-HCl pH 8.0, 300 mM KCl, 10 mM 
imidazole (800g, 2 min).  Bound protein was eluted using 200 uL 50 mM Tris-HCl pH 







H6PurS and H6OrfY (pJK522).  T. J. Kappock expressed pJK522 in BL21(DE3) cells in 
ZYM-5052-Amp medium [17].  All the following steps were performed at 4°C.  The cell 
pellet was resuspended in 50 mM Tris-HCl pH 8.0, 100 mM KCl (5 ml/g pellet) and 
disrupted by sonication using a Fisher Sonic Dismembrator at 12% output with a microtip.  
Cell debris was removed by centrifugation (30,000g, 30 min).  Streptomycin sulfate (10% 
w/v stock) was added to a final concentration of 1% w/v, incubated on ice for 10 min, 
then spun (30,000g, 10 min).  Ammonium sulfate fractionation was performed as 
described above:  0-25% cut (144 g/L); 25-65% cut (265 g/L).  The last cut was 
equilibrated overnight.  The 25-65% pellet was resuspended in about twice the volume of 
the pellet and applied to a previously equilibrated and charged Ni-NTA column (1.5 cm x 
4 cm, 7 mL) in the above buffer.  The column was washed with 10 column volumes of 10 
mM imidazole in the above buffer.  A linear imidazole gradient (10-500 mM) was used to 
elute the protein (70 mL x 70 mL).  Fractions containing pure protein by SDS-PAGE 
were pooled and the protein was stored as an 85% saturated ammonium sulfate pellet 
(608 g/L).  214 mg of H6PurS was isolated.  The sample was to the Purdue University 
Campus-Wide Mass Spectrometry Center for MALDI-TOF. 
 
Ammonium sulfate fractionation of PurS (pJK533).  A single colony of BL21(DE3) 
transformed with pJK533 was used to inoculate a 50-mL LB-Amp starter culture and 
grown to saturation (37°C, 200 rpm).  1 L of ZYM-5052-Amp medium [17] was 
inoculated 1:100 and grown overnight (37°C, 200 rpm).  Cells were harvested (5,000g, 
15 min) and stored at -80°C until use.  All the following steps were performed at 4°C.  
The cell pellet was resuspended in 50 mM Tris-HCl pH 8.0, 100 mM KCl (5 mL/g pellet) 
and disrupted by sonication using a Fisher Sonic Dismembrator at 20% output (3 cycles: 
1 min on, 1 min off) on ice.  Cell debris was removed by centrifugation (30,000g, 30 
min).  Streptomycin sulfate (10% w/v stock) was added to a final concentration of 1% 
w/v, incubated on ice for 10 min, then spun (30,000g, 10 min).  Ammonium sulfate 
fractionation was performed as described above:  0-25% (144 g/L); 25-35% (60 g/L); 35-





H6PurS (pJK620).  A single colony of BL21(DE3) transformed with pJK620 was used to 
inoculate a 50-mL LB-Kan starter culture and grown to saturation (37°C, 200 rpm).  1 L 
of ZYM-5052-Kan medium [17] was inoculated 1:100 and grown overnight (37°C, 200 
rpm).  Cells were harvested (5,000g, 15 min) and stored at -80°C until use.  All the 
following steps were performed at 4°C.  The cell pellet was resuspended in 50 mM Tris-
HCl pH 8.0, 100 mM KCl (5 mL/g pellet) and disrupted by sonication using a Fisher 
Sonic Dismembrator at 20% output (3 cycles: 1 min on, 1 min off) on ice.  Cell debris 
was removed by centrifugation (30,000g, 30 min).  Streptomycin sulfate (10% w/v stock) 
was added to a final concentration of 1% w/v, incubated on ice for 10 min, then spun 
(30,000g, 10 min).  The cleared lysate was loaded onto a previously equilibrated and 
charged Ni-NTA column (1.5 cm x 1.5 cm, 2.7 mL) and the column was washed with 10 
column volumes of 10 mM imidazole in 50 mM Tris-HCl pH 8.0, 100 mM KCl buffer.  
A linear imidazole gradient (10-500 mM) was used to elute the protein (5 mL x 5 mL).  
Fractions containing pure protein by SDS-PAGE were pooled and the protein was 




Co-expression of PurQ with pREP4-GroESL.  C41(DE3)-pREP4-GroESL were 
transformed with pJK555 and used to inoculate a 50-ml LB-Amp culture which was 
grown to saturation.  Two 250 mL cultures of ZYM-5052-Amp medium[17] were 
inoculated 1:50 and grown overnight at 30°C or 37°C (200 rpm).  For the 15°C auto-
induction, the culture was first grown at 37°C for two hours and then moved to 15°C for 
overnight growth and induction.  Cells were harvested (5,000g, 15 min) and stored at -
80°C until use.  All the following steps were performed at 4°C.  The cell pellet was 
resuspended in 50 mM Tris-HCl pH 8.0, 100 mM KCl (5 mL/g pellet) and disrupted by 
sonication using a Fisher Sonic Dismembrator at 20% output (3 cycles: 1 min on, 1 min 
off) on ice.  Cell debris was removed by centrifugation (max speed, 15 min) in an 
Eppendorf microfuge 5415D at 4°C. 
 




transformed with pJK555 were used to inoculate 1 L of ZYM-5052-Amp medium [17] at 
1:200 and grown for 24 hours (37°C, 200 rpm).  All the following steps were performed 
at 4°C.  Cells were harvested (5,000g, 15 min) and used immediately or stored at -80°C 
until use.  The cell pellet was resuspended in 50 mM Tris pH 8.0, 100 mM KCl (5 mL/g 
pellet) and disrupted by sonication using a Fisher Sonic Dismembrator at 20% output (3 
cycles: 1 min on, 1 min off) on ice.  Cell debris was removed by centrifugation (30,000g, 
30 min).  The pellet was resuspended in 100 mM Tris HCl pH 7.0, 5 mM EDTA, 15 mM 
βME, 2 M urea, 2% Triton X-100 (5 mL/g) using transfer pipets (Wash 1).  The solution 
was centrifuged (30,000g, 30 min).  2 additional washes were performed as described 
previously.  The final washing step was the same as above except for the buffer did not 
contain any urea or Triton X-100.  4 different extracting conditions were used at room 
temperature:  6 M guanidine-HCl, 8 M guanidine-HCl, 6 M urea, and 8 M urea.  The 
pellet from the final wash was split up into 4 aliquots and resuspended in 50 mM Tris 
HCl, 5 mM EDTA, 15 mM βME, and urea or guanidine-HCl (4 mL/g).  The solutions 
were centrifuged (30,000g, 30 min).  The guanidine-HCl samples were subjected to 
ethanol precipitation to avoid precipitation when running SDS-PAGE:  225 uL of cold 
100% ethanol was added to 25 uL of sample and vortexed.  After 10 min at -20°C, the 
solution was pelleted at max speed in a microcentrifuge for 10 min.  The ethanol was 
removed and 25 uL of H2O  and 225 uL of cold 100% ethanol was added to the pellet.  
After resuspension, the solution was pelleted at max speed for 5 min.  The pellet was 
resuspended in 25 uL 2X SDS buffer prior to loading. 
 
d. PurL 
H6PurL (pJK622).  A single colony of BL21(DE3) transformed with pJK622 was used to 
inoculate a 50-mL LB-Amp starter culture and grown to saturation (37°C, 200 rpm).  1 L 
of ZYM-5052-Amp medium [17] was inoculated 1:100 and grown overnight (37°C, 200 
rpm).  Cells were harvested (5,000g, 15 min) and stored at -80°C until use.  All the 
following steps were performed at 4°C.  The cell pellet was resuspended in 50 mM Tris-
HCl pH 8.0, 100 mM KCl (5 mL/g pellet) and disrupted by sonication using a Fisher 
Sonic Dismembrator at 20% output (3 cycles: 1 min on, 1 min off) on ice.  Cell debris 




was added to a final concentration of 1% w/v, incubated on ice for 10 min, then spun 
(30,000g, 10 min).  The cleared lysate was loaded onto a previously equilibrated and 
charged Ni-NTA column (1.5 cm x 1.5 cm, 2.7 mL) and the column was washed with 10 
column volumes of 10 mM imidazole in 50 mM Tris-HCl pH 8.0, 100 mM KCl buffer.  
A linear imidazole gradient (10-500 mMin 50 mM Tris-HCl pH 8.0, 100 mM KCl) was 
used to elute the protein (5 mL x 5 mL).  Fractions containing pure protein by SDS-
PAGE were pooled and the protein was concentrated to 3.4 mg/mL using an an Amicon 
ultrafiltration 8050 cell with a Millipore PL-30 membrane. 
 
PurLH6 (pJK575).  A single colony of BL21(DE3) transformed with pJK575 was used to 
inoculate a 50-mL LB-Amp starter culture and grown to saturation (37°C, 200 rpm).  1 L 
of ZYM-5052-Amp medium [17] was inoculated 1:100 and grown overnight (37°C, 200 
rpm).  Cells were harvested (5,000g, 15 min) and stored at -80°C until use.  All the 
following steps were performed at 4°C.  The cell pellet was resuspended in 50 mM Tris-
HCl pH 8.0, 100 mM KCl (5 mL/g pellet) and disrupted by sonication using a Fisher 
Sonic Dismembrator at 20% output (3 cycles: 1 min on, 1 min off) on ice.  Cell debris 
was removed by centrifugation (30,000g, 30 min).  Streptomycin sulfate (10% w/v stock) 
was added to a final concentration of 1% w/v, incubated on ice for 10 min, then spun 
(30,000g, 10 min).  The cleared lysate was loaded onto a previously equilibrated and 
charged Ni-NTA column (1.5 cm x 1.8 cm, 3.2 mL) and the column was washed with 10 
column volumes of 10 mM imidazole in 50 mM Tris-HCl pH 8.0, 100 mM KCl buffer.  
A linear imidazole gradient (10-500 mM in 50 mM Tris-HCl pH 8.0, 100 mM KCl) was 
used to elute the protein (15 mL x 15 mL).  Fractions containing pure protein by SDS-
PAGE were pooled and the protein was concentrated to 3.2 mg/mL using an an Amicon 
ultrafiltration 8050 cell with a Millipore PL-30 membrane. 
 
PurSQLH6 (pJK606).  A single colony of BL21(DE3), C41(DE3)-pREP4-GroESL, 
C41(DE3)  transformed with pJK606 was used to inoculate a 50-mL LB starter culture 
and grown to saturation (37°C, 200 rpm).  BL21(DE3) cells were propagated in1 L of 
ZYM-5052 medium [17] was inoculated 1:100 and grown overnight (37°C, 200 rpm).  




LB was inoculated 1:100 and grown to OD600 ~0.4 at 37°C.  The temperature was 
decreased to 15°C and when the OD600 reached 0.6, isopropyl-β-thiogalactopyranoside 
(IPTG) was added to a final concentration of 0.4 mM  from a 1M stock and the cells were 
induced for 20 hrs.  Cells were harvested (5,000g, 15 min) and stored at -80°C until use.  
All the following steps were performed at 4°C.  The cell pellet was resuspended in 50 
mM Tris-HCl pH 8.0, 100 mM KCl (3 mL/g pellet) and disrupted by sonication using a 
Fisher Sonic Dismembrator at 20% output (3 cycles: 1 min on, 1 min off) on ice.  If 
metabolites were included, ATP, ADP, and/or glutamine would be spiked into cell lysates 
in this step to a final concentration of 1 mM.  Cell debris was removed by centrifugation 
(30,000g, 30 min).  Streptomycin sulfate (10% w/v stock) was added to a final 
concentration of 1% w/v, incubated on ice for 10 min, then spun (30,000g, 10 min).  The 
cleared lysate was loaded onto a previously equilibrated and charged Ni-NTA column 
(1.5 cm x 1.5 cm, 2.7 mL) and the column was washed with 1-5 column volumes of 10 
mM imidazole in 50 mM Tris-HCl pH 8.0, 100 mM KCl buffer.  A linear imidazole 
gradient (10-500 mM in 50 mM Tris-HCl pH 8.0, 100 mM KCl) was used to elute the 
protein (5 mL x 5 mL) or an EDTA elution using 50 mM EDTA in 50 mM Tris-HCl pH 
8.0, 100 mM KCl buffer.  Batch purification using Qiagen Ni-NTA columns were used 
according to the manufacturer’s instruction instead of using the 1.5 cm x 1.5 cm column. 
 
Co-expression studies of AaFS proteins.  LB starter cultures containing appropriate 
antibiotic (Tables 3-6) were inoculated with single colonies and grown to saturation 
(37°C, 200 rpm).  Empty vector controls included pET23a, pET-Duet, or pCDF-Duet 
vectors.  250 mL of ZYM-5052 medium [17] supplemented with appropriate antibiotics 
was inoculated 1:100 and grown overnight (30°C, 200 rpm).  Cells were harvested 
(5,000g, 15 min) and stored at -80°C until use.  All the following steps were performed at 
4°C.  Cell pellets were resuspended in 50 mM Tris-HCl pH 8.0, 100 mM KCl (5 mL/g 
pellet) and disrupted by sonication using a Fisher Sonic Dismembrator at 20% output (3 
cycles: 1 min on, 1 min off) on ice.  Cell debris was removed by centrifugation (30,000g, 





Table 1.3 Single-gene constructs (Figure 1.8, top) 
pJK Vector Antibiotic Gene(s) S Y Q L 
531 pET23d Amp orfY  x   
555 pET23a Amp purQ   x  
533 pET23d Amp purS x    
539 pET23a Amp purL    x 
 
Table 1.4 Duet vector constructs (Figure 1.8, bottom) 
pJK Vector Antibiotic Gene(s) SL YQ SYQL SQL QL 
532 pET28a Kan H6purQ    x  
543 pCDF-Duet Stm purS and purL x  x x x 
548 pET-Duet Amp orfY and purQ  x x   
549 pCDF-Duet Stm purL     x 
 
Table 1.5 Overlapping gene constructs as in the native A. aceti sequence (Figure 1.9) 
pJK Vector Antibiotic Gene(s) SYQL SYQLH6 SQL SQLH6 SYQL* SYQLH6* 
567 pCDF-Duet Stm orfY     x x 
598 pET23a Amp purS-orfY-purQ-purL x      
599 pET23a Amp purS-orfY-purQ-purLH6  x     
605 pET23a Amp purS-purQ-purL   x  x  
606 pET23a Amp purS-purQ-purLH6    x  x 
*OrfY was expressed in trans 
 
Table 1.6 purQ-purL constructs (Figure 1.10) 
pJK Vector Antibiotic Gene(s) QL QLH6 
610 pET23a Amp purQ-purL x  




ESI-MS.  OrfYH6 from prep 1 was analyzed on a Thermo Scientific LTQ (Parker 
laboratory) with Steven Ouellette’s assistance.  Samples were diluted by volume in 
50:50:01 water: acetonitrile: formic acid.   MS peaks were analyzed using ESIprot1.0 
[22].  
Tandem-MS.  OrfYH6 was analyzed by Anton Iliuk (Tao laboratory) as follows.  The 
protein sample was denatured and reduced in 50 mM trimethyl ammonium bicarbonate.  
Three sample preparations were performed:  (i) 0.1% RapiGest (Waters) and 5 mM 




DTT were omitted).  Rapigest and/or DTT treatments were incubated for 30 minutes at 
50°C.  Only the sample in condition (i) was further alkylated in 15 mM iodoacetamide 
for 1 hour in the dark at room temperature.  All samples were digested with proteomics 
grade trypsin at 1:100 ratio overnight at 37 °C.  The pH was adjusted below 3 and the 
sample was incubated for 40 minutes at 37 °C.  The sample was centrifuged down at 
16,100g to remove RapiGest and to collect supernatant.  The sample was desalted with a 
100-mg Sep-Pak C18 column (Waters) and dried completely.  Peptide samples were re-
dissolved in 8 uL of 0.1% formic acid and injected into an Agilent nanoflow 1100 HPLC 
system.  The reverse phase C18 was performed using an in-house C18 capillary column 
packed with 5 µm C18 Magic beads resin (Michrom; 75 µm i.d. and 12 cm of bed length) 
on an 1100 Agilent HPLC.  The mobile phase buffer consisted of 0.1% HCOOH in ultra-
pure water with the eluting buffer of 100% CH3CN run over a shallow linear gradient 
over 60 min with a flow rate of 0.3 µl/min.  The electrospray ionization emitter tip was 
generated on the prepacked column with a laser puller (Model P-2000, Sutter Instrument 
Co.).  The Agilent 1100 HPLC system was coupled online with a high resolution hybrid 
linear ion trap orbitrap mass spectrometer (LTQ-Orbitrap XL; Thermo Fisher).  The mass 
spectrometer was operated in the data-dependent mode in which a full-scan MS (from 
m/z 300-1700 with the resolution of 30,000 at m/z 400) was followed by 4 MS/MS scans 
of the most abundant ions. Ions with charge state of +1 were excluded. The mass 
exclusion time was 180 s.  The LTQ-Orbitrap raw files were searched directly against 
Saccharomyces cerevisiae database with no redundant entries using SEQUEST algorithm 
on Proteome Discoverer (Version 1.0; Thermo Fisher).  Proteome Discoverer created 
DTA files from the raw data with minimum ion threshold of 15 and absolute intensity 
threshold of 50.  Peptide precursor mass tolerance was set at 5 ppm, and MS/MS 
tolerance was set at 0.8 Da. Search criteria included a static modification of cysteine 
residues of +57.0214 Da and a variable modifications of +15.9949 Da to include potential 
oxidation of methionines and carbamidomethylation of cysteines.  Searches were 
performed with full tryptic digestion and allowed a maximum of two missed cleavages on 
the peptides analyzed from the sequence database.  False discovery rates (FDR) were set 





Antibody generation.  Purified antigens OrfYH6 (pJK530) and PurLH6 (pJK575) were 
sent to Cocalico Biologicals Inc. for custom polyclonal antibody generation (Cocalico 
ELISA titers for anti-OrfYH6 and anti-PurLH6 showed signal at 1:10000 dilution).  
Antisera were tested by dot blot [23] or Western blotting as described below. 
 
Western blot protocol.  Protocol adapted from [24].  In short, soluble proteins from 
soluble lysates (A. aceti or E. coli) were separated by SDS-PAGE and transferred to a 
nitrocellulose membrane (0.2 or 0.45 µm, Osmonics, Inc.).  Transfer was performed at 
100V for 1 h in Towbin Buffer (25 mM Tris, 192 mM glycine, 20% (v/v) methanol, 0.1 % 
(w/v) SDS).  The membrane was blocked in TBS (100 mM Tris-HCl pH 7.5, 150 mM 
NaCl) with 5% (w/v) nonfat milk for 1 h, shaking at room temperature, followed by three 
10 min washes in TBST (TBS with 0.1% (v/v) Tween-20).   The membrane was probed 
for 1 h with custom polyclonal rabbit primary antibody (1:10,000 for anti-OrfYH6 
antibody; 1:20,000 dilution for anti-PurLH6 antibody in TBS with 2% (w/v) nonfat milk) 
or anti-His H15 probe (1:50,000, Santa Cruz Biotechnology).  Excess antibody was 
removed by three TBST washes.  The membrane was then probed for 1 h with goat anti-
rabbit IgG (H+L) HRP conjugate secondary antibody (1:10,000 dilution in TBS with 2% 
(w/v) nonfat milk, Jackson ImmunoResearch).  Excess antibody was removed by three 
TBST washes.  The membrane was soaked for 5 min in a 1:1 mixture of stable peroxide 
and luminol/enhancer solutions (ThermoScientific).  Typically, signal was recorded by 
film or using a ChemiImager 5500 imaging system (Alpha Innotech) where membranes 
were exposed 30 s - 5 min.   
 
The LI-COR Odyssey was also used with Brett Bishop’s help (Ogas laboratory).  For the 
LI-COR, membranes were blocked using the LI-COR Blocking buffer, incubated with 
custom antiserum for the primary and goat anti-rabbit IRDye 800 CW secondary 






Dot blot.  Protocol adapted from [23].  In short, typically 1-5 µg protein or lysate were 
spotted onto nitrocellulose membrane and let to dry.  Non-specific sites were blocked by 
soaking the membrane in 5% (w/v) BSA or nonfat milk in TBST for 1 hr at room 
temperature in a Petri dish, followed by three 5 min washes in TBST.  The membrane 
was incubated with primary antibody (diluted 1:25,000; 1:10,000; or 1: 5,000 in 0.1% 
BSA or 0.2% nonfat milk in TBS) for 30 min - 1 h.  Excess antibody was removed by 
three TBST washes.  Secondary antibody (anti-rabbit) was diluted 1:10,000 and 
incubated for 30 min at room temperature.  Excess antibody was removed by three TBST 
washes and the signal was recorded as previously described. 
 
Anti-OrfYH6 and anti-PurLH6 antibody purification.  Protocol adapted from [25].  In 
short, Ni-IDA resin (~1.5 mL) was stripped using 100 mM EDTA.  The resin was washed 
twice with water and recharged with 50 mM CoCl2.  Excess solution was removed and 
washed with PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 1.8 mM KH2PO4, pH 
7.2 [26].  14 mg of OrfYH6 (prep 1) was used to bind the resin in PBS (30 min on ice 
with constant mixing, 10 mL total volume).  No wash step was performed to remove 
unbound protein.  200 uL of 30% H2O2 was added to the resin and the latter was 
incubated at room temperature for 1 hr (Co2+ oxidation to Co3+ leads to a color change 
from pink to purple).  The resin was then washed with PBS+100 mM EDTA and stored at 
4°C in PBS until use.  2 mL of antiserum was incubated for 25 min with the resin on ice 
while mixing.  The suspension was poured into a 0.75 cm diameter column (final 
dimensions 0.75 cm x 3.3 cm).  Flowthrough was collected and the resin was washed 
with 10 column volumes of 20 mM Tris-HCl, pH 7.5, 150 mM NaCl (binding buffer) and 
10 column volumes of 20 mM Tris-HCl, pH 7.5, 1 M NaCl (washing buffer).  The 
antibody was eluted from the column with 5 column volumes of 100 mM Tris-acetate, 
pH 4, 150 mM NaCl; 5 column volumes of 100 mM acetate, pH 3, 150 mM NaCl; and 5 
column volumes of 100 mM glycine-HCl, pH 2.5, 150 mM NaCl.  Drops were collected 
in ~1 mL aliquots in tubes containing 100 uL 1M Tris-HCl pH 8.3.  Fractions containing 
protein by A280nm (> 0.2 were collected), concentrated, and buffer exchanged into PBS 
using an Amicon UltraCentrifugal filter (2 mL; 30,000 MWCO).  Purified antibody was 





OrfYH6 Crystallization.  Previously isolated OrfYH6 (prep 9 and 10) was used to set up 
crystallization trays by the hanging drop diffusion method using the Emerald Biosystems 
Wizard Kits I and II.  In short, 500 uL of crystallization solution was aliquoted 24-well 
crystallization plates (Hampton Research). 4 uL drops were set up by mixing 2 uL of well 
solution and 2 uL of protein solution at various concentrations.  Protein concentrations 
were determined by the Bradford assay after buffer exchanging into 10 mM Tris-HCl, pH 
8.0 using Millipore Microcon YM-10 centrifugal concentrators.  Trays were stored at the 
Hockmeyer building at Purdue University in the 21.5°C temperature-controlled 
crystallization room.  Cryo solutions were made up by adding 15% w/v ethylene glycol to 
the mother liquor (Wizard Kit 1 Solution 13 (1.26 M ammonium sulfate (dibasic), 0.1 M 
sodium cacodylate/HCl pH 6.5) aka 1-13 or Wizard Kit 2 Solution 17 (2.5 M sodium 
chloride, 0.1 M Tris/HCl pH 7.0, 0.2 M magnesium chloride) aka 2-17.  K. Sullivan 
dipped the crystals in cryo solution prior to freezing them in liquid nitrogen.  Crystals 
were shot via remote data collect LS-CAT beam line 21-ID-F. 
 
OrfYH6 alkylation with N-ethylmaleimide (NEM) and methoxypolyethylene glycol 
maleimide MAL-PEG.  Samples that were used were unpurified periplasmic fraction 
containing OrfYH6, purified OrfYH6 (from total lysate, prep 11), and A. aceti 
thioredoxin (Jesse Murphy).  The periplasmic fraction from cells overexpressing OrfYH6 
were freeze-thawed once as described above, and the supernatant was kept for further 
processing.  NEM was added to samples to a final concentration of 10 mM in 50 mM 
TrisHCl, pH 6.5.  As for MAL-PEG, 5 molar equivalents over the total number of 
cysteines was added in 50 mM TrisHCl, pH 6.5.  Samples that were first treated with 
DTT had 5 molar equivalents over the total number of cysteines found in OrfYH6.  
Excess MAL-PEG was neutralized with 5 molar equivalents of β-mercaptoethanol (BME) 





1.3 Results and Discussion 
 ExPASy [27] predicted the sizes of PurS, OrfY, PurQ, and PurL to be 8.7 kDa, 
12.9 kDa, 25.1 kDa, and 77.7 kDa, respectively.  The sizes of A. aceti PurS, PurQ, and 
PurL are similar to previously characterized Gram-positive FS [5-7]. 
   
Co-expression studies of AaFS proteins 
 After single gene constructs were obtained, double gene constructs were made in 
Duet vectors where each gene was under its own T7 promoter.  A preliminary 




Figure 1.8  Expression of AaFS proteins.   
Top, individual construct expression.  Bottom, Duet vector constructs (NB - PurQ is 
actually H6PurQ (pJK532) in the last 2 lanes of the gels).  Tables 3 and 4 in Materials 
and Methods lists the plasmids used for expression.   SDS-PAGE (12% acrylamide), 10 




















































































































































OrfY, PurS, and PurL were soluble.  PurQ, like its tagged version (data not shown), was 
insoluble.  When PurQ is co-expressed with the other three A. aceti genes, a portion 
becomes soluble, thus PurQ might rely on the other subunits of the AaFS complex or 
even GroESL for proper folding and therefore solubility.  An OrfY dimer is visible and 
looks to co-migrate with PurQ when expressed alone (Western blotting in Figure 24, right, 
on purified OrfYH6 with purified anti-OrfYH6 antibody probing supports the dimer 
hypothesis).  Induction failed with pJK548, which carries OrfY and PurQ on the same 
Duet vector. 
 
 Constructs where the overlapping nucleotides were conserved between the AaFS 
genes were obtained and expressed as shown in Figure 1.9.  Additionally, OrfY on a 
separate plasmid (pJK567) was re-added to the 3-gene constructs (pJK605/606) to test if 




Figure 1.9  Expression of FS proteins (overlapping genes).   
Table 1.5 lists the plasmids used for expression.  For trans, pCDF-Duet was used in the -
OrfY lanes (right-most lanes).  * denotes duplicate sample.  SDS-PAGE (12% 


























pJK606 induction failed in the cis experiment, but OrfY was observed to have a 
repressive effect in cis on PurQ and potentially PurL.  Re-addition of OrfY (in trans) has 
no effect on the over-expression of PurQ or PurL.  More definitive conclusions could be 
drawn if the same amount of protein was loaded.  A small amount of soluble PurQ was 
observed in the presence of PurS and PurL.  QL(H6) constructs were obtained and 
expressed (Figure 1.10). 
 
 
Figure 1.10  Coexpression of PurQL.   
Expressed constructs were as follows:  PurQL (pJK610) and PurQLH6 (pJK611).  SDS-
PAGE (12% acrylamide), 10 uL/lane after 1:10 dilution (protein concentration unknown). 
 
 
The solubility of PurQ seems to require the presence of both PurS and PurL, as not much 
soluble PurQ was observed when only PurL is present. 
 
H6PurS/H6OrfY (pJK522) 
 pJK522 encodes for H6PurS and H6OrfY, where the 4-nucleotide overlap was 
preserved as in the native sequence, despite the presence of the His-tag at the N-term of 
OrfY.  The idea behind using pJK522 for purification was that both H6PurS and H6OrfY 
would be able to be purified in the same prep.  214 mg of protein was isolated.  Since one 
band was observed by SDS-PAGE, the sample was analyzed by MALDI-TOF where 
only H6PurS was detected (10703.33 Da).  The expected sizes for H6PurS-Met1 and 














by ESI-MS below revealed that OrfY is N-terminally processed, thus explaining why 
only H6PurS was isolated here.  
 
OrfYH6 (pJK530) 
Prep 1.  Expression of OrfYH6 showed that the protein was soluble (data not shown).  
The elution profile is shown in Figure 1.11. 
 
 
Figure 1.11  OrfYH6 prep 1 elution profile (linear imidazole gradient).   
Ladder used was bovine serum albumin (BSA, 66 kDa) and hemoglobin, Hb (Chain A, 
16 kDa; Chain B, 17 kDa).  SDS-PAGE (12% acrylamide), 10 uL/lane (protein 
concentration unknown). 
 
Flaky precipitate was observed after overnight dialysis and was spun down.  The final 




Figure 1.12  OrfYH6 final purification gel (prep 1).   
SDS-PAGE (12% acrylamide); 5 ug/lane except for the pellet post-dialysis (protein 
concentration unknown). 






































The observed flaky precipitate after dialysis is likely OrfYH6 by SDS-PAGE (Figure 
1.14).  33 mg of soluble protein was isolated and appeared to remain in solution when 
stored at 4°C in 50 mM Tris pH 8.0, 300 mM KCl at a protein concentration of 7.5 
mg/mL,; 50 mM Tris pH 8.0; 50 mM Tris pH 9.0; 50 mM CHES pH 9.0; or 50 mM 
ammonium formate pH 4.0 at 2 mg/mL for at least one year.   
 
Steven Ouellette (Parker laboratory) and Anton Iliuk (Tao laboratory) helped with ESI-
MS analysis of OrfYH6 and after deconvolution using ESIprot 1.0, the molecular weight 
was determined to be 11927.45 Da (expected 14094.76 Da).  SignalP 3.0 algorithm 
analysis [28] of the OrfYH6 sequence predicts a cleavage site between A22 and Q23 
(Figure 1.13 shows those residues to be A21 and Q22 as Met1 was omitted when the 
protein sequence was entered into the algorithm). 
 
 
Figure 1.13  SignalP 3.0 output for the analysis of OrfYH6.   
A cleavage site is predicted between A22 and Q23 (A21 and Q22 in graph as Met1 was 
omitted). 
 
The SignalP 3.0 output for OrfYH6 resembles that of a secretory or periplasmic protein 
thus suggesting OrfYH6 secretion or export.  The predicted molecular weight of 
processed OrfYH6 is 11935.6 Da, a few Da off from the ESI-MS experimental value of 




 Elwood Mullins used circular dichroism (CD) to further characterize OrfYH6.  
The CD spectrum is shown in Figure 1.14 and the data summary is in Table 1.7. 
 
 
Figure 1.14  CD spectrum of OrfYH6.   
Refer to EAM Data Report 2013-01-07 for experimental details. 
Table 1.7 CD structural element summary for OrfYH6. 
 
According to CD, OrfYH6 is 40% α-helical while β-sheets and random coils make up the 
remaining 60%. 
 
 Anton Iliuk (Tao laboratory) helped with tandem MS analysis of OrfYH6.  
Multiple cysteine residues can be found within the OrfY protein sequence (C13, C36, 
C45, C76, and C119).  The last four residues were found to be conserved in at least 14 







Figure 1.15  Sequence logo for the conserved residues of 14 OrfY sequences.   
The more highly conserved residues are larger. 
 
OrfYH6 was analyzed by tandem-MS analysis in reducing and non-reducing conditions 
in attempt to identify any existing disulfide bridges (Figure 1.16). 
 
 
Figure 1.16  Tandem-MS peptide coverage of OrfYH6.   
Detected peptides were underlined in different sample prep conditions (black - no 
RapiGest/no DTT; red - no RapiGest/ + DTT; blue - + RapiGest/no DTT).  The vertical 
dashed line denotes the predicted N-term processing site and the vertical green lines, 
tryptic digest site. 
 
Out of the 111 amino acids in processed OrfYH6, only 12 amino acids were not covered 
when the three experiments were combined (89% coverage).  As expected, the first 22 
amino acids (note that the accommodation of the NcoI site at the N-term leads to an 
additional alanine residue at position 2, which was not included in the Figure 1.18 
sequence) were not detected.  The first cysteine residue, C13, is part of the processed N-
term.  In untreated cell lysate (black underline in Figure 1.16), C45 and C72 were 
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detected (their reduced state may have been due to reductants found in cell lysate).  In 
reducing conditions (red underline in Figure 1.16), C45, C72, and C119 were detected.  
In non-reducing conditions (blue underline in Figure 1.16), C45 and C72 were detected.  
For all experiments, C36 was likely on a peptide that was too small for detection.  Since 
only the +DTT sample was alkylated with iodoacetamide, it is still unclear if all the 
cysteine residues in OrfYH6 are reduced. 
 
 Isolation of OrfYH6 in 100 mM KCl (vs. 300 mM KCl in prep 1) showed a poor 
yield of OrfYH6 as only 2 mg of protein was isolated in prep 2 (data not shown).  A 
decrease in the auto-induction temperature from 37°C to 30° seemed to help expression 
in prep 3 (data not shown).  A spreading out effect was observed in both the imidazole 
and EDTA elutions (data not shown).  
 
Prep 9-11.  The buffer conditions from prep 1 were used and a linear imidazole gradient 
(10-500 mM) was used to elute the protein.  The final purification gel and accompanying 
Western blot using custom antiserum (not antigen-affinity purified yet) for prep 9 and the 
final purification gel for prep 10 is shown in Figure 1.17. 
 
Figure 1.17  OrfYH6 preps 9 and 10 final purification gels.   
Left, final gel for prep 9.  Center, Western blot using custom antiserum (LI-COR).  Right, 
final gel for prep 10.  SDS-PAGE (15%), 5 ug protein/lane. 
49 mg of OrfYH6 was isolated from 4L of cells for prep 9, and 15 mg from 1L for prep 




































































the crude, soluble, and OrfYH6 lanes, two strong signals were observed at higher 
molecular weights.  At first glance, the bands could be OrfYH6 oligomers.  However due 
to the lack of marker signals and a very faint signal for the purified protein, possible 
explanations include non-specific reactivity of the antiserum to E. coli contaminating 
proteins or the latter’s emission at 800 nm.  Other Western blots where signal was 




Figure 1.18  PU81 Antiserum has non-specific reactivity to E. coli lysate.  
Left, Coomassie-stained SDS-PAGE (12%), 5 ug protein/lane.  Right, Western (15 s 
exposure). 
 
M. Hall and N. Dudareva suggested antigen affinity purification of the antiserum to 
enrich for the anti-OrfYH6 antibody.  Dot blot results showed interaction with OrfYH6, 
as expected, but also, E. coli and A. aceti lysates, likely due to an error in the blocking 
step where 5% BSA (w/v) was used instead of 5% nonfat milk (w/v) in TBST (data not 
shown).  Instead of repeating the dot blot, a Western blot was performed using the 







Figure 1.19  Western blot of OrfYH6 total lysate and purified OrfYH6. 
Santa Cruz H-15 His probe or antigen affinity purified anti-OrfYH6 antibody were used.  
Left, SDS-PAGE (12% acrylamide), 5 ug protein/lane.  Center, blot using anti-His 
antibody.  Right, blot using purified anti-OrfYH6 antibody.  2 min exposure.  Legend: 
molecular weight standard, S; total lysate, Tot; purified OrfYH6 (prep 9), YH6. 
 
Both the anti-His and the purified OrfYH6 antibodies were able to detect monomeric 
OrfYH6 in total lysates, although the signal was very faint.  In the purified OrfYH6 lanes, 
both antibodies were observed to probe for the monomeric and potentially dimeric 
OrfYH6.  The putative OrfYH6 dimer was not observed in the total lysate lane.  The 
antigen purified antibody seemed to work well as the anti-His antibody was observed to 
from non-specific interactions at very high molecular weights in the purified OrfYH6 
lane. 
 
 Purified OrfYH6 from preps 9 and 10 were used to set up crystal trays.  After 4 
months, some crystals were observed in two buffers:  (1-13) 1.26 M ammonium sulfate, 
0.1 M sodium cacodylate/HCl, pH 6.5 and (2-17) 2.5 M sodium chloride, 0.1 M Tris/HCl 
pH 7.0, 0.2 M magnesium chloride.   
 
Tray 1 Well C1 (NB3-137, 2012-06-15) with crystallization buffer 1-13 contained a 
single crystal with 2 faces and was also not birefringent and Izit negative.  This crystal 








The F 2 3 space group calculated for OrfY2 is not common, therefore crystallization 
conditions should be optimized in 1.26M ammonium sulfate, 0.1M sodium 
cacodylate/HCl, pH 6.5 for OrfYH6 for further crystallographic studies. 
 
 OrfYH6 prep 11, which yielded 39 mg of protein from 3 L of cells (Figure 1.20), 
was used for NEM and MAL-PEG alkylation of cysteine residues (Figure 1.21). 
 
 
Figure 1.20  OrfYH6 prep 11.   
Left, elution gel (10 uL/lane, protein concentration unknown).  Right, final purification 






















Figure 1.21 Alkylation of OrfYH6 with NEM and MAL-PEG.   
Left, NEM alkylation (SDS-PAGE, 15%; 10 uL/lane).  Center and right, alkylation of 
isolated OrfYH6 with MAL-PEG (SDS-PAGE, 15% urea and 9% urea, respectively; 7.5 
ug protein/lane).  * indicates sample was purified with a Ni-NTA spin column. 
 
 
Successful NEM and MAL-PEG modification of cysteine residues in the absence of DTT 
would indicate reduced cysteines.  On the other hand, if no shift is observed in the 
absence of DTT, the cysteine residues are likely to be oxidized.  Regardless of the state of 
the cysteines (oxidized or reduced), a shift should be observed in the presence of both 
DTT and alkylator.  The NEM treatment did not yield a large enough shift to be 
convincing by SDS-PAGE (Figure 1.21, left) so MAL-PEG was used on purified 
OrfYH6 (Figure 1.21, center and right) since it would add ~ 5 kDa per modified cysteine.  
SDS-PAGE urea gels were used to hopefully get better band resolution; however urea 
does not seem to help as smears and fuzzy bands were observed.  Since 12% gels led to 
OrfYH6 migrating to the very bottom of the gel (Figure 1.18) and 15% caused smearing 
(Figure 1.20), 13.5% gels should be used.  Previous studies have reported that MAL-PEG 
alkylation caused a greater mass shift of 10-15 kDa than the expected 5 kDa by SDS-
PAGE [29].  OrfYH6 treated with MAL-PEG in the absence of DTT showed a smear at ~ 
25 kDa.  In reducing conditions, a smear was observed at higher molecular weights, 
however it is unclear how many MAL-PEG residues are attached to OrfYH6 (Figure 1.21, 
right).  Together with the tandem MS data obtained thus far (Figure 1.16) and the 



















































reduced or not.  More samples and new gels (i.e. 13.5% acrylamide) will have to be used 
to resolve the different molecular weight species due to alkylation. 
 
An attempt at isolating MAL-PEG-modified OrfYH6 (no DTT) using Ni-NTA spin 
columns failed (Figure 1.21, right, last lane) in order to eventually use that method to 
concentrate OrfYH6 isolated from the periplasm.  One reason is that a small amount of 
protein was input (45 ug protein) onto the spin-column for recommended elution volume 
(>200 uL). 
 
Periplasmic Isolation of OrfYH6 
 OrfY was predicted to be an exported protein by SignalP 3.0 (Figure 1.13) and 
ESI-MS data supports N-term processing of OrfYH6.  Many, but not all, secreted and/or 
periplasmic proteins undergo N-term processing.  To test this hypothesis, OrfYH6 
periplasmic isolations were attempted. 
 
 In prep 1, cells were lysed by osmotic shock [18]; however, the OrfYH6 in the 
periplasmic fraction was extremely dilute, well below the level of detection by SDS-
PAGE and Coomassie staining (data not shown).  Lysozyme was used in another 
periplasmic isolation and was utilized in prep 2, followed by a freeze-thaw protocol [19].  




Figure 1.22  Periplasmic isolation of OrfYH6 using lysozyme (prep 2).   























































Once again, the isolated OrfYH6 was very dilute and below the detection level of 
Coomassie staining.  Lysozyme and OrfYH6 are very close in size and were observed to 
migrate closely on SDS-PAGE (Figure 1.22).  A higher percentage gel may be useful for 
better resolution of both proteins as it is unclear if OrfYH6 is present at all; a Western 
blot was performed using an anti-His antibody to determine the presence of OrfYH6 
(Figure 1.23). 
 
Figure 1.23  Western blot visualization of periplasmic OrfYH6. 
Santa Cruz H-15 anti-His probe was used.  Left, SDS-PAGE (9% acrylamide), 10 ug/lane.  
Left, chemiluminescence signal after 1 min exposure. 
 
 
OrfYH6 migrated with the dye front; however, successful probing of periplasmic 
OrfYH6 and previously purified protein was observed.  As expected, lysozyme was not 
detected by Western blot.  The Western protocol seemed to work well and periplasmic 
OrfYH6 was isolated although very dilute.  Switching some of the steps around may 
increase yield.  In prep 3, ammonium sulfate was performed after running the affinity 
column; however, there was still 4 mM EDTA, which was enough to strip the Ni-NTA 
column.  The flowthrough was dialyzed and the affinity purification was repeated.  As in 
the OrfYH6 prep 1, flaky precipitate after overnight dialysis (no buffer changes) was 
observed so dialysis should be avoided.  No signal by Western blot was observed in preps 
























































Prep 5.  The protocol for prep 3 was attempted again since no OrfYH6 was detected by 
Western blot.  OrfYH6 was once again very dilute and was not visualized on SDS-PAGE 
by Coomassie staining (data not shown).  A Western was performed using anti-His and 
the custom antisera from Cocalico (Figure 1.24). 
 
 
Figure 1.24  Western blot for the periplasmic isolation of OrfYH6 prep 5.   
Different primary antibodies were used:  left, anti-His (Santa Cruz); center, custom 
antiserum from PU80 rabbit (Cocalico); right, custom antiserum from PU81 rabbit 
(Cocalico).  The last 2 lanes denoted “OrfYH6” were from prep 1. 
 
The secondary bleed antiserum from Cocalico (note that this periplasmic prep was 
performed before the OrfYH6 antibody was purified) were able to successfully detect 
purified OrfYH6 but not the periplasmic form likely due to exported OrfYH6 being too 
dilute. 
 
Prep 6.  Issues encountered in previous preps included using too much lysozyme and a 
very dilute periplasmic fraction, both of which contributed to visualizing OrfYH6 
difficult by SDS-PAGE.  Cells were resuspended in a smaller amount of buffer (5 mL/g 


































































































The gels for the periplasmic purification attempt and Western are shown in Figure 1.25. 
 
 
Figure 1.25  Periplasmic isolation of OrfYH6 prep 6.   
Left, isolation of OrfYH6 from periplasmic and spheroplasts (periplasmic fraction: 12 ug; 
periplasmic OrfYH6: 6 ug; spheroplast solubly lysate: 22 ug; spheroplast OrfYH6: 6 ug; 
other lanes: protein concentration not determined).  Center, Coomassie gel for Western 
blot analysis of periplasmic fractions for OrfYH6 (5 ug protein/lane).  Right, Western 
blot detection of OrfYH6 (5 ug protein/lane) using the purified anti-OrfYH6 custom 
antibody (Cocalico), 5 min exposure.  SDS-PAGE (13.5% acrylamide).  Legend:  M - 
marker; P - periplasmic fraction; D - dialyzed periplasmic fraction; FT - flowthrough; W 
- wash; C - crude; S - soluble; SO - spheroplast (cytoplasmic) OrfYH6; PO - periplasmic 
OrfYH6; O - purified OrfYH6 from total lysate (prep 11). 
 
The amount of lysozyme loaded onto the SDS-PAGE gels in Figure 1.25, left, was 
determined to be 1.5 ug in the periplasmic fraction lane.  By SDS-PAGE, it is unclear if 
the protein band at ~ 12 kDa is OrfYH6 or lysozyme, but it is present in all the lanes, 
including the spheroplasts (cytoplasmic) fractions with the exception of the periplasmic 
wash.  Previous experience with the periplasmic fraction was the inability to detect much 
protein since it was so dilute.  A Western blot was performed on the periplasmic, 
dialyzed periplasmic, purified periplasmic OrfYH6 and previously purified OrfYH6 from 
total cells (prep 11) as a positive control (Figure 1.25, center and right).  The anti-
OrfYH6 antibody was found to have some non-specific interaction with the protein 
marker; however, as expected, a strong signal was observed for the isolated monomeric 
OrfYH6 (Figure 25, right, last lane, band at ~ 12 kDa).  A strong signal at ~25 kDa, 
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OrfYH6 antibody in the pre and post-dialysis periplasmic fraction (Figure 1.25, right), 
but the monomeric form of OrfYH6 was not detected.  The SDS-PAGE loading buffer 
contained 300 mM BME yet the dimer was resistant to denaturing and reducing 
conditions.  One hypothesis is that OrfYH6 exists as a dimer in the periplasm and binds a 
metabolite (maybe iron?).  No signal for the monomeric or the dimeric forms of OrfYH6 
were observed after the Ni-NTA spin column was used (Figure 1.25, right, PO lane), 
which suggests that the His tags of OrfYH6 in the dimer failed to interact with the resin.  
It is important to note that isolated OrfYH6 from total lysate has yielded the monomeric 
form, although a faint dimer was observed by SDS-PAGE in crude/soluble lysates 
(Figure 1.8).  It has not yet been determined if the dimer flowed through and/or came out 
in the wash (flowthrough and wash have not been tested by Western blot).  One possible 
explanation for the OrfYH6 dimer failing to interact with the Ni-NTA resin is that the 
His-tags become buried upon dimer formation and are no longer solvent-exposed.  A 
larger tag (i.e. GST) could be used however its size may interfere with dimer formation. 
 
PurSQLH6 (pJK606) 
 B. subtilis FS, composed of PurS, PurQ, and PurL, was purified and assembled in 
vitro [7] in the presence of small metabolites.  If AaFS behaves like BsFS, the complex 
could be co-purified using the pJK606 construct since it encodes for PurS, PurQ, and 
PurLH6.  Prep 1 buffers did not contain any metabolites.  Although not much PurL or 
PurQ was expressed, some PurLH6 and PurQ enrichment was observed (data not shown); 
however, since the buffer only contained 100 mM KCl, higher salt may help with 
maintaining electrostatic interactions between subunits. 
 
 C41(DE3) carrying the pREP4-GroESL and pJK606 constructs successfully 
expressed GroEL and GroES but failed to produce PurSQLH6 (data not shown).  PurS 
could have migrated with GroES in the dye front.  A band migrating at ~ 25 kDa was 
observed and could correspond to PurQ (data not shown); however, there still is work to 





Batch purifications using the Ni-NTA spin columns proved unsuccessful as well (data not 
shown) mainly due to the small amount of starting recombinant protein.  A quick and 
dirty attempt where a larger pellet was processed and a Ni-NTA column was used for co-
purification in the presence of metabolites is shown in Figure 1.26. 
 
 
Figure 1.26  PurSQLH6 pulldown in the presence of metabolites.   
SDS-PAGE (15% acrylamide), 10 uL/lane undiluted (protein concentration unknown).  
Legend:  PSS - post streptomycin sulfate, FT - flowthrough. 
 
The elution fractions were dirty, due to the small volume of wash buffer applied (1 
column volume), but bands that could correspond to PurS, PurQ and PurL were able to be 
visualized.  A 15% acrylamide gel was used here for better visualization of PurS.  The 
presence of small metabolites ATP, ADP, glutamine, or combinations of those did not 
seem to improve complex formation for co-isolation.  PurS seemed to be enriched 
compared to PurQ and PurL, maybe due to the 2 PurS : 1 PurQ : 1 PurL as previously 
described in BsFS [3, 7] and TmFS [5].  Since PurQ was found to be insoluble even in 
the presence of PurL (Figure 1.9), characterization of AaFS may best be achieved by 
kinetic studies of a ΔpurL BL21(DE3) strain overexpressing pJK605 (PurSQL) or 
pJK606 (PurSQLH6). 
 
Ammonium sulfate fractionation of PurS (pJK533).  The salting out profile of PurS is 
































































Figure 1.27  Ammonium sulfate fractionation of PurS (pJK533).   
SDS-PAGE (15%), 5 ug protein/lane.  The six right-most lanes are the ammonium sulfate 
cuts (numbers denote percentages). 
 
PurS seems to precipitate out of solution in all cuts; however, the cleanest and most 
highly concentrated (at 26 mg/mL) cut was the 35-45% cut, which will be used in 
subsequent purifications.  No further work on untagged PurS was performed. 
 
H6PurS (pJK620).  Some H6PurS was isolated from the pJK522 construct, however, 
pJK522 also coded for H6OrfY, which was not isolated due to an N-terminal truncation 
(consistent with ESI-MS data).  The N-terminal His tag on PurS should not affect FS 
complex formation as crystal structures show it to be solvent exposed even when PurS 
was crystallized alone [5, 30].  The pJK620 construct only encodes for H6PurS.  The 






Figure 1.28  Purification of H6PurS (pJK620). 




Fractions 2 and 3 were pooled and a total of 20 mg H6PurS was isolated from 1 L of cells.  
No further characterization has been done for H6PurS. 
 
PurQ.   
Co-expression of PurQ with pREP4-GroESL.  In the preliminary co-expression studies 
above, PurQ was observed to be produced in large amounts but as an insoluble protein.  
Co-expression of PurQ with pREP4-GroESL may help solubilize PurQ.  Different 
expression temperatures were tested and the gel is shown in Figure 1.29. 
 
 
Figure 1.29  Co-expression of PurQ (pJK555) with plasmid pREP4-GroESL. 
Protein expression was tested at 15°C, 30°C, and 37°C.  SDS-PAGE (12%), 10 uL/lane 






































The presence of GroESL does not seem to improve PurQ solubility regardless of the 
growth temperature.  Other alternatives to solubilize PurQ are inclusion body preps or 
fusion constructs.   
 
Inclusion body prep of PurQ (pJK555).  Co-expression of PurQ with GroESL failed to 
improve PurQ solubility so inclusion body prep was attempted (Figure 1.30). 
 
 
Figure 1.30  Inclusion body prep of PurQ (pJK555).   
SDS-PAGE (12%), 10 uL/lane (crude and soluble samples diluted 1:5). 
 
 
Extraction was successful and it looks like inclusion body prep will work for PurQ, 
although the presence of double bands may be due to proteolytic cleavage.  Refolding of 
denatured PurQ was not attempted. 
 
PurL 
H6PurL (pJK622).  Protein-protein interaction interfaces between PurS, PurQ, and PurL 
are currently unknown for the AaFS complex.  The TmFS complex shows that both the C 
and N-termini of PurL are solvent exposed [5].  The elution and final purification gels are 





Figure 1.31  Purification of H6PurL (pJK622).   
Left, elution gel, 10 uL/lane (protein concentration unknown).  Right, final purification 
gel, 5 ug/lane.  SDS-PAGE (9% acrylamide). 
 
Fractions 3 and 4 were pooled.  The column was overloaded as a lot of unbound H6PurL 
was observed in the flowthrough.  11 mg of protein was isolated with some lower 
molecular weight contaminating proteins, however a bigger column should be used for 
future isolations. 
 
PurLH6 (pJK575).  The C-terminally tagged PurL was also isolated and the gels are 
shown in Figure 1.32   
 
 
Figure 1.32  Purification of PurLH6 (pJK575).   
Left, elution profile, 10 uL/lane.  Right, final purification gel, 5 ug/lane.  SDS-PAGE 
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Fractions 7-9 were pooled and 12 mg were isolated.  This prep was sent to Cocalico 
Biologicals in order to get a custom antibody made for PurLH6.  As for the OrfYH6 
antibody, PurLH6 antiserum was affinity purified and tested via dot blot (Figure 1.33). 
 
 
 Figure 1.33  Dot blot for purified PurLH6 antibody.   
4 ug each of PurLH6, lysozyme, E. coli, and A. aceti lysates were spotted on 
nitrocellulose membrane.  30 min exposure using the ChemImager.  Image is reverse of 
original and auto-contrast was used. 
 
 
The Prozone effect was observed, where a stronger signal was observed at the lower 
dilution (1:20,000) than at the higher dilution (1:5,000).  According to J. Whitesell 
(Cocalico), the ELISA results also reflect this effect.  The Prozone effect [31] occurs 
when there is more antibody than there is antigen, the antibody of interest cannot attach 
to the antigen due to the presence of other antibodies so a lower signal is observed at the 
lower dilution than at the higher dilution.  The purified antibody will be used at a 
1:20,000 dilution and it has not yet been tested for Western blots.  The purified antibody 
will not only be able to be used for Westerns but also pull-down of the AaFS complex, 




 OrfYH6 was isolated on multiple occasions from total cell lysate and was 
observed to be monomeric and stable at 4°C for over a year in 50 mM Tris pH 8.0, 300 
mM KCl at a concentration of 4.3 mg/mL to 7.5 mg/mL.  Overnight dialysis of OrfYH6 



















the next morning.  The higher amount of salt (300 mM KCl) in the buffer led to a greater 
yield of purified OrfYH6.  From nickel affinity chromatography, the majority of the 
isolated species was observed to be monomeric by reducing and denaturing SDS-PAGE; 
the Western blot in Figure 1.19 suggests that some OrfYH6 dimer was detected in the 
purified fraction.  ESI-MS data supported the prediction of an N-terminally processed 
protein; however further work needs to be performed in isolating OrfYH6 in the 
periplasm so the identity of the cysteine residues (oxidized or reduced) and why the 
dimer is visible by reducing SDS-PAGE can be elucidated.  Current hypotheses are that 
OrfYH6 may contain disulfide bonds or that it could be involved in binding iron for iron-
sulfur cluster biogenesis due to the proximity of bolA and grx (Chapter 4).  The dimer 
was also detected by Western blot in the periplasmic OrfYH6 isolation prep 6 (Figure 
1.25) and potentially rules out the disulfide hypothesis since the dimer subunits would 
become monomeric in reducing SDS-PAGE sample buffer.  Conclusions cannot be 
drawn at this time for the oxidized or reduced states of the cysteines within OrfYH6 from 
tandem-MS and MAL-PEG alkylation data.  Optimization for the enrichment of the 
periplasmic OrfYH6 dimer should consider the possibility of the C-term His-tags being 
buried upon dimer formation as no signal at ~ 25 kDa was detected by Western blot in 
the Ni-NTA resin elution fraction (Figure 1.25). 
 
 Tagged FS proteins (H6PurS, H6PurL, and PurLH6) have been isolated except for 
H6PurQ which was found to be insoluble like the untagged protein.  None of the 
untagged AaFS proteins were isolated, but some preliminary work was done for the 
ammonium sulfate fractionation of PurS (pJK533). 
 
 Further work will have to be performed on the co-purification of the AaFS 
complex.  Preliminary results suggest that the PurSQL complex may not require 
metabolites (ATP, ADP, and/or glutamine) to assemble; however due to the low amount 
of starting recombinant protein, protein expression for the pJK606 construct may have to 
be optimized.  Enzymatic characterization of the active AaFS complex may be performed 
in a ΔpurL BL21(DE3) strain as an alternative to purifying the complex; however 




will make the purification of the individual subunit difficult and unlike BsFS, the 
presence of PurL does not drive PurQ into the soluble fraction significantly [7].  
Functional complementation studies (Chapter 2) have determined that functional AaFS is 
composed of PurS, PurQ, and PurL, although the stoichiometry of the subunits is still 
unknown.  If enough AaFS can be co-purified, gel filtration or Edman degradation and 
crystallization could be performed to define the subunit composition stoichiometry of 
AaFS. 
 
 Anti-OrfYH6 and anti-PurLH6 antibodies were generated and will be useful to 
detect OrfY and PurL in A. aceti crude lysates, where their expression levels may be low, 
depending on the culture conditions, which have yet to be developed for A. aceti 
(preliminary work in Chapter 5).  For Westerns, the final dilutions for probing were 
1:10,000 for the anti-OrfYH6 and 1:20,000 for the anti-PurLH6 antibodies.  The 
antibodies could also be used for immunoprecipitation of any interacting partners (for 
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CHAPTER 2. FUNCTIONAL COMPLEMENTATION STUDIES OF AAFS 
2.1 Introduction 
 Previous characterizations of FS have revealed the existence of a complex of 
single domain proteins versus one large multi-domain protein, both of which are able to 
catalyze the same reaction, the conversion of FGAR, ATP, and L-Gln to FGAM, ADP, Pi, 
and L-Glu [1-7].  Gene cluster alignments suggest that AaFS is composed of PurS, PurQ 
and PurL (Chapter 1); however the presence of orfY is unexpected.  OrfY can be found in 
the genomes of other α-proteobacteria but to date, there are no characterized OrfY 
orthologs.  This chapter focuses on functional complementation studies of the AaFS 
genes in a ΔpurL E. coli strain. 
 
2.2 Materials and Methods 
Materials 
All materials and chemicals were from Sigma Aldrich or Fisher Scientific and of the 
highest purity unless otherwise noted.  E. coli Keio JW2541 (ΔpurL::kanR) and parent 
(wild-type) BW25113 strains were obtained from the Keio Collection [8].  pET vectors 





Table 2.1 Oligodeoxynucleotides used in this chapter. 





aLetters shown in lower case code for mutagenesis. 
 
Table 2.2 Plasmids used in this chaptera. 
pJK Vector Description Source 
530 pET23d orfYH6 Chapter 1 
531 pET23d orfY Chapter 1 
532 pET28a purQ (silA63) Chapter 1 
533 pET23d purS Chapter 1 
539 pET23a purL Chapter 1 
543 pCDF-Duet purS and purL Chapter 1 
544 pCDF-Duet purS Chapter 1 
546 pET-Duet orfY Chapter 1 
548 pET-Duet orfY and purQ Chapter 1 
549 pCDF-Duet purL Chapter 1 
555 pET23a purQ Chapter 1 
556 pET22bHT EcH6purLb This study 
567 pCDF-Duet orfY Chapter 1 
598 pET23a purS-orfY-purQ-purLa Chapter 1 
599 pET23a purS-orfY-purQ-purLH6a Chapter 1 
605 pET23a purS-purQ-purLa Chapter 1 
606 pET23a purS-purQ-purLH6a Chapter 1 
610 pET23a purQ-purLa Chapter 1 
623 pET23a orfY-purQ-purLa Chapter 1 
674 pET22bHT EcH6purL2 [9] 
NA pCP20 FLP recombinase [8] 
aHyphens indicate overlapping genes (as in the native A. aceti sequence).  bEc indicates 
the E. coli gene.  NA - not applicable 
 
Media were supplemented with antibiotics in the final concentrations as follows:  Amp 
(ampicillin, 100 ug/mL) for overnight cultures or Cb (carbenicillin, 100 ug/mL) for long-




Repaired E. coli H6purL construct plasmid pJK556.  QuikChange mutagenesis (Qiagen) 
was performed on pJK674 [9] to repair a frame shift mutation using ODNs 2154 and 
2155. 
 
Preparation of competent cells.  Keio JW2541 cells were made competent for 
transformation as previously described [10]. 
 
Keio strain JW2541 kanamycin cassette pop-out.  The kanamycin cassette was removed 
by homologous recombination as previously described [11] by transforming pCP20 [12] 
into the strain of interest.  In short, pCP20-transformed JW2541 cells were plated and 
grown for 42 hrs at room temperature on LB-Amp.  The pCP20 plasmid was obtained 
from Charles Constantine’s -20°C box and no glycerol stocks were made from the 
intermediate strains.  A single colony was picked to inoculate a 5 mL LB culture (no 
antibiotics) and grown for 4 hrs at 42°C to induce expression of FLP [12].   After making 
a 1:1000 dilution, 50 uL of cells were plated on LB, LB-Amp, and LB-Kan, to test for 
loss of antibiotic resistance and of the plasmid.  The plates were incubated at 42°C 
overnight.  To further confirm loss of the kanamycin cassette to generate Keio JW2541 
KanS, colony PCR was performed on colonies from the LB plate using ODNs 2146 and 
2147.   
 
Complementation on M9 minimal medium.  Procedure adapted from [13, 14].  Keio 
JW2541 KanR and KanS were transformed with pET23a, AaFS plasmids, or pJK674 [9].  
For growth on solid M9 medium, a single colony was used to inoculate a 5 mL LB 
culture and grown at 37°C to OD600 ~ 0.5 (~3 hr).  Cultures were diluted to a final OD600 
of 0.0005 and 50 uL was plated on M9 agar plates supplemented with 
antibiotic(s)/thiamin or antibiotic(s)/thiamin/hypoxanthine (10 uM thiamin and 1.5 
ug/mL hypoxanthine final).  Antibiotics are listed in Table 2.3.  For growth in liquid M9 
medium, single colony was used to inoculate a 5-mL LB culture and grown at 37°C to 
OD600 ~ 0.5 (~3 hr).  Cells were harvested at 4,000 rpm, 10 min and washed with M9 
medium.  250 mL Klett flasks containing 50 mL of M9 minimal medium (supplemented 




The cultures were grown at 37°C (200 rpm) and growth was monitored using a Klett-
Summerson colorimeter (blue filter #42, spectral range 400-465 nm).  No other filter was 
available at the time. 
 
Table 2.3 Antibiotic list used in the M9 medium.   
  Antibiotics 
Plasmid(s) JW2541 Kan Cb Stm 
No plasmid KanR + - - 
pET23a (Empty Vector, EV) KanR + + - 
544 (purS) + 531 (orfY) KanS - + + 
544 (purS) + 532 (purQ) KanS + - + 
543 (purS and purL) KanS - - + 
548 (orfY and purQ) KanS - + - 
530 (orfY) + 549 (purL) KanR + + + 
532 (H6purQ) + 549 (purL) KanR + - + 
544 (purS) + 548 (orfY and purQ) KanS - + + 
543 (purS and purL )+ 531 (orfY) KanS - + + 
548 (orfY and purQ) + 549 (purL) KanS - + + 
532 (H6purQ) + 543 (purS + purL) KanS + - + 
543 (purS and purL) + 548 (orfY and purQ) KanR + + + 
539 (purL) KanR - + - 
533 (purS) KanS - + - 
531 (orfY) KanS - + - 
532 (H6purQ) KanS + - - 
+ denotes use, - omission. R resistant, S sensitive. 
 
Complementation on MOPS minimal medium.  Growth medium was prepared as 
previously described [15, 16].  The M9 protocol was followed as described above using 
JW2541 KanS but 1X MOPS was used to wash the cells twice.  For the second liquid 
complementation (8 hr intervals), the green filter #54 (spectral range 500-570 nm) was 
used for a closer approximation to typical O.D.600 nm  readings.  All media were 
supplemented with Amp or Cb since only overlapping gene constructs for AaFS genes 





96-well plate format (MOPS).  Nina Serratore helped with setting up a 96-well plate 
growth assay on the Briggs lab Biotek Synergy 4 heated microplate reader.  Each well 
contained 150 uL of media (n=3 for each strain ± hypoxanthine) and 2xMOPS-washed 
cells were used to inoculate the wells to a final O.D.600 nm of 0.005.  The plate that was 
used was a sample from MidSci (Brandplates(R) pureGrade S, Ref. 781660, U-bottom).  
The instrument parameters were for a Grainer 96 round bottom plate, set point 
temperature of 37°C, shake: fast (continuously), (A) 600 nm, and read every 2 hrs.  Blank 
and WT wells did not contain any carbenicillin; however all wells contained thiamin.  
Unused wells were filled with 150 uL sterile water and the sides of the plate were 
parafilmed to minimize evaporation effects. 
 
 
2.3 Results and Discussion 
Complementation in M9.  Keio JW2541 KanS and KanR were used for the 
complementation on M9 medium (solid or liquid).  Since 2 different strains were used 
those results were not comparable.  Additionally the cells were not washed so some 
growth was observed on all plates, even on the negative control, pET23a.  Despite those 
mistakes, the major trend was that the addition of thiamin and hypoxanthine helped 
growth.  Studies of liquid cultures would better resolve the differences between growth 
phases better in the different constructs (e.g. lag phase).  Klett flasks were used in order 
to minimize contamination opportunities as the flasks do not need to be open to take 
aliquots for turbidity readings.  In the liquid cultures, pJK674 [9], which was used as a 
positive control, did not complement as well as expected (data not shown), and 
sequencing revealed a base insertion at position 51 (right after the N-term His-tag), 
multiple silent mutations (G729, G761, G769, L770, S803, V811, P817, A1043, V1044, 
and V1223), and a N869E missense mutation, the latter which seems to be located on the 
surface of the protein (based on the Salmonella typhimurium PurL structure (PDB: 1T3T 
[6]).  The frame-shift was repaired by site-directed mutagenesis to yield pJK556.  It is 





Complementation in MOPS Minimal Medium.  The recipe for M9 does not contain metal 
supplements (i.e. iron) whose presence may be necessary for growth so MOPS minimal  
medium [15] was chosen.  Figure 2.1 shows the preliminary MOPS growth curves. 
 
 
Figure 2.1  Preliminary MOPS growth curves.   
Constructs used were pET23a (empty vector, EV), pJK556 (EcH6L, labeled EcL); 
pJK539 (AaL); pJK598 (SYQL); pJK599 (SYQLH6); pJK605 (SQL); and pJK606 
(SQLH6). 
 
The E. coli H6PurL (pJK556) successfully complemented the deletion strain in the 
thiamin only medium.  Cells transformed with the empty vector pET23a showed poor 
growth in thiamin only medium (the curve is hidden underneath AaL, A. aceti PurL 
alone), but it should be noted that the culture touched the foil lid at 48 hours therefore 
time points thereafter were omitted due to possible contamination.  Cells carrying the 






















































aceti PurL showed very poor complementation.  The presence of the C-term His tag on 
PurL did not affect its ability to complement the purL deletion in JW2541 for the 
constructs containing PurS-PurQ-PurL (SQL) and PurS-OrfY-PurQ-PurL (SYQL).  It is 
important to note that the wild type E. coli BW25113 strain was not tested here. 
 
 Functional AaFS seems to be composed of PurS, PurQ, and PurL as the SQL and 
EcH6PurL lag phases were very similar.  The stoichiometry of the subunits required for a 
functional AaFS complex cannot be determined from these functional complementation 
studies. The presence of OrfY seems to delay reaching stationary phase and is not 
necessary for FS complementation as observed by the growth of SQL being similar to 
that of E. coli H6PurL.  The presence of a His-tag at the C-term of AaPurL does not seem 
to affect complex formation and complementation ability.  The observed growth of AaL 
after 64 hrs may be due to high enough concentrations of free ammonia in the medium.  
Previous B. subtilis in vitro characterization determined that small PurL had 50-fold less 
activity when enough ammonia was in the assay buffer compared to PurL complexed 
with PurS and PurQ [2].   
 
The growth curves were repeated once the QL and YQL constructs were obtained (pJK 
610 and pJK 623, respectively), with monitoring at 8 hr intervals in MOPS minimal 
medium are summarized in Figure 2.2 (error bars included) and Figure 2.3 (error bars 
omitted).  Figures 2.4 and 2.5 show the unaveraged curves for each strain.  It is important 
to note that the wild type E. coli BW25113 strain did not grow when monitored for 80 hrs 
in thiamin or thiamin and hypoxanthine-supplemented MOPS medium (one biological 





Figure 2.2  Functional complementation of AaFS proteins in JW2541 KanS in MOPS 
minimal medium including error bars.   
Biological replicates were n = 3.  Constructs used were pET23a (EV), pJK556 (EcH6L); 






















































Figure 2.3  Functional complementation of AaFS proteins in JW2541 KanS in MOPS 
minimal medium excluding error bars.   
Biological replicates were n = 3.  Constructs used were pET23a (EV), pJK556 (EcH6L); 






















































Figure 2.4  Unaveraged curves for JW2541 KanS in MOPS minimal medium with thiamin.   
Constructs used were pET23a (EV), pJK556 (EcH6L); pJK539 (AaL); pJK598 (SYQL); 












































































































































Figure 2.5  Unaveraged curves for JW2541 KanS in MOPS minimal medium with thiamin 
and hypoxanthine.   
Constructs used were pET23a (EV), pJK556 (EcH6L); pJK539 (AaL); pJK598 (SYQL); 
pJK605 (SQL); pJK610 (QL); and pJK623 (YQL). 
 
 
As previously observed, SQL grew similarly if not better than EcH6L.  SYQL showed a 









































































































































significant delay in the lag phase and the EV curve surprisingly mirrored the QL growth 
profile, where growth was not expected.  Upon disposal, cultures smelled sweet therefore 
growth observed after 72 hrs may not have been solely E. coli JW2541.  Cells containing 
YQL did not grow much at all and an unpredictable growth pattern was observed for AaL 
(one culture did not grow at all, the second started at 72 hrs, and the third at 96 hrs). 
 
 A higher concentration of hypoxanthine may have to be supplemented as cultures 
containing nonfunctional AaFS constructs (i.e. AaL, YQL, and EV) could not grow past a 
Klett reading of 100 (O.D.600 nm equivalents still have not been determined experimentally - 
the Klett meter manual suggests the use of R = 1000 x D / 2 for conversion, where R: 
Klett reading; D: optical density, so 100 Klett units would correspond to 0.2 O.D. 
according to the formula).  The other strains thrived as they carried the right combination 
of AaFS genes to make up active AaFS.   
 
 Use of the green filter (#54, spectral range 500-570 nm) rather than the blue filter 
(#42, spectral range 400-465 nm) on the Klett meter gave lower readings likely due to the 
absorbance of compounds (i.e. flavins) in the blue filter range.  When the Klett meters 
were first obtained from Vic Rodwell, no other filters other than the blue one were 
available.   
 
96-well plate MOPS complementation.  The 8-hr interval readings used previously were 
too far apart to monitor the lag phase.  Nina Serratore (Briggs laboratory) had been using 
a heated microplate reader for growth curves so experimental parameters were designed 
according to her experience.  150 uL of MOPS minimal medium were inoculated at a 
starting O.D.600 nm and monitored every two hours (n = 3).  Figures 2.6 through 2.8 show 





Figure 2.6  Averaged curves for the 96-well plate complementation with error bars for 
BW25113 (WT) and JW2541 KanS in MOPS + thiamin.   
Constructs were pET23a (EV), pJK556 (EcH6L); pJK539 (AaL); pJK598 (SYQL); 

























































Figure 2.7  Averaged curves for the 96-well plate complementation without error bars for 
BW25113 (WT) and JW2541 KanS in MOPS + thiamin.   
Constructs were pET23a (EV), pJK556 (EcH6L); pJK539 (AaL); pJK598 (SYQL); 

























































Figure 2.8  Unaveraged curves for the 96-well plate complementation for BW25113 (WT) 
and JW2541 KanS in MOPS + thiamin or MOPS + thiamin + hypoxanthine.   
Constructs were pET23a (EV), pJK556 (EcH6L); pJK539 (AaL); pJK598 (SYQL); 









































































































































































































































































































































The WT strain (BW25113) grew the best out of all of the strains tested and reached a 
maximum O.D.600 nm of ~ 1.2 (Figures 2.6-2.8).  No other strain was able to reach that high 
of an O.D. thus indicating that the leakiness of the pET constructs was not enough to 
complement the purL deletion.  JW2541 may have to have the genes of interest inserted 
into the genome for full complementation of the purL deletion. 
 
 No contamination was observed in the blanks over the course of 70 hrs (Figure 8, 
± hypoxanthine).  Some of the curves suddenly dipped in the middle of the growth (i.e. 
MOPS+Thiamin EcH6L), showed biphasic growth (i.e. MOPS+Thiamin SYQL and 
MOPS+Thiamin+Hypoxanthine QL), or suddenly dropped and stabilized (i.e.  
MOPS+Thiamin EV, AaL, SQL) (Figure 2.8).  Nina Serratore did not observe any 
anomalies in her yeast growth curves but Luyen Nguyen and Michael Melesse mentioned 
some inconsistencies in theirs (i.e. the instrument appeared to reset itself in the middle of 
a run for random wells and at random times).  Although, this experiment should be 
repeated when the instrument issues are fixed, the same general trends observed in the 
100 mL scale were seen in the 96-well plate format (Figures 2.6 and 2.7):  SQL entered 
the lag phase sooner than EcH6L and the latter grew better than SYQL.  A delay in lag 
phase was observed for EV, AaL, and QL (Figures 2.6-2.8).  Growth of the YQL strain 
was not observed in the 100 mL scale however, in the 150 uL scale, a variable delay in 
entering the lag phase was observed at  20, 30, 40 hrs for no hypoxanthine and 0, 20, 30 
hrs for + hypoxanthine (Figure 2.8, ± hypoxanthine).  No growth was observed in two out 
of the three hypoxanthine SQL replicates even though those wells were inoculated.  It is 
still unclear why cells cannot grow to as high of a density as the wild type in the presence 
of hypoxanthine.   
 
 The 150 uL 96-well plate scale with starting O.D. 600 nm of 0.005 seemed to work 
well for monitoring the functional complementation of AaFS genes in JW2541.  All 
unused wells should be filled with water or fresh media to minimize evaporation, as 
recommended by Nina Serratore.  Saturation of the WT strain was observed after 16 hrs 
and the slowest growing strain, EV, after 40 hrs (Figure 2.8), so the experiment could be 





 OrfY is not required for AaFS activity and active AaFS is composed of PurS, 
PurQ, and PurL (Figure 2.4), although the stoichiometry of the subunits cannot be 
determined at this time.  PurS does not seem necessary when PurQ and PurL are present, 
but there is a significant delay in growth (unless cultures were contaminated), which may 
indicate that similarly to TmFS, PurS may contribute to an ammonia channel that links 
the glutaminase and FGAR synthetase active sites [3, 4].  The A. aceti PurS-PurQ-PurL 
(SQL) construct was observed to complement as well, if not better, than E. coli H6PurL.    
Other combinations of the AaFS genes showed a significant delay in entering the lag 
phase.  Although the wild type strain, BW25113, did not grow at the 100 mL scale (n = 
1), it did grow in the 150 uL (96-well plate) format (n = 3).  The same general trends for 
SQL, SYQL, and EcH6L were observed despite instrument issues.  Surprisingly, YQL 
growth was observed at the 150 uL scale, but with a significant delay when compared to 
WT and SQL.  It is still unclear why the different strains do not grow to the same density.  
One suggestion is to insert the genes of interest in JW2541 to test if they can complement 
the purL deletion. 
 
 The presence of OrfY was observed to cause a slight delay in the lag phase when 
the other three AaFS genes (PurS, PurQ, and PurL) were present, but no growth was 
observed in the OrfY-PurQ-PurL (YQL)-carrying strain.  Taken together with the protein 
overexpression studies (Chapter 1), OrfY may have a regulatory role on PurQ (and 
potentially PurL) and be involved in iron-sulfur biosynthesis due to the proximity of bolA 
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CHAPTER 3. CONSTRUCTION GENERATION AND ENZYME PURIFICATION 
FOR FGAR SYNTHESIS 
3.1 Introduction 
 Formylglycinamide ribonucleotide (FGAR), the FGAM synthetase (FS) substrate, 
cannot be chemically synthesized, therefore constructs for the de novo purine enzymes 
were obtained from E. coli, where they have been extensively characterized.  The de novo 
purine biosynthetic pathway begins with phosphoribosylpyrophosphate (PRPP) (Figure 




Figure 3.1  FGAR biosynthesis schema (modified from [1]).   
Legend for substrates/products:  R5P, ribose-5-phosphate; PRPP, 
phosphoribosylpyrophosphate; PRA, phosphoribosylamine; GAR, glycinamide 
ribonucleotide; FGAR, formylglycinamide ribonucleotide.  Recycling systems are 
denoted by the red (ATP regeneration) and blue circles (glutamine regeneration).  NTP, 
NDP, and NMP would have adenosine as the base. 
 
E. coli FS will be used to monitor successful FGAR synthesis via the Bratton-Marshall 










































3.2 Materials and Methods 
Materials 
All materials were from Sigma Aldrich or Fisher Scientific and of the highest purity 
unless otherwise noted.  Vent DNA polymerase, OneTaq polymerase, all restriction 
endonucleases, T4 DNA ligase, and T4 polynucleotide kinase were from New England 
Biolabs.  Phusion Hot Start polymerase was from Finnzymes.  GoTaq polymerase and 
deoxynucleotides (dATP, dGTP, dCTP, and dTTP) were from Promega.  Mutagenesis 
was performed using QuikChange Mutagenesis kits from Stratagene (Pfu Polymerase).  
Oligodeoxynucleotides (ODNs) were from Integrated DNA Technologies (Table 1).  
Plasmid Miniprep kits were from either Sigma, Fermentas Life Sciences, or Qiagen.  
QIAquick PCR Purification kit was from Qiagen.  Chemically competent DH5α cells 
were from Invitrogen.  Vectors pET23a and pET28a were from Novagen.  Centrifugation 
steps were performed on a tabletop Eppendorf 5415D centrifuge.  PCR reactions were 
performed in a Bio-Rad MyCycler Thermal Cycler or a MJ Research Inc. Programmable 
Thermal Cycler PTC-100.  
 
Table 3.1 Oligodeoxynucleotides used in construction of plasmids and sequencing. 












aLetters shown in lower case code for mutagenesis. 
 
Methods 
General cloning procedure.  Each recombinant gene was amplified by PCR with gene-




aceti 1023 genomic DNA, or plasmid DNA as specified below.  E. coli BL21(DE3) 
genomic DNA was isolated using the Promega Wizard Genomic DNA Purification kit 
according to the manufacturer’s instructions.  A. aceti 1023 genomic DNA was isolated 
using the Qiagen Genomic-tip 20/G (E. A. Mullins).  E. coli DH5α was used for cloning 
and plasmid maintenance.  All constructs were screened by restriction mapping or colony 
PCR.  All numbered plasmids were verified by DNA sequencing at the Genomics Core 
Facility DNA Sequencing Low Throughput Laboratory at Purdue University, using 
primers for both directions.  
 
Table 3.2 Plasmids used in this chaptera. 
pJK Vector Description Source 
515 pET23a EcpurTH6b TJK 
556 pET22bHT EcH6purLb Ch. 2 
592 pET23a EcpurDb This study 
614 pET23a EcpurDH6b This study 
621 pET28a EcH6purDb This study 
630 pET23d AaprsAa This study 
631 pET23d AaprsAH6a This study 
633 pET22b EcH6purMb This study 
638 pET23a EcT7purFH6b This study 
639 pET23a EcpurFH6b This study 
642 pET28a EcH6glnAb This study 
649 pET23a EcpurFb This study 
650 pET23a EcglnAb This study 
668 pET22bHT EcH6glnAb [1] 
669 pET22bHT EcH6plsAb [1] 
670 pET22bHT EcH6prsAb [1] 
673 pET22bHT EcH6purFb [1] 
675 pET22bHT EcH6purM G324Eb [1] 
aAa indicates the A. aceti gene.  bEc indicates the E. coli gene. 
 
Construction of E. coli intermediate T7-tagpurFH6 construct plasmid pJK638.  A 1.5 kb 
product was amplified from E. coli BL21(DE3) genomic DNA, using Taq Polymerase 




annealing temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, 
and 1 min 30 s for 25 cycles.  The product was purified using a Qiagen PCR purification 
kit, digested with BamHI and XhoI, and ligated into the BamHI and XhoI restriction sites 
of the destination vector pET23a to yield pJK638.  The plasmid encodes for E. coli T7-
tagPurFH6. 
 
Construction of E. coli PurFH6 construct plasmid pJK639.  pJK638 was partially 
digested with NdeI due to an additional internal NdeI site within the purF sequence 
where the reaction was stopped after 10 min by the addition of EDTA.  After using the 
Qiagen PCR purification kit, the digested DNA was re-ligated and digested with BamHI 
before transforming the reaction into DH5α cells.  The plasmid, pJK639, encodes for E. 
coli PurFH6. 
 
Construction of E. coli purF construct plasmid pJK649.  A 1.5 kb product was amplified 
from pJK639, using Vent Polymerase (New England Biolabs) and ODNs 2197 and 2334 
with an annealing temperature of 50°C and melting, annealing, and extension times of 30 
s, 1 min, and 1 min 30 s for 25 cycles.  The product was purified using a Qiagen PCR 
purification kit, digested with NdeI and XhoI.  Digestion with NdeI was limited to 5 min 
where the reaction was stopped by the addition of EDTA.  The digested PCR product was 
re-purified using a Qiagen PCR purification kit and ligated into the NdeI and XhoI 
restriction sites of the destination vector pET23a to yield pJK649.  The plasmid encodes 
for E. coli PurF.  
 
Construction of E. coli purD construct plasmid pJK592.  A 1.3 kb product was amplified 
from BL21(DE3) genomic DNA, using ODNs 2222 and 2223 with an annealing 
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 1min 
30 s for 25 cycles using Vent polymerase.  The product was purified using a Qiagen PCR 
purification kit, digested with NdeI and XhoI, and ligated into the NdeI and XhoI 
restriction sites of the destination vector pET23a to yield pJK592.  The plasmid encodes 





Construction of E. coli purDH6 construct plasmid pJK614.  A 1.3 kb product was 
amplified from BL21(DE3) genomic DNA, using ODNs 2222 and 2224 with an 
annealing temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, 
and 1min 30 s for 25 cycles using Vent polymerase.  The product was purified using a 
Qiagen PCR purification kit, digested with NdeI and XhoI, and ligated into the NdeI and 
XhoI restriction sites of the destination vector pET23a to yield pJK614.  The plasmid 
encodes for E. coli PurDH6.  
 
Construction of E. coli H6purD construct plasmid pJK621.  pJK592 was digested with 
NdeI and XhoI and ligated into the NdeI and XhoI restriction sites of the destination 
vector pET28a to yield pJK621.  The plasmid encodes for E. coli H6PurD. 
 
Construction of A. aceti prsA construct plasmid pJK630.  A 0.9 kb product was amplified 
from A. aceti strain 1023 genomic DNA, using ODNs 2219 and 2226 with an annealing 
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 30 s 
for 25 cycles using Phusion polymerase.  The product was purified using a Qiagen PCR 
purification kit, digested with NcoI and XhoI, and ligated into the NcoI and XhoI 
restriction sites of the destination vector pET23d to yield pJK630.  The plasmid encodes 
for A. aceti PrsA. 
 
Construction of A. aceti prsAH6 construct plasmid pJK631.  A 0.9 kb product was 
amplified from A. aceti strain 1023 genomic DNA, using ODNs 2219 and 2225 with an 
annealing temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, 
and 30 s for 25 cycles using Phusion polymerase.  The product was purified using a 
Qiagen PCR purification kit, digested with NcoI and XhoI, and ligated into the NcoI and 
XhoI restriction sites of the destination vector pET23d to yield pJK631.  The plasmid 
encodes for A. aceti PrsAH6. 
 
Repair of E. coli purM construct plasmid pJK633.  QuikChange mutagenesis was 





Construction of E. coli H6glnA construct plasmid pJK642.  A 1.5 kb product was 
amplified from pJK668 using Vent Polymerase (New England Biolabs) and ODNs 2332 
and 2333 with an annealing temperature of 50°C and melting, annealing, and extension 
times of 30 s, 1 min, and 1 min 30 s for 25 cycles.  The product was purified using a 
Qiagen PCR purification kit, digested with NdeI and XhoI, and ligated into the NdeI and 
XhoI restriction sites of the destination vector pET28a to yield pJK642.  The plasmid 
encodes for E. coli H6GlnA Y397F. 
 
Construction of E. coli glnA construct plasmid pJK650.  pJK642 was digested with NdeI 
and XhoI and ligated into the NdeI and XhoI sites of the destination vector pET23a to 
yield pJK650.  The plasmid encodes for E. coli GlnA Y397F. 
 
Protein expression and purification 
Underlined headers indicate the final purification protocol.  Antibiotics were used as 
follows:  Amp (ampicillin, 100 ug/mL) and Kan (kanamycin, 70 ug/mL). 
 
PurF 
E. coli H6PurF (pJK673 [1]).  Protocol adapted from Schultheisz et. al [1].  A single 
colony of BL21 (DE3) cells transformed with pJK673 [1] was used to inoculate a 50 mL 
LB-Amp starter culture and grown to saturation (37°C, 200 rpm).  1 L of ZYM-5052-
Amp medium [2] was inoculated 1:100 and grown overnight (37°C, 200 rpm).  Cells 
were harvested (5,000g, 15 min) and used immediately or stored at -80°C until use.  All 
the following steps were performed at 4°C.  The cell pellet was resuspended in 40 mL of 
50 mM Tris-HCl pH 7.5, 250 mM NaCl and disrupted by sonication using a Fisher Sonic 
Dismembrator at 20% output (3 cycles: 1 min on, 1 min off) on ice.  Cell debris was 
removed by centrifugation (30,000g, 30 min).  Streptomycin sulfate (10% w/v stock) was 
added to a final concentration of 1% w/v, incubated on ice for 10 min, then spun 
(30,000g, 10 min).  The cleared lysate was loaded onto a nickel-charged and equilibrated 
(in 50 mM Tris-HCl pH 7.5, 250 mM NaCl) Ni-NTA agarose column (1.5 cm x 1.5 cm, 




imidazole.  The protein was eluted using 250 mM imidazole in the above buffer.  Since 
the protein is catalytically inactive, it was discarded. 
 
E. coli PurFH6 (pJK639).  BL21(DE3) cells transformed with pJK639 were used to 
inoculate a 50 mL LB-Amp starter culture and grown to saturation (37°C, 200 rpm).  1 L 
of ZYM-5052-Amp [2] was inoculated 1:100 from a starter culture and grown overnight 
(37°C, 200 rpm).  The following steps were performed at 4°C.  Cells were harvested 
(5,000g, 15 min) and used immediately or stored at -80°.  All the following steps were 
performed at 4°C.  The cell pellet was resuspended in 50 mM phosphate buffer pH 7.5 (5 
mL/g pellet) and disrupted by sonication (3 cycles, 1 min on, 1 min off) at 20-25% output 
using a Fisher Sonic Dismembrator.  Cell debris was removed by centrifugation (30,000g, 
30 min).  Streptomycin sulfate (10% w/v stock) was added to a final concentration of 1% 
and the lysate was cleared by centrifugation (30,000g for 10 min).  The cleared lysate 
was loaded onto a previously equilibrated (in 50 mM phosphate buffer pH 7.5) and 
charged Ni-NTA column (1.5 cm x 4.4 cm, 7.8 mL) and the column was washed with 10 
column volumes of 10 mM imidazole in 50 mM phosphate buffer pH 7.5.  A linear 
imidazole gradient (10-500 mM in 50 mM phosphate buffer pH 7.5) was used to elute the 
protein (20 mL x 20 mL).  Fractions containing pure protein by SDS-PAGE were pooled 
and the protein was concentrated to 19.1 mg/mL using an an Amicon ultrafiltration 8050 
cell with a Millipore PL-30 membrane.  Isolated PurFH6 was stored at -80°C. 
   
E. coli PurF (pJK649).  Protocol adapted from [3, 4].  In short, BL21(DE3) cells 
transformed with pJK649 were used to inoculate a 50 mL LB-Amp starter culture and 
grown to saturation (37°C, 200 rpm).  2 L of LB-Amp were inoculated 1:100 from a 
starter culture and grown overnight (37°C, 200 rpm).  The following steps were 
performed at 4°C.  Cells were harvested (5,000g, 15 min) and used immediately or stored 
at -80°.  All the following steps were performed at 4°C.  The cell pellet was resuspended 
in Buffer A (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 5 mM MgCl2, and 1 mM glutamine 
(3.5 mL/g pellet)) and disrupted by sonication (3 cycles, 1 min on, 1 min off) at 20-25% 
output using a Fisher Sonic Dismembrator.  Cell debris was removed by centrifugation 




concentration of 1% and the lysate was cleared by centrifugation (30,000g for 10 min).  
The cleared lysate was loaded onto a previously equilibrated (in Buffer A) DEAE-
Sepharose CL6B column (2.5 x 14.5 cm, 71.2 mL) and the column was washed with 250 
mL Buffer A.  A linear ammonium sulfate gradient (0.14-0.3 M in Buffer A) was used to 
elute the protein (200 mL x 200 mL).  Fractions containing activity were pooled and 28.3 
mg protein was concentrated to 10.1 mg/mL using an an Amicon ultrafiltration 8050 cell 
with a Millipore PL-30 membrane in 57.5 mM Tris-HCl pH 7.5.  Glycerol was added to a 
final concentration of 15%.  Isolated E. coli PurF was stored at -80°C. 
 
E. coli PurD.     
E. coli PurD (pJK592) Prep 1.  Protocol adapted from [5].  BL21(DE3) cells transformed 
with pJK592 were used to inoculate a 50 mL LB-Amp starter culture and grown to 
saturation (37°C, 200 rpm).  1 L of ZYM-5052-Amp medium [2] was inoculated 1:100 
and grown overnight (37°C, 200 rpm).  Cells were harvested (5,000g, 15 min) and used 
immediately or stored at -80°.  All the following steps were performed at 4°C.  The cell 
pellet was resuspended in 50 mM KPi pH 7.5, 5 mM β-mercaptoethanol (BME), and 1 
mM phenylmethanesulfonyl fluoride (PMSF) (5 mL/g pellet) and disrupted by sonication 
(3 cycles, 1 min on, 1 min off) at 20-25% output using a Fisher Sonic Dismembrator.  
Cell debris was removed by centrifugation (30,000g, 30 min).  Streptomycin sulfate (10% 
w/v stock) was added to a final concentration of 1% and the lysate was cleared by 
centrifugation (30,000g for 10 min).  Ammonium sulfate fractionation was performed as 
described previously:  0-33% (196 g/L); 33-65% (214 g/L).  The 33-65% ammonium 
sulfate pellet was resuspended in a minimal amount of 50 mM KPi pH 7.5, 5 mM BME, 1 
mM PMSF buffer and loaded onto a Sephadex G25 medium column (2.5 cm x 34 cm, 
167 mL).  The column was developed and fractions containing protein (A280nm > 0.2) were 
pooled and loaded onto a Whatman DE52 cellulose column (2.5 cm x 29.5 cm, 145 mL).  
The DE52 column was washed with 300 mL 50 mM KPi pH 7.5, 5 mM BME, 1 mM 
PMSF buffer before the protein was eluted with a linear gradient (0-300 mM KCl, (300 
mL x 300 mL) in 50 mM KPi pH 7.5, 5 mM BME, 1 mM PMSF).  Fractions were pooled 




exchanged using an Amicon ultrafiltration 8400 cell and a YM-10 membrane.  The 
isolated protein was discarded due to lack of detectable activity. 
 
E. coli PurD (pJK592) Prep 2.  LB-IPTG was used for protein production.  1 L of LB-
Amp was inoculated 1:25 with a starter culture and grown (37°C, 200 rpm) until an 
O.D.600 ~0.7 was reached.  IPTG was then added to a final concentration of 0.4 mM from 
a 1M stock.  The culture was induced for 2.5 hrs at 37°C, and the cells were harvested.  
The same protocol as prep 1 was followed except for buffers did not contain PMSF or 
BME. 
 
E. coli PurDH6 (pJK614).  BL21(DE3) cells transformed with pJK614 were used to 
inoculate a 50 mL LB-Amp starter culture and grown to saturation (37°C, 200 rpm).  2 L 
of LB-Amp were inoculated 1:100 from a starter culture and grown overnight (37°C, 200 
rpm).  The following steps were performed at 4°C.  Cells were harvested (5,000g, 15 min) 
and used immediately or stored at -80°C.  All the following steps were performed at 4°C.  
The cell pellet was resuspended in 50 mM phosphate buffer pH 7.5 (3.5 mL/g pellet) and 
disrupted by sonication (3 cycles, 1 min on, 1 min off) at 20-25% output using a Fisher 
Sonic Dismembrator.  Cell debris was removed by centrifugation (30,000g, 30 min).  
Streptomycin sulfate (10% w/v stock) was added to a final concentration of 1% and the 
lysate was cleared by centrifugation (30,000g for 10 min).  The cleared lysate was loaded 
onto a previously equilibrated (in 50 mM phosphate buffer pH 7.5) and charged Ni-NTA 
column (1.5 cm x 4.9 cm, 8.7 mL) and the column was washed with 10 column volumes 
of 10 mM imidazole in 50 mM phosphate buffer pH 7.5.  A linear imidazole gradient (10-
500 mM) was used to elute the protein (30 mL x 30 mL).  Fractions containing pure 
protein by SDS-PAGE were pooled and the protein was concentrated to 107 mg/mL 
using an an Amicon ultrafiltration 8050 cell with a Millipore YM-10 membrane.  Isolated 
E. coli PurDH6 was discarded due to low activity. 
  
E. coli H6PurD (pJK621) Prep 1.  BL21(DE3) cells transformed with pJK621 were used 
to inoculate a 50 mL LB-Kan starter culture and grown to saturation (37°C, 200 rpm).  1 




200 rpm).  The following steps were performed at 4°C.  Cells were harvested (5,000g, 15 
min) and used immediately or stored at -80°.  All the following steps were performed at 
4°C.  The cell pellet was resuspended in 50 mM phosphate buffer pH 7.5 (5 mL/g pellet) 
and disrupted by sonication (3 cycles, 1 min on, 1 min off) at 20-25% output using a 
Fisher Sonic Dismembrator.  Cell debris was removed by centrifugation (30,000g, 30 
min).  Streptomycin sulfate (10% w/v stock) was added to a final concentration of 1% 
and the lysate was cleared by centrifugation (30,000g for 10 min).  The cleared lysate 
was loaded onto a previously equilibrated (in 50 mM phosphate buffer pH 7.5) and 
charged Ni-NTA column (1.5 cm x 4.9 cm, 8.7 mL) and the column was washed with 10 
column volumes of 10 mM imidazole in 50 mM phosphate buffer pH 7.5 buffer.  A linear 
imidazole gradient (10-500 mM in 50 mM phosphate buffer pH 7.5) was used to elute the 
protein (25 mL x 25 mL).  Fractions containing pure protein by SDS-PAGE were pooled 
and the protein (14.4 mg) was concentrated to 2.9 mg/mL using an an Amicon 
ultrafiltration 8050 cell with a Millipore PL-30 membrane.  Isolated E. coli H6PurD was 
not kept. 
 
E. coli H6PurD (pJK621) Prep 2.  Same protocol as prep 1 except 1 L ZYM-5052-Kan [2] 
was used as the production culture and 1 mM PMSF was added to the buffers.  The 
isolated protein (117 mg) was concentrated to 14.7 mg/mL and stored at -80°C. 
 
E. coli PurTH6 (pJK515).  A C41(DE3) cell pellet grown by T. J. Kappock was 
resuspended in 50 mM Tris-HCl pH 8.0 (5 mL/g cell pellet) and disrupted by sonication 
using a Fisher Sonic Dismembrator at 20% output (3 cycles: 1 min on, 1 min off) on ice.  
All the following steps were performed at 4°C.  Cell debris was removed by 
centrifugation (30,000g, 30 min).  Streptomycin sulfate (10% w/v stock) was added to a 
final concentration of 1% w/v, incubated on ice for 10 min, then spun (30,000g, 10 min).  
Ammonium sulfate fractionation was performed by the addition of solid ammonium 
sulfate over the course of 30 min and letting the solution equilibrate for another 30 min;  
0-25% (144 g/L) and 25-45% (123 g/L).  Precipitated protein was cleared by 
centrifugation (30,000g, 10 min).  The 25-45% pellet was resuspended in a minimal 




50 mM Tris-HCl pH 8.0) Ni-NTA agarose column (1.75 cm x 2.2 cm, 5.3 mL) and 
washed with 10x column volumes of 10 mM imidazole in 50 mM Tris-HCl pH 8.0.  The 
protein was eluted using a linear imidazole gradient (10-500 mM in 50 mM Tris-HCl pH 
8.0, 30 mL x 30 mL).  Fractions containing pure protein by SDS-PAGE were pooled, 
concentrated to 36.2 mg/mL (145 mg total), and buffer exchanged into 50 mM Tris-HCl 
pH 8.0 using an Amicon Ultra-15 30,000 MWCO centrifugal device (4,000 rpm, 15 min).  
Isolated E. coli PurTH6 was stored at -80°C. 
 
E. coli H6PlsA (pJK669) [1].  Protocol adapted from Schultheisz et. al [1].  A single 
colony of BL21 (DE3) cells transformed with pJK669 [1] was used to inoculate a 50 mL 
LB-Amp starter culture and grown to saturation (37°C, 200 rpm).  1 L of ZYM-5052-
Amp medium [2] was inoculated 1:100 and grown overnight (37°C, 200 rpm).  Cells 
were harvested (5,000g, 15 min) and used immediately or stored at -80°C until use.  All 
the following steps were performed at 4°C.  The cell pellet was resuspended in 40 mL of 
50 mM Tris-HCl pH 7.5, 250 mM NaCl and disrupted by sonication using a Fisher Sonic 
Dismembrator at 20% output (3 cycles: 1 min on, 1 min off) on ice.  Cell debris was 
removed by centrifugation (30,000g, 30 min).  Streptomycin sulfate (10% w/v stock) was 
added to a final concentration of 1% w/v, incubated on ice for 10 min, then spun 
(30,000g, 10 min).  The cleared lysate was loaded onto a nickel-charged and equilibrated 
(in 50 mM Tris-HCl pH 7.5, 250 mM NaCl) Ni-NTA agarose column (1.5 cm x 1.5 cm, 
2.7 mL) and washed with 10x column volumes of the above buffer with 20 mM 
imidazole.  The protein was eluted using 250 mM imidazole in the above buffer.  
Fractions containing pure protein by SDS-PAGE were pooled, concentrated to 7.5 
mg/mL (37 mg protein total), and buffer exchanged into 50 mM postassium phosphate, 5 
mM β-ME, 50% glycerol using an an Amicon ultrafiltration 8050 cell with a Millipore 
PL-5 membrane.  Isolated E. coli H6PlsA was stored at -20°C. 
 
PrsA 
E. coli H6PrsA (pJK670 [1]) prep 1.  Same protocol as for the isolation of E. coli H6PlsA 
above, using a JM109(DE3) cell pellet grown by T. J. Kappock.  The Ni-NTA column 




E. coli H6PrsA (pJK670 [1]) Prep 2.  Same protocol as prep 1 but using BL21(DE3) cells 
grown in ZYM-5052-Amp [2].   A Millipore YM-10 was used in the Amicon 
ultrafiltration 8050 cell.  The protein was discarded due to low yield. 
 
E. coli H6PrsA (pJK670 [1]) Prep 3.  Protocol adapted from [6].  In short, the BL21(DE3) 
cell pellet (ZYM-5052-Amp [2]) was resuspended in 35 mL 50 mM KPi, pH 6.9 and 
disrupted by sonication using a Fisher Sonic Dismembrator at 20-25% output (3 cycles: 1 
min on, 1 min off) on ice.  Cell debris was removed by centrifugation (30,000g, 30 min).  
Streptomycin sulfate (10% w/v stock) was added to a final concentration of 1% w/v, 
incubated on ice for 10 min, then spun (30,000g, 10 min).  The soluble lysate was heated 
to 55°C as follows.  The beaker containing lysate was placed in a boiling water bath until 
the temperature reached 54°C and transferred to a 55°C water bath for 5 min.  The 
solution was transferred into an ice cold beaker and chilled for 5 min.  Denatured proteins 
were removed by centrifugation (13,000g, 20 min).  Ammonium sulfate fractionation was 
performed as described previously:  0-35% (209 g/L).  After centrifugation, the pellet 
was resuspended in a minimal amount of 50 mM KPi, pH 6.9 buffer.  The protein was 
discarded due to low yield. 
 
E. coli H6PrsA (pJK670 [1]) Prep 4.  Protocol adapted from [7].  In short, the BL21(DE3) 
cell pellet (ZYM-5052-Amp [2]) was resuspended in 50 mM NaH2PO4 pH 8.0, 1 M NaCl 
(5 mL/g pellet) and disrupted by sonication using a Fisher Sonic Dismembrator at 20-25% 
output (3 cycles: 1 min on, 1 min off) on ice.  Cell debris was removed by centrifugation 
(30,000g, 30 min).  The soluble lysate was loaded onto a nickel-charged and equilibrated 
Ni-NTA agarose column (in 50 mM NaH2PO4 pH 8.0, 1 M NaCl, 1.5 cm x 1.5 cm, 2.7 
mL) and washed with 10x column volumes of the above buffer with 75 mM imidazole.  
The protein was eluted using 75 mM imidazole in the above buffer.  Fractions containing 
pure protein by SDS-PAGE were pooled, concentrated to 0.2 mg/mL, and buffer 
exchanged into 50 mM NaH2PO4 pH 8.0, 400 mM NaCl using an an Amicon 
ultrafiltration 8050 cell with a Millipore YM-10 membrane.  The protein was discarded 





E. coli H6PrsA (pJK670 [1]) Prep 5.  Protocol adapted from [8].  The BL21(DE3) cell 
pellet (ZYM-5052-Amp [2]) was resuspended in 50 mM KPi, pH 7.5 (5 mL/g cell pellet) 
and disrupted by sonication using a Fisher Sonic Dismembrator at 20-25% output (3 
cycles, 1 min on, 1 min off).  All the following steps were performed at 4°C.  Cell debris 
was removed by centrifugation (30,000g, 30 min).  Streptomycin sulfate (10% w/v stock) 
was added to a final concentration of 1% and the lysate was cleared by centrifugation 
(30,000g,10 min).  The streptomycin sulfate pellet was resuspended in a minimal amount 
of 50 mM KPi, pH 7.5 and dialyzed overnight against 200 volumes (1 L) of 50 mM KPi, 
pH 7.5 (no changes).  The dialyzed extract was cleared by centrifugation as above and 
loaded onto a previously equilibrated (in 50 mM KPi, pH 7.5) and charged Ni-NTA 
column (4.8 cm x 1.5 cm, 8.5 mL).  The column was washed with 10 column volumes of 
10 mM imidazole in 50 mM KPi, pH 7.5 buffer and the protein was eluted using a linear 
10-500 mM imidazole gradient in 50 mM KPi, pH 7.5 (25 mL x 25 mL, 200 drop 
fractions).  Ammonium sulfate precipitation (0-25%, 144 g/L) was performed on the 
flowthrough of the column.  The protein was stored as an ammonium sulfate 75% (516 
g/L) slurry at 4°C. 
 
A. aceti PrsAH6 (pJK631).  pJK631 was expressed in BL21(DE3) using ZYM-5052 
(37°C) [2], C41(DE3) using LB-IPTG, and C41(DE3)/pREP4-GroESL using LB-IPTG 
as described above. 
 
GlnA 
E. coli H6GlnA Y397F (pJK642) Prep 1.  BL21(DE3) cells transformed with pJK642 
were used to inoculate a 50 mL LB-Kan starter culture and grown to saturation (37°C, 
200 rpm).  1 L of ZYM-5052-Kan [2] was inoculated 1:100 from a starter culture and 
grown overnight (37°C, 200 rpm).  The following steps were performed at 4°C.  Cells 
were harvested (5,000g, 15 min) and used immediately or stored at -80°.  All the 
following steps were performed at 4°C.  The cell pellet was resuspended in 50 mM Tris-
HCl pH 8.0, 100 mM KCl (5 mL/g pellet) and disrupted by sonication (3 cycles, 1 min on, 
1 min off) at 20-25% output using a Fisher Sonic Dismembrator.  Cell debris was 




added to a final concentration of 1% and the lysate was cleared by centrifugation 
(30,000g for 10 min).  The cleared lysate was loaded onto a previously equilibrated (in 50 
mM Tris-HCl pH 8.0, 100 mM KCl) and charged Ni-NTA column (1.5 x 1.5 cm, 2.7 mL) 
and the column was washed with 10 column volumes of 10 mM imidazole buffer in 50 
mM Tris-HCl pH 8.0, 100 mM KCl.  A linear imidazole gradient (10-500 mM in 50 mM 
Tris-HCl pH 8.0, 100 mM KCl) was used to elute the protein (5 mL x 5 mL).  Fractions 
containing pure protein by SDS-PAGE were pooled and the protein was concentrated to 
2.8 mg/mL using an an Amicon ultrafiltration 8050 cell with a Millipore PL-30 
membrane.  Isolated E. coli H6GlnA Y397F was stored at -80°C. 
 
E. coli H6GlnA Y397F (pJK642) Prep 2.  Protocol adapted from [9].  In short, 
BL21(DE3) cells transformed with pJK642 were grown and harvested as in prep 1.  The 
cell pellet was resuspended in 10 mM imidazole, 50 mM MgCl2 pH 7.0 (3 mL/g pellet) 
and disrupted as in prep 1.  The pH of the soluble lysate was adjusted to pH 5.85 by the 
addition of fresh 1 M KOH or 1 M acetic acid and monitored using a pH meter.  1 g of 
solid streptomycin sulfate was added for each 100 mL of extract and equilibrated with 
mixing on ice.  The pH was again adjusted to pH 5.85 following the streptomycin sulfate 
equilibration with fresh 1 M KOH or 1 M acetic acid and monitored using a pH meter.  
The cleared supernatant (30,000g, 30 min) was brought to 25˚C using a water bath.  
ZnSO4 was added to 1.5 mM [final Zn2+] and the solution was incubated at 25˚C for 30 
min.  The precipitated protein was centrifuged (30,000g, 30 min) and the pellet was 
washed in half the original volume of cold resuspension buffer (1.5 mL/g original cell 
pellet) and centrifuged (30,000g, 30 min).  The washed protein pellet was dissolved in 2.5 
mM MgCl2, 10 mM imidazole, pH 7.0 (1.5 mL/g original cell pellet).  Insoluble material 
was pelleted (12,000g, 15 min).  MgCl2 was added to the supernatant to 50 mM [final 
MgCl2] and incubated at 25˚C for 30 min with occasional stirring (gradual increase in 
turbidity over time).  The solution was centrifuged (30,000g, 30 min).  The pellet was 
dissolved in 75% of the volume of the post-12,000g spin in 2.5 mM MgCl2, 10 mM 
imidazole, pH 7.0.  Insoluble material was removed by centrifugation (12,000g, 15 min).   





E. coli GlnA (pJK650).  Same protocol as for prep 2 for the isolation of E. coli H6GlnA.  
Following the 25˚C Mg2+ crystallization, another MgCl2 crystallization was repeated at 
37˚C as previously described [9].  In short, the same procedure as the 25˚C crystallization 
was used for the 37˚C crystallization.  The protein pellet was resuspended in a minimal 
amount of 2.5 mM MgCl2, 10 mM imidazole, pH 7.0 buffer and dialyzed overnight in 
200 volumes (1 L) of 10 mM imidazole, 100 mM KCl, 1 mM MgCl2, pH 7.0 and stored at 
4˚C as previously described [10]. 
 
E. coli H6PurL (pJK556).  A single colony of BL21(DE3) transformed with pJK556 was 
used to inoculate a 50-mL LB-Amp starter culture and grown to saturation (37°C, 200 
rpm).  1 L of ZYM-5052-Amp medium [2] was inoculated 1:100 and grown overnight 
(37°C, 200 rpm).  Cells were harvested (5,000g, 15 min) and stored at -80°C until use.  
All the following steps were performed at 4°C.  The cell pellet was resuspended in 50 
mM Tris-HCl pH 8.0, 100 mM KCl (5 mL/g pellet) and disrupted by sonication using a 
Fisher Sonic Dismembrator at 20% output (3 cycles: 1 min on, 1 min off) on ice.  Cell 
debris was removed by centrifugation (30,000g, 30 min).  Streptomycin sulfate (10% w/v 
stock) was added to a final concentration of 1% w/v, incubated on ice for 10 min, then 
spun (30,000g, 10 min).  The cleared lysate was loaded onto a previously equilibrated (50 
mM Tris-HCl pH 8.0, 100 mM KCl) and charged Ni-NTA column (4.9 cm x 1.5 cm, 8.7 
mL) and the column was washed with 10 column volumes of 10 mM imidazole buffer in 
50 mM Tris-HCl pH 8.0, 100 mM KCl.  A linear imidazole gradient (10-500 mM in 50 
mM Tris-HCl pH 8.0, 100 mM KCl) was used to elute the protein (20 mL x 20 mL).  
Fractions containing pure protein by SDS-PAGE were pooled and the protein was 
concentrated to 16.0 mg/mL using an an Amicon ultrafiltration 8050 cell with a Millipore 
PL-30 membrane.  Isolated E. coli H6PurL was stored at -80°C. 
 
E. coli H6PurM (pJK633).  BL21(DE3) cells transformed with pJK633 were used to 
inoculate a 50 mL LB-Amp starter culture and grown to saturation (37°C, 200 rpm).  1 L 
of ZYM-5052-Amp medium [2] was inoculated 1:100 and grown overnight (37°C, 200 
rpm).  Cells were harvested (5,000g, 15 min) and used immediately or stored at -80°.  All 




Tris pH 8.0, 300 mM KCl.  (5 mL/g pellet) and disrupted by sonication (3 cycles, 1 min 
on, 1 min off) at 20-25% output using a Fisher Sonic Dismembrator.  Cell debris was 
removed by centrifugation (30,000g, 30 min).  Streptomycin sulfate (10% w/v stock) was 
added to a final concentration of 1% and the lysate was cleared by centrifugation 
(30,000g for 10 min).  The cleared lysate was loaded onto a previously equilibrated (in 50 
mM Tris pH 8.0, 300 mM KCl) and charged Ni-NTA column (1.5 cm x 4.9 cm, 8.7 mL) 
and the column was washed with 5 column volumes of 10 mM imidazole in 50 mM Tris 
pH 8.0, 300 mM KCl buffer.  A linear imidazole gradient (10-500 mM in 50 mM Tris pH 
8.0, 300 mM KCl) was used to elute the protein (15 mL x 15 mL).  Fractions containing 
pure protein by SDS-PAGE were pooled and the protein was concentrated to 18.6 mg/mL 
(136 mg total) using an an Amicon ultrafiltration 8050 cell with a Millipore YM-10 
membrane.  Isolated E. coli H6PurM was stored at -80°C. 
 
Activity Assays 
PurF.  The final assay conditions for PurF were 100 mM Tris-HCl pH 8.0, 50 mM KCl, 1 
mM magnesium acetate, 2 mM glycine, 2 mM glutamine, 2 mM ATP, 2 mM PEP, 0.2 
mM NADH, 15 units/mL LDH/PK mix (Sigma P0294 solution, according to the 
manufacturer’s determined activity), 0.5 mM phosphoribosylpyrophosphate (PRPP), 5 U 
PurD, and PurF in a final volume of 700 uL.  The reaction mix was pre-incubated at 24°C 
for 2 min, and the reaction was initiated by the addition of PRPP in a quartz 0.5 mL 
cuvette (1 cm pathlength).  Enzymatic activity was monitored at 24°C in an Agilent 
diode-array spectrophotometer by the decrease at 340 nm with ε = 6200 M-1 cm-1.  No 
detectable activity was observed prior to PRPP addition. 
 
PurD.  The final assay conditions were 100 mM Tris-HCl (pH 8.0), 50 mM KCl, 1 mM 
phosphoenolpyruvate (PEP), 0.2 mM NADH, 15 units/mL each of LDH/PK (Sigma 
P0294 solution, according to the manufacturer’s determined activity), 2 mM magnesium 
acetate, 1 mM phosphoribosylamine (PRA), 2 mM glycine, 2 mM ATP, and PurD in a 
final volume of 700 uL.  The reaction mix was pre-incubated at 18°C for 2 min, and the 
reaction was initiated by the addition of PRA in a quartz 0.5 mL cuvette (1 cm 




monitored at 18°C in an Agilent diode-array spectrophotometer or an Agilent Cary 
spectrophotometer by the decrease at 340 nm with ε = 6200 M-1 cm-1.  No detectable 
activity was observed prior to PRA addition. 
 
PurTH6.  Assay conditions were adapted from the PurD assay above. The final assay 
conditions for PurTH6 were 100 mM Tris-HCl pH 8.0, 50 mM KCl, 2 mM magnesium 
acetate, 2 mM glycine, 2 mM ATP, 1 mM PEP, 0.2 mM NADH, 1 mM 
phosphoribosylamine (PRA), 5 units/mL LDH/PK mix (Sigma P0294 solution, according 
to the manufacturer’s determined activity), 4 units H6PurD, 5 units H6PrsA, and PurTH6 
in a final volume of 700 uL.  The reaction mix was pre-incubated at 18°C for 2 min, and 
the reaction was initiated by the addition of PRA in a quartz 0.5 mL cuvette (1 cm 
pathlength).  Enzymatic activity was monitored at 18°C in an Agilent diode-array 
spectrophotometer by the decrease at 340 nm with ε = 6200 M-1 cm-1.  No detectable 
activity was observed prior to PRA addition.  Calculated activity was divided by 2 to take 
into account the generation of 2 ADP molecules from the PurD and PurT reactions. 
 
H6PlsA.  The final assay conditions for H6PlsA were 100 mM Tris-HCl pH 8.0, 50 mM 
KCl, 2 mM magnesium acetate, 2 mM AMP, 2 mM ATP, 1 mM PEP, 0.2 mM NADH, 5 
units/mL LDH/PK mix (Sigma P0294 solution, according to the manufacturer’s 
determined activity), and H6-PlsA in a final volume of 700 uL.  The reaction mix was 
pre-incubated at 24°C for 2 min, and the reaction was initiated by the addition of AMP in 
a quartz 0.5 mL cuvette (1 cm pathlength).  Enzymatic activity was monitored at 24°C in 
an Agilent diode-array spectrophotometer by the decrease at 340 nm with ε = 6200 M-1 
cm-1.  No detectable activity was observed prior to AMP addition.  Calculated activity 
was divided by 2 to take into account the generation of 2 ADP molecules per reaction. 
 
H6PrsA.  The final assay conditions for H6PrsA were 100 mM Tris-HCl pH 8.0, 50 mM 
KCl, 2 mM magnesium acetate, 2 mM ATP, 1 mM PEP, 0.2 mM NADH, 2 mM ribose-5-
phosphate (R5P), 5 units/mL LDH/PK mix (Sigma P0294 solution, according to the 
manufacturer’s determined activity), 5 units H6-PlsA, and H6-PrsA in a final volume of 




initiated by the addition of R5P in a quartz 0.5 mL cuvette (1 cm pathlength).  Enzymatic 
activity was monitored at 24°C in an Agilent diode-array spectrophotometer by the 
decrease at 340 nm with ε = 6200 M-1 cm-1.  No detectable activity was observed prior 
to R5P addition. 
 
GlnA. Assay conditions were adapted from the PurD assay above. The final assay 
conditions for GlnA were 100 mM Tris-HCl pH 8.0, 50 mM KCl, 1 mM magnesium 
acetate, 3 mM ATP, 2 mM PEP, 0.2 mM NADH, 15 units/mL LDH/PK mix (Sigma 
P0294 solution, according to the manufacturer’s determined activity), 50 mM glutamate, 
and 40 mM ammonium chloride in a final volume of 700 uL.  The reaction mix was pre-
incubated at 37°C for 2 min, and the reaction was initiated by the addition of glutamate in 
a quartz 0.5 mL cuvette (1 cm pathlength).  Enzymatic activity was monitored at 37°C in 
an Agilent diode-array spectrophotometer by the decrease at 340 nm with ε = 6200 M-1 
cm-1.  No detectable activity was observed prior to glutamate addition. 
 
 
3.3 Results and Discussion 
E. coli PurF.  The JRW construct (pJK673 [1]) was purified (data not shown), however, 
previous characterization of the non-iron sulfur cluster enzyme indicated that the N-term 
cysteine residue is the catalytic nucleophile [11].   Therefore the protein encoded by 
pJK673 should code for a catalytically inactive PurF since it codes for H6PurF, so the 
activity was not tested.  The C-term His-tagged construct was obtained (pJK639) and 
purified (data not shown).  A total of 95 mgs of protein was isolated; however, no activity 
was detected, even when PRPP was used as the starting substrate.  The untagged 
construct E. coli PurF (pJK649) was obtained as it was characterized previously [12] 





Figure 3.2  Purification of E. coli PurF (pJK649).   
Final purification gel.  SDS-PAGE (9% acrylamide), 5 ug protein/lane.  Legend:  C - 
crude; S - soluble; PSS- post streptomycin sulfate; W1 and W2 - washes 1 and 2; P - 
pooled elution fractions; F - pure PurF. 
 
Table 3.3 Summary of the PurF purification. 
Step Volume (mL) Protein (mg) Sp. Activity (U/mg) Activity (U) Purification (fold) 
Soluble 35 495.4 0.081 40.1 1 
Strep Sulf 37.5 464.3 0.115 53.4 1.4 
DEAE 90 184.32 0.244 45.0 3.0 
Pure PurF 2.6 28.34 18.46 523 228 
 
28.3 mg of E. coli PurF was obtained from 2 L of culture with a specific activity of 18.5 
U/mg at 24°C, compared to 17.7 U/mg glutamine-dependent specific activity as 
previously reported at 37°C [11]. 
 
E. coli PurD (pJK592).  pJK72 [1] contained silent A38 and G382 mutations and multiple 
sequencing attempts from the T7 promoter region failed, so the gene was cloned in-house 
(purD - pJK592; purDH6 - pJK614; H6purD - pJK621).  B. subtilis PurD (pJK034) was 
purified by K. Nyffeler; however the protein sat diluted for over a week at 4°C and 
activity was very low; since then, isolating B. subtilis PurD again has not been attempted.  
Although there were issues at the beginning with setting up the activity assay, all of the 
purified PurD proteins (tagged and untagged) were assayed again for activity as soon as 










The E. coli PurD (pJK592) construct was shown to be leaky (data not shown); growth in 
ZYM-5052 failed to reproducibly induce expression of the protein.  Prep 1 failed to yield 
active or clean protein (data not shown).  Prep 2 yielded 20 mg of isolated protein (gels 
not shown) , with a specific activity of 3 U/mg.  Future isolations of untagged PurD 
should include a low-salt wash (100-150 mM KCl) of the DE52 column prior to elution 
and the DE52 elution should be performed in a higher linear salt gradient (150 mM - 1M 
KCl) since PurD was found in the last 3 fractions (data not shown). 
 
E. coli PurDH6 (pJK614).  PurDH6 had the same leaky expression as the untagged 
version (data not shown).  A total of 186 mg of protein was obtained (gels not shown) 
and had 0.19 U/mg activity.  A doublet was observed in the purified protein lane that may 
correspond to proteolytic cleavage products.  Since both the untagged and the C-term 
His-tagged proteins were not very active, the N-terminally tagged protein construct 
(which has been previously characterized [13]) was obtained. 
 
E. coli H6PurD (pJK621).  Prep 1 yielded 14.4 mg of protein (gels not shown) with a 
specific activity of 79.9 U/mg, which is about four times the specific activity that was 
reported previously [13].  Error in calculations and the Bradford may be attributed to the 
large difference in specific activity.  A doublet was again observed in the purified protein 
lane so PMSF may be a necessary addition to the buffers.  Since not much protein was 
obtained, the purification was attempted once more. 
 
Prep 2.  Cells were grown in ZYM-5052 [2] to increase protein yield.  The purification 





Figure 3.3  Purification of H6PurD (pJK621) prep 2.   
Left, elution gel, 10 uL/lane (protein amount unknown).  Numbers denote elution 
fractions.  Right, final purification gel, 5 ug protein/lane.  SDS-PAGE (9% acrylamide). 
 
 
A total of 117 mg of protein was isolated with a specific activity of 40 U/mg, which is 
similar to the previously characterized wild-type E. coli PurD [14] but twice of that of 
H6PurD [13].  Even though PMSF was present in the buffers, the lower molecular weight 
band, likely due to proteolysis was still present.  Active PurD has finally been isolated! 
 
E. coli PurTH6 (pJK515).  PurT, or GAR tranformylase, catalyzes the third step in the de 
novo purine pathway and the C-terminally His-tagged version was isolated as shown in 
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Figure 3.4  Purification of PurTH6 (pJK515).   
Left, elution profile, 10 uL/lane (protein amount unknown).  Numbered lanes denote the 
elution fractions.  Right, final purification gel, 5 ug/protein/lane.  SDS-PAGE (9% 
acrylamide). 
 
The column was overloaded as PurTH6 was present in the wash; however 145 mg of 
protein was isolated (fractions 2-6 were pooled, Figure 3.4).  When formate was omitted 
from the activity assay, the total ATPase activity was calculated to be 0.25 U.  Once 
formate was added, the total ATPase activity increased to 0.29 U (previous calculation of 
1.5 U/mg value was wrong).  The C-term form of the enzyme has not been characterized 
previously; however, the untagged E. coli protein was reported to have a specific activity 
of 52 ug/min*mg*mL [15].  It is important to note that the enzymatic activity of PurTH6 
was tested over a year after purification and no enzyme dilutions were made.  The C-term 
His-tag may be to blame as it may interfere with homodimer formation as it is located 
close to the dimer interface (PDB 1KJ8).  H6PurT (not previously characterized) may 
yield active protein as a maltose-binding protein (MBP) N-term tag PurT was 
characterized previously [16]. 
 
E. coli H6PlsA (pJK669 [1]).  PlsA, or adenylate kinase, catalyzes the γ-phosphate 
transfer from ATP to AMP to yield two ADPs.  The elution and purification gels are 
shown in Figure 3.5. 
!
"#$


















































Figure 3.5  Purification of H6PlsA.   
Left, elution gel, 10 uL/lane (protein amount unknown).  Numbered lanes denote the 
elution fractions.  Right, final purification gel, 5 ug/lane.  SDS-PAGE (12% acrylamide). 
 
 
37 mg of protein was isolated with a specific activity of 1.9 U/mg for the reaction, or 0.9 
U/mg/ADP; compared to 1 U for the N-term tagged-protein [1] (taking into account of 
the ADP molecules in activity calculation was not mentioned).   
 
PrsA.  PrsA, or PRPP synthase, catalyzes the phosphorylation of ribose-5-phosphate to 
yield PRPP. 
 
E. coli H6PrsA (pJK670 [1]).  Sequencing of this construct did not reveal any mutations.  
Expression in JM109(DE3) cells showed no induction (prep 1, data not shown) so the 
construct was isolated from BL21(DE3) cells in prep 2, where 1 mg was isolated with a 
specific activity of 0.9 U/mg, compared to 2.5 U/mg as previously reported for the C-
term tagged form [1].  The protein was observed to precipitate out after streptomycin 
sulfate treatment in preps 2 and 3 (data not shown).   
 
 The A. aceti PrsAH6 construct was obtained (pJK631), however, the protein was 
found to be insoluble (data not shown).  Co-expression with GroESL did not improve its 
solubility (data not shown), so the E. coli protein was revisited.  The protocol for prep 5 









































precipitating in the presence of streptomycin sulfate [8].  The purification gels are shown 
in Figure 3.6.  
 
 
Figure 3.6  Purification of E. coli H6PrsA (pJK670).   
Left, elution, 10 uL/lane (protein amount unknown).  Right, final purification gel, 5 ug 
protein/lane.  SDS-PAGE (12% acrylamide).  Legend:  D - dialyzed extract after 




A doublet in the elution fractions was observed which may indicate proteolytic products, 
therefore no protein was pooled off of the Ni-NTA column.  However, since the column 
was overloaded and much recombinant protein was found in the flowthrough, an 
ammonium sulfate step (0-25%) was performed.  A total of 95 mgs was obtained with a 
specific activity of 3.7 U/mg.  Future isolations of E. coli H6PrsA should omit the Ni-
NTA column.  After dialysis of the resuspension of the streptomycin pellet, a simple 0-25% 
ammonium sulfate cut should yield pure H6PrsA. 
 
E. coli GlnA.  GlnA, or glutamine synthase, catalyzes the ATP-dependent condensation 
of glutamate with ammonium to yield glutamine.  
 
E. coli H6GlnA Y397F (pJK642).  pJK668 [1] contained multiple base insertion at the N-
terminus, a silent G157 mutation, and a Y397F mutation, which is one of the sites of 
adenylation [10].  The Y397F mutant was reported to have a lower turnover number but 
is less subject to feedback inhibition and monovalent cation inhibition [10] therefore 









protein was obtained by affinity chromatography (data not shown) despite reprocessing 
the flowthrough.   Prep 1 enzyme activity was not tested.  A Zn precipitation protocol 
was attempted as previously reported and described [9, 10], however, it did not work for 
H6GlnA as most of the expressed protein was insoluble (data not shown).  The 
insolubility of H6GlnA was not observed for prep 1.  The N-term His-tag may interfere 
with the homomultimeric complex formation which led to the failure of zinc precipitation 
therefore the untagged protein construct was obtained. 
 
E. coli GlnA (pJK650) purification.  The zinc crystallization protocol was used to isolate 
untagged GlnA as shown in Figure 3.7. 
 
 
Figure 3.7  Purification of EcGlnA (pJK650).   
Legend:  C, crude; S, soluble; PSS, post streptomycin sulfate; ZP, Zn precipitation pellet; 
M1-M4, magnesium steps 1-4; D, dialyzed protein.  SDS-PAGE (9% acrylamide), 10 uL 
(protein amount unknown) except for the last lane which contained 5 ug protein. 
 
 
10 mg of protein were isolated, and despite the low yield, the Zn precipitation protocol 
yielded pure material.  Activity was not used to track the protein therefore the appropriate 
resuspension time was unknown (for this prep, the pellets were resuspended for 1 hour).  
The specific activity of purified GlnA for this prep was 3 U/mg compared to 50 U/mg as 
previously reported using the Zn crystallization method [9]. 
 
E. coli H6PurL (pJK556).  Large PurL from E. coli will be used as a control for FS 










Figure 3.8  Purification of EcH6PurL (pJK556).   
Left, elution profile, 10 uL/lane (protein amount unknown).  Right, final gel, 5 ug 
protein/lane.  Legend:  PSS, post streptomycin sulfate; FT, flowthrough; W, wash; F, 
fraction.  SDS-PAGE (9% acrylamide). 
 
 
H6PurL was found to be a very soluble protein.  A total of 136 mgs were isolated; 
however activity was not tested. 
 
E. coli H6PurM (pJK633).  PurM catalyzes the cyclization of FGAM to aminoimidazole 
ribonucleotide (AIR).  FGAM, the FS substrate, is unstable, but AIR, the product of the 
PurM reaction, which follows FS in the de novo pathway, is not.  Additionally, the 
Bratton Marshall assay is very sensitive to diazotizable amines, including the exocyclic 
one on AIR.  Sequencing of the pJK675 [1] revealed a G324E mutation.  Site-directed 
mutagenesis was performed to yield pJK633 and the protein was isolated as shown in 



































Figure 3.9  Purification of H6PurM (pJK633).   
Left, elution gel, 10 uL/lane (protein amount unknown).  Right, final purification gel, 5 
ug protein/lane.  SDS-PAGE (12% acrylamide).  Legend:  PSS- post streptomycin sulfate; 
FT - flowthrough; W - wash; F - fraction. 
 
 




 All the constructs for the enzymes needed for FGAR biosynthesis have been 
obtained.  E. coli PurF (pJK649), H6PurD (pJK621), H6PlsA (pJK669), and H6PrsA 
(pJK670) have been purified and shown to be active.  Activity was not determined for E. 
coli H6PurL and H6PurM since the other enzymes needed for FGAR synthesis were not 
available at the time.  PurTH6 (pJK515) was tested more than one year post-purification 
and low activity was observed.  C and N-term His-tagged PurT have not been 
characterized; however one study has demonstrated that MBP-PurT was active [16] so 
H6PurT or the untagged protein may be a better candidates than PurTH6.  Purification of 
GlnA (pJK650) still needs to be optimized.  Although the zinc precipitation protocol 
seemed to yield a significant amount a material, the amount of time required to fully 
resuspend the various pellets after zinc and magnesium precipitation to fully recuperate 
























-. / -' -< -! 92




obtained, combinations of the purine (PurF, PurD, and PurT) and regeneration pathway 
enzymes (PrsA, PlsA, and GlnA) will be able to be mixed together in one reaction to 
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CHAPTER 4. THE AAFS OPERON 
4.1 Introduction 
 Previous observations in the AaFS protein co-expressions and functional 
complementation profiles (Chapters 1 and 2, respectively) have determined that 
functional AaFS does not contain OrfY and that the presence of the latter affects PurQ 
expression.  If OrfY does have a regulatory role for AaFS, its position allows for the 
encoding of the much smaller PurS protein without expending too much energy on 
transcribing and translating PurQ and PurL (Figure 4.1). 
 
 
Figure 4.1  FS gene cluster alignment in select Gram-negative α-proteobacteria. 
Alignment includes A. aceti, Gram-negative E. coli, and Gram-positive B. subtilis.  To 
date, acetic acid bacteria are the only Gram-negative bacteria that may contain PurS, 
PurQ, PurL, and even OrfY in some.  Legend:  S = purS ; Y = orfY. 
 
 
 As mentioned previously, purS, orfY, purQ, and purL all overlap (by four 
nucleotides) and are likely co-translated.  The current hypothesis is that purC, purS, orfY, 
purQ, purL, bolA, and grx are transcribed on the same transcript.  purC is 28 bp upstream 
of purS, purL 26 bp upstream of bolA, which is 26 bp upstream of grx.  purB is located 




remaining genes.  In B. subtilis, all the de novo purine genes are clustered [1, 2]; however 
this is not the case in A. aceti. 
 
 Since OrfY shows a repressive effect on PurQ expression by SDS-PAGE 
(Chapter 1), OrfY may have a regulatory role.  Previously reported purine pathway 
regulation mechanisms include feedback inhibition, riboswitches, and the presence of a 
transcription repressor protein [3-5].  Previous studies elucidated the negative feedback 
inhibition mechanism of purines on the first enzyme of the de novo purine biosynthetic 
pathway, PurF [6, 7], as well as the presence of a repressor protein, PurR, that binds the 
promoter region and prevents transcription from occuring [8].  Another method of 
regulation is at the mRNA level, where upon the presence of purines, RNA forms a 
secondary structure, preventing the ribosome from binding [2].  
 
 A prediction of the secondary structure of OrfY mRNA by RibEx [9] reveals the 
potential formation of an attenuator sequence within the orfY gene (Figure 2). 
 
 
Figure 4.2  RibEx prediction of the attenuator formation within orfY.   
Top, DNA coding sequence and corresponding amino acids of OrfY.  Bottom, the 
formation of an anti-antiterminator loop allows for the formation of a terminator loop 
thus terminating transcription and turning off FS activity.  Upon binding of an unknown 
RNA binding protein, the anti-antiterminator loop cannot form but instead an 





The hypothesis presented in Figure 4.2 follows that of the B. subtilis pyrimidine pathway 
[10].  In short, in B. subtilis, the RNA binding protein PyrR interacts with mRNA 
carrying pyrimidine synthesis genes in the presence of uridine nucleotides, causing 
changes in the mRNA secondary structure and inhibiting transcription.  Similarly, in the 
regulation of AaFS, the absence of a currently unknown orfY mRNA binding protein 
would allow for the formation of an anti-antiterminator loop and therefore a terminator 
loop leading to the termination of transcription of AaFS.  Upon the binding of the RNA 
binding protein to the orfY mRNA sequence, an antiterminator loop is able to form which 
allows for transcription to proceed and produce an active FS.  The export of OrfY may or 
may not affect the attenuator hypothesis.  This chapter focuses on the isolation and 
characterization of RNA from A. aceti, specifically the AaFS operon. 
 
 
4.2  Materials and Methods 
Materials 
All materials and chemicals were from Sigma Aldrich or Fisher Scientific and of the 
highest purity unless otherwise noted.  Taq polymerase was from the Chapple laboratory 
(Purdue University) or Promega.  SuperScript II and Mu-MLV reverse transcriptases 





Table 4.1 Oligodeoxynucleotides used in this chapter. 
ODN Sequence (5'=>3')a 



























*Primer originally designed for mutagenesis 
 
Table 4.2 Plasmids used in this chapter. 
pJK Vector Description Source 
537 pDrive AamutS This study 
Aa denotes A. aceti gene. 
 
Construction of A. aceti mutS construct plasmid pJK637.  A 1.5 kb product was amplified 
from A. aceti 1023 genomic DNA, using Taq Polymerase from the Chapple laboratory 




55°C and melting, annealing, and extension times of 20 s, 30 s, and 1 min 30 s for 25 
cycles.  The product was purified using a Qiagen PCR purification kit and ligated into 
pDrive with the Qiagen QIAexpress UA cloning kit following the manufacturer’s 
instructions.  The plasmid encodes for a fragment of A. aceti MutS. 
 
PCR controls.  Previously isolated A. aceti 1023 genomic DNA (E. A. Mullins) was used 
as the template for PCR using ODNs from Table 2 and Taq polymerase (Chapple 
laboratory, Purdue University) with an annealing temperature of 55°C and melting, 
annealing, and extension times of 30 s, 30 s, and 30 s for 25 cycles. 
 
Denaturing formaldehyde agarose gel electrophoresis.  A 1% gel was used to check RNA 
integrity.  A 50 mL gel was prepared by melting 0.5 g of agarose in 36 mL of water.  5 
mL 10X MOPS buffer (0.4 M MOPS pH 7.0, 0.1 M NaOAc, 0.01 M EDTA), 1.8 mL 37% 
formaldehyde (0.22M final), and 5 uL 1 mg/mL ethidium bromide was added once the 
melted agarose had cooled slightly.  Once solidified, the gel was presoaked for 30 min in 
1X MOPS buffer and prerun for 10 min at 70 V. 
 
RNA quantification.  The Nanodrop 2000 (Thermo Scientific, Inc.) was used.  1.25 uL of 
sample was analyzed after blanking the instrument in TE buffer (10 mM Tris-HCl pH 8.0, 
1 mM EDTA).  For later O.D. readings, samples were diluted from 1:20 to 1:50 for 
quantification.  Typically, 3 reads were averaged. 
 
RNA isolation.  Buffers including lysozyme, proteinase K, and TE were made in-house in 
RNase-free water (autoclaved MilliQ water in RNase-free setting); all other buffers were 
provided by the Qiagen or Ambion kits.   
 
RNA isolation using Qiagen RNeasy Mini Kit.  A. aceti 1023 cell pellets grown in YPD 
for 36-38 hrs (OD600 ~1.1) were stored at -80˚C and treated with Qiagen RNAProtect 
according to the manufacturer’s instructions.  In short, 1 volume of A. aceti culture was 
incubated with 2 volumes of RNAProtect reagent for 5 min, after which cells were 
pelleted and stored at -80°C for up to 4 weeks until use.  Cell pellets were thawed on ice.  




8.0), and 20 mg/mL proteinase K was added to a separate 1 mL TE buffer.  200 uL of 
lysozyme-TE buffer and 20 uL of proteinase K-TE buffer solutions were added to the cell 
pellets and resuspended by pipetting.  The mixture was vortexed for 10 s and incubated at 
room temperature for 30 min.  Samples were vortexed for 10 s every 2 min.  700 uL of 
Buffer RLT (Qiagen) was added to each sample and mixed by vortexing.  10 uL of BME 
was added for every mL of buffer RLT.  500 uL of 100% EtOH was added to each 
sample and mixed by pipetting up and down.  Lysate was transferred to the spin columns 
in 700 uL aliquots.  Columns were centrifuged for 30 s at 8,000g.  Liquid was discarded 
and the process was repeated until all the lysate was processed.  350 uL of RW1 (Qiagen) 
was applied to the spin column and centrifuged.  10 uL of Qiagen DNase I stock was 
added to 70 uL Buffer RDD (Qiagen) and 80 uL of the DNase-RDD solution was added 
to the column membrane.  The columns were incubated at room temperature for 15 min.  
350 uL of RW1 buffer was added to the column, incubated for 5 min, and removed by 
centrifugation.  The on-column DNase treatment was repeated once more.  The column 
was washed twice with 500 uL RPE buffer (Qiagen).  The column was placed in a new 
1.5 mL tube, and eluted with 50 uL RNase-free water by centrifuging for 1 min.  The 
same 50 uL was used again to elute more RNA from the same column.  An additional in-
solution DNase treatment was performed where the reaction was incubated at 37°C for 30 
min.  The RNA was aliquoted, frozen, and stored at -80C until use.  Alternatively, New 
England Biolabs DNase was used in the same way as Qiagen’s. 
 
RNA isolation using Ambion PureLink RNA Mini Kit.  A. aceti 1023 cell pellets grown 
in YPD for 36-38 hrs (OD600 ~1.1) were stored at -80˚C.  E. coli DH5α cells were 
grown to saturation overnight and the cells were used immediately.  The cell pellet (E. 
coli or A. aceti) was thawed on ice.  Following the manufacturer’s instructions, 100 uL of 
lysozyme solution (1 mg lysozyme in 10 mM Tris-HCl pH 8.0, 0.1 M EDTA) was added 
to the cell pellet with resuspension by vortexing.  0.5 uL of 10% SDS (w/v) solution was 
added and mixed by vortexing.  350 uL of lysis buffer (with 3.5 uL βME) was added and 
mixed by vortexing.  For the homogenization of the cells, the lysate was passed 5 times 
through an 18-gauge needle with a syringe.  The homogenized lysate was centrifuged at 




RNase-free tube.  250 uL of 100% ethanol was added to the cell homogenate and mixed 
by vortexing to disperse any precipitate.  The sample (including any precipitate) was 
transferred to a Spin Cartridge with collection tube.  After a spin at 12,000g for 15 s at 
room temperature, the flowthrough was discarded.  350 uL of Wash buffer I (Ambion) 
was added to the column and spun at 12,000g for 15 s.  On-column DNase digest was 
performed here; otherwise, 500 uL of Wash Buffer II (Ambion) was added to the column 
and spun.  After 1 min spin to remove any residual solvent, RNA was eluted by placing 
the spin cartridge into a clean RNase-free recovery tube.  RNase-free water (Ambion) 
was added to the column and incubated at room temperature for 1 min.  The RNA was 
eluted by centrifuging at 12,000g for 2 min.  The elution step was repeated once more. 
 
On-column NEB DNase treatment.  50 uL of the DNase mixture (5 uL 10X reaction 
buffer; 1.25 uL 200 mM EDTA, 1 uL DNase, 42.75 uL RNase-free water) was loaded 
onto the column.  The column was incubated at 37˚C for 10 min.  350 uL of Wash buffer 
I was added and spun and the rest of the protocol above was followed. 
 
On-column Qiagen DNase treatment.  As described previously, 10 uL of Qiagen DNase I 
stock was added to 70 uL Buffer RDD and 80 uL of the DNase-RDD solution was added 
to the column membrane.  The columns were incubated at room temperature for 15 min.  
350 uL of Wash buffer I was added and spun and the rest of the protocol above was 
followed. 
 
A. aceti RNA isolation using hot acid phenol.  Cells from 10 mL of culture were 
harvested and the supernatant was discarded.  Cell pellets were frozen for storage at -
80˚C or used immediately.  Cells were resuspended in 400 uL freshly made and cold AE 
buffer (50 mM NaOAc pH 5.2, 10 mM EDTA pH 8.0) and transferred to an RNase-free 
tube.  40 uL of 10% SDS (w/v) and 400 uL acid phenol:chloroform (Amresco 
Phenol:Chloroform::5:1) was added.  The mixture was vortexed briefly and placed in a 
65˚C heat block for 10 min, vortexing for 5 s every minute.  Cells were incubated on ice 
for 5 min and spun for 5 min at 14,000 g at 4˚C.  The aqueous (upper) layer was 




to mix and spun for 5 min at 14,000 g at 4˚C.  The aqueous layer was transferred to 
another tube.  50 uL of ice cold 3M NaOAc (pH 5.2) and 1 mL ice cold 100% ethanol 
was added to the tube and mixed by inverting several times.  The tube was chilled at -
80˚C for 30 min or at -20˚C overnight and spun down for 10 min at 14,000 g at 4˚C.  
Ethanol was removed, the pellet was rinsed with ice cold 70% ethanol, and the tube was 
spun for 5 min at 14,000 g at 4˚C.  As much of the 70% ethanol was removed using a 
pipettor and the pellet was allowed to air dry (~5 min at room temperature).  The pellet 
was resuspended in 100 uL of RNase-free water by vortexing and samples were stored at 
-20°C or -80°C. 
 
In solution Qiagen DNase treatment.  87.5 uL DNA-contaminated RNA (at ~1 ug/uL 
[RNA]), 10 uL RDD buffer, and 2.5 uL DNaseI reconstituted DNase I were mixed 
together.  The reaction was incubated at 37˚C for 30 min.  DNase was removed by 
phenol:chloroform extraction as described above. 
 
In solution cDNA synthesis.  Invitrogen SuperScript II or NEB M-MuLV Reverse 
Transcriptase (RT) was used according to the manufacturers’ instructions.  In short, 100-
500 ng total RNA, 2 pmol of gene specific antisense primer, and 0.5 mM dNTPs were 
mixed in a tube in a final volume of 12 uL.  The RNA mixture was heated to 65°C for 5 
min and chilled on ice.  1X Buffer, 10 mM DTT, and 200 U of enzyme was added to the 
RNA mixture and the whole reaction was incubated at 42°C for 30 min.  The reverse 
transcriptase was heat inactivated at 65°C for 20 min.  
 
Two-step RT-PCR.  1 uL of the cDNA reaction above with 200ng RNA input was used 
for the +RT reactions.  200ng of total RNA was used for the -RT reactions.  GoTaq 
polymerase (Promega) or Taq polymerase from the Chapple laboratory (Purdue 
University) was used for the amplification reactions.  30 cycles were run. 
 
rRNA depletion.  The Ambion MICROBExpress™ Bacterial mRNA Enrichment Kit 
was used according to the manufacturer’s instructions.  In short, 10 ug RNA (subjected to 
2 in-solution Qiagen DNase treatments) in a maximum volume of 15 uL was added to  




Capture Oligo Mix was added to the RNA in Binding Buffer and the tube was gently 
vortexed to mix.  The tube was microfuged briefly to get the mixture to the bottom of the 
tube.  The RNA/Capture Oligo reaction was heated to 65°C for 10 min and incubated at 
37°C for 15 min.   During this incubation, the Oligo MagBeads were prepared by 
resuspending the beads by vortexing.  50 uL of beads were aliquoted into a 1.5 mL tube.  
The beads were captured using a magnetic stir bar and the supernatant was removed 
carefully and discarded.  The beads were washed by adding 50 uL of nuclease-free water 
and resuspending the beads by brief, gentle vortexing.  The beads were recaptured and 
the supernatant was removed and discarded.  The beads were equilibrated by adding 50 
uL of Binding Buffer and resuspending them by brief, gentle vortexing.  The beads were 
recaptured and the supernatant was removed and discarded.  The Oligo MagBeads were 
resuspended in 50 uL Binding Buffer, and the slurry was incubated at 37°C until use.  
The Wash solution was heated to 37°C.  The washed and equilibrated beads were 
resuspended by gentle vortexing and 50 uL was added to the RNA/Capture Oligo Mix.  
The reaction was gently vortexed to mix, microfuged briefly, and incubated for 15 min at 
37°C.  The beads were recaptured and the supernatant (containing the enriched mRNA) 
was carefully aspirated into a Collection Tube on ice.  100 uL of preheated Wash 
Solution was added to the Oligo MagBeads and the latter were resuspended by brief, 
gentle vortexing.  The beads were recaptured and the supernatant was pooled with the 
RNA already in the Collection Tube on ice.  The enriched mRNA was ethanol 
precipitated by adding 1/10th volume of 3 M sodium acetate, 1/50th volume 5 mg/mL 
glycogen, and 3 volumes ice cold 100% ethanol.  After mixing thoroughly by vortexing, 
the RNA was precipitated at –20°C for 1 hr.  The tube was centrifuged for 10 min at 
14,000g and the supernatant was decanted and discarded.  750 uL of ice cold 70% 
ethanol was added to the RNA pellet and the tube was vortexed briefly.  The tube was 
centrifuged for 5 min at 14,000g.  The supernatant was discarded and an additional wash 
was performed.  Any remaining supernatant was removed with a pipettor and the pellet 
was air dried for 5  min.  The RNA pellet was resuspended in 10 uL TE (10 mM Tris-HCl 




by capturing the beads and removing the enriched mRNA solution to a new RNase-free 
tube.  Samples were stored at -20°C or -80°C. 
 
 
4.3 Results and Discussion 
PCR controls.  A. aceti 1023 genomic DNA was used to test primers designed for RT-
PCR.  Figure 4.3 shows the general annealing region for the AaFS cluster. 
 
 
Figure 4.3  ODN priming sites for the AaFS operon. 
 
Primers were designed to yield amplification products ~750 bp as summarized in Table 
4.3 for all amplicons used in this chapter.  PCR controls for the AaFS and purXEK 
operons are shown in Figure 4.4 and 4.5, respectively. 
 
Table 4.3 RT-PCR amplicon characteristics summary. 
Spanning Expected Size (bp) ODN (fwd) ODN (rev) 
purC-purS 458 2299 2302 
purS-orfY (post-attenuator) 393 2301 2304 
purS-orfY (pre-attenuator) 153 2301 2326 
orfY-purQ 500 2303 2306 
purS-purQ 790 2301 2306 
purQ-purL 454 2305 2308 
purL-bolA 254 2307 2310 
bolA-grx 485 2309 2311 
purF (short) 167 2312 2313 
purF (long) 397 2371 2313 
mutS (short) 200 2327 2322 
mutS (medium) 662 2370 2322 
mutS (long) 1363 2323 2322 
orfX-purE 541 2130 1012 
purE-purK (short) 246 404 622 
purE-purK (long) 744 614 622 










Figure 4.4  PCR controls for the AaFS operon of A. aceti 1023.   




Figure 4.5  PCR controls for the purXEK operon of A. aceti 1023.   
5 uL/lane, 2% agarose. 
 
 
The primers designed for RT-PCR were shown to work on A. aceti 1023 genomic DNA 
so RNA isolation from A. aceti was the next step. 
 
RNA isolation optimization.  Very low yields of total RNA (<40 ng) were obtained when 
the Qiagen or the Ambion kits were used.  Note that buffers including lysozyme, 
proteinase K, and TE were made in-house in RNase-free water; all other buffers were 
provided by the Qiagen or Ambion kits.  Kit-isolated samples could not be visualized by 
denaturing formaldehyde agarose gels and RT-PCR results showed extensive genomic 





























































since cell pellets would not be used for any other assays (i.e. kinetic characterization) and 
to increase isolated RNA yield.  Additionally, in-solution DNase treatments appeared to 
be more effective than on-column treatments (data not shown).  The final preps included 
two in-solution DNase I treatments. 
 
MutS, involved in DNA double-strand break repair, was previously established as a qRT-
PCR control for Acetobacter pasteurianus, as growth under various stressors such as heat, 
higher ethanol concentrations, and acidic conditions in the growth media did not affect 
mutS transcription levels [11].  Since A. aceti does not have a characterized housekeeping 
gene and is closely related to A. pasteurianus, MutS was chosen as a control.  
Additionally, purF was chosen as a purine pathway control since PurF catalyzes the first 
committed step in de novo purine biosynthesis [12].   
 
A successful total RNA isolation with no detectable genomic DNA contamination by 
PCR is shown in Figure 4.6.   
 
 
Figure 4.6  Total RNA from A. aceti 1023.   
Left, denaturing formaldehyde agarose gel (1%, 5 ug RNA).  Right, RT-PCR, 2% agarose, 
5 uL/lane (200 ng starting RNA).  30 cycles of PCR.  2 amplicon sizes were tested for 
mutS and purF (S- short; L- long).  M - marker.  NB - the “mutS L” product here 










































A. aceti ribosomal RNA, unlike E. coli rRNA, appears to have two distinct bands at ~1.2 
kb.  10 mL of culture would typically yield ~100 ug of total RNA.   Two in-solution 
DNase treatments followed by 30 cycles of RT-PCR showed a strong signal in the +RT 
reactions, and no amplification from contaminating DNA in the -RT reactions.  Smaller 
amplicons, except for mutS and purF, were found to amplify contaminating genomic 
DNA even after three DNase treatments (data not shown), therefore larger amplicons 
were used for characterization of the AaFS and orfX-purE-purKK operons.  The 
transcripts for orfY and orfX seem to be encoded on the same mRNA as AaFS and PurE-
PurK, respectively.   
 
 Transcriptome analysis via RNA-Seq requires enrichment of mRNAs (as 
recommended by Phillip San Miguel from the Purdue University Genomics Core 
Facility).  10 ug of the total RNA isolated in Figure 4.6 was used as the input for rRNA 
depletion by the Ambion MICROBExpress Bacterial mRNA Purification kit, which relies 
upon hybridization of capture oligonucleotides to rRNA.  RT-PCR results post-rRNA 
depletion are shown in Figure 4.7. 
 
	  
Figure 4.7  Enriched mRNA from A. aceti 1023 and RT-PCR.   
Left, denaturing formaldehyde agarose gel (1%) before (AaRNA, 1ug) and after rRNA 
depletion (Aa mRNA, 50 ng).  Right, RT-PCR, 2% agarose, 5 uL/lane (200 ng starting 






































No detectable genomic DNA contamination was observed by RT-PCR, even after mRNA 
enrichment (Figure 4.7).  Very faint amplification products were observed in the mutS 
and EK lanes, which was not the case for purF, SQ, QL, and XE.  Ambion mentioned that 
the typical yield of enriched mRNA would be roughly 10% of the input total RNA 
(therefore from the recommended 10 ug total RNA, 1 ug of mRNA should be obtained).  
The yield of mRNA was ~30 ng.  The absence of the 23S and 16S bands by denaturing 
agarose gel electrophoresis or the Agilent Bioanalyzer is the only indicator of 
(presumably) successful rRNA depletion.  The latter method has been implemented as a 
typical quality control step for next generation sequencing (i.e. RNA-Seq).   
 
 A. aceti total RNA and rRNA-depleted mRNA samples were sent for a quality 
control check on the Agilent Bioanalyzer.  Allison Sorg from the Purdue Genomics 
Center noted that the RNA concentrations (by Nanodrop) were very low.  They 
recommend submitting 2 ug of RNA with an RNA integrity number (RIN) of 8 of higher 
before proceeding forward to making a library and sequencing.  On a scale of 1-10, a 
high RIN indicates a high quality RNA sample [13].  Bioanalyzer traces for total RNA 
and rRNA-depleted samples can be accessed through the following link: 
http://www.genomics.purdue.edu/cgi-
bin/cgiwrap/core/wiki.cgi/hr_00571_kappock_acetobacter_1_2013-06-05.  The RIN for 
total RNA and rRNA-depleted A. aceti 1023 samples were determined to be 7.1 and 8.6, 
respectively.  It is important to note that in order to get a RIN number for the rRNA-
depleted sample (AA2), Allison Sorg changed the threshold of zero due to the low 
concentration of the RNA.  Peaks at ~1200 and 1400 nt are rRNA peaks, which were also 
observed by denaturing formaldehyde agarose gels in lanes containing total RNA 
(Figures 4.6 and 4.7).  The peak at 25 nt is a standard.  For the total RNA sample, peaks 
at ~100 nt may be degradation products.  A strong signal was observed for the rRNA 
peaks, which decreased significantly to below 15 FU after rRNA-depletion, indicating 
that mRNA enrichment with the MICROBExpress kit is compatible with A. aceti RNA.  
The Life Technologies website lists compatible, partially compatible, and incompatible 
bacteria for the kit, where A. aceti was not listed.  Although the rRNA depletion was not 




the low yield.  More mRNA is required for RNA-Seq therefore one suggestion is to 
process multiple rRNA-depletion reactions, pool, and concentrate the enriched mRNA in 
order to proceed forward.  
 
 orfY was established to be on the same mRNA transcript as purSQL, therefore the 
other genes (purC, bolA, and grx) in the gene cluster were also tested as shown in Figure 
4.8.  ODN 2311 was used for cDNA synthesis of the whole gene cluster (starting from 
grx) using the same batch of mRNA-enriched sample that was sent to the BioAnalyzer. 
 
 
Figure 4.8  RT-PCR for the AaFS gene cluster  
2% agarose, 5 uL/lane from 200 ng starting RNA.  30 cycles of PCR.  Legend:  M - 100 
bp marker; 1 - A. aceti genomic DNA template (PCR control), 2 - A. aceti total RNA 
template (-RT); 3 - A. aceti cDNA template (+RT); B - blank lane. 
 
 
No contaminating genomic DNA was observed in the -RT reactions.  Amplification 
products were observed for all targets in the +RT reactions, therefore bolA and grx are 




 RNA was successfully isolated from A. aceti 1023 grown in YPDE via the hot 
acid phenol extraction method.  When total RNA is analyzed by denaturing formaldehyde 
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mutS, purF, orfX-purE-purK, and purC-purS-orfY-purQ-purL-bolA-grx were detected by 
RT-PCR.  orfX-purE-purK and purC-purS-orfY-purQ-purL-bolA-grx were found to be on 
the same mRNA transcript, respectively.  For mRNA enrichment, the Ambion 
MICROBExpress kit was found to be compatible with A. aceti 1023 although a scale-up 
will be required to obtain enough material for quality control on the Agilent Bioanalyzer 
(and ultimately RNA-Seq). 
 
In Chapters 1 and 2, OrfY was shown to have a regulatory role on PurQ and potentially 
PurL protein expression and in functional complementation studies.  However, due to its 
proximity to bolA and grx in the gene cluster (Figure 4.1), bolA and grx being found on 
the same mRNA transcript (Figure 4.8), and four conserved cysteine residues in the OrfY 
amino acid sequence (Chapter 1), OrfY may have a role in iron-sulfur cluster biogenesis.  
None of the genes in the operon encode for a Fe-S cluster-containing protein... but there 
is an iron-sulfur protein in the de novo purine biosynthetic pathway, PurF.  PurF in B. 
subtilis [14] and chicken [15] were shown to contain a Fe-S cluster; E. coli does not.  A. 
aceti PurF is predicted to also contain an Fe-S cluster (T. J. Kappock, unpublished 
observations).   Now that bolA and grx were shown to be on the same mRNA transcript 
as orfY, the current hypothesis is that in purine-starvation conditions, PurF, OrfY, BolA, 
and Grx (and PurL) would all be expressed together.  Preliminary work on developing a 
defined minimal medium for A. aceti 1023 to turn on (or off) purine genes can be found 
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CHAPTER 5. A. ACETI 1023 GROWTH IN MINIMAL MEDIA 
5.1 Introduction 
 A. aceti has been used for the commercial production of vinegar for centuries [1]. 
Multiple cytoplasmic A. aceti proteins have been characterized [2-5] and shown to be 
acid, and coincidentally, thermo-stable [2-5].   
 
 Propagation of A. aceti in rich medium simply uses YPDE [2]; however a defined 
minimal medium has not been developed for culturing A. aceti 1023. 
 
 
5.2 Materials and Methods 
 All materials and chemicals were from Sigma Aldrich or Fisher Scientific and of 
the highest purity unless otherwise noted.  CSM-Ade-His-Leu-Trp was from BIO 101, 
Inc.  Yeast nitrogen base without amino acids was from Difco.  Strains used in this 
chapter are summarized in Table 5.1.  MilliQ water was used for all media prep. 
 
Table 5.1 Strains used in this study. 
Organism Strain Genotype 
Acetobacter aceti  1023 wild type 
Saccharomyces cerevisiae W1588-4C MATa ade2-1 can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1 
 
 
YPDE.  10g yeast extract, 20g bacto-peptone, and 20g dextrose [6] were sterilized by 
autoclaving.  2% (v/v) ethanol was supplemented prior to inoculation when YPD was 
cooled down.  A single colony of A. aceti 1023 was used to inoculate 500 mL of YPDE 




Minimal media.  Media were supplemented with hypoxanthine (1.5 ug/mL) wherever 
applicable.  All cultures contained thiamin (10 uM final) unless otherwise indicated. 
 
Ohmori medium.  As previously described [7, 8].  Detailed composition is summarized in 
Table 5.2.  Cells grown to O.D.600 ~1 were washed with 1/15 M Na, KPi, pH 6.5 buffer 
and used to inoculate 100 mL of Ohmori medium in 500 mL Klett meter flasks.  Cultures 
with starting O.D.600 ~0.005-0.1 were grown at 30°C (200 rpm).  “Modified Ohmori” 
medium was Ohmori medium supplemented with the AMM metals.  “Ohmori+” medium 
was modified Ohmori supplemented with 2% (w/v) peptone. 
 
Table 5.2 Summary of minimal media composition. 
 pH 5.0 pH 6.5 pH 6.0 
 Acetobacter Minimal Medium Ohmori modified Ohmori 
K2HPO4  0.57 mM 0.57 mM 
KH2PO4 7.3 mM 3.67 mM 3.67 mM 
(NH4)2SO4 25 mM  25 mM 
MgSO4(7H2O) 1 mM 1 mM 1 mM 
CaCl2(2H2O) 0.1 mM 0.68 mM 0.68 mM 
Na2MoO4(2H2O) 0.001 mM  0.001 mM 
FeCl3(6H2O)  0.03 mM 0.03 mM 
CuSO4 2E-4 mM  2E-4 mM 
MnCl2 0.006 mM  0.006 mM 
ZnSO4 0.006 mM  0.006 mM 
FeSO4(7H2O) 0.013 mM   
Na Glutamate  23.7 mM 23.7 mM 
KCl  1.3 mM 1.3 mM 
Glucose 2% 3% 3% 
Reference [9] [7]  
 
Complete supplement medium (CSM).  Plates were prepared as described [10].  Plates 
were kept at 30°C for 72 hrs. 
 
Supplements 
Amino Acid mix.  A 1:1000 stock was used to supplement minimal media.  The final 
concentrations of 1.5 nM each of Asp, His, Ile, Leu, Phe, Val, Ala, Lys, and Arg; 1 nM 





UHWL mix.  A 1:1000 stock was used to supplement minimal media.  The final 
concentrations of 1.5 ug/mL uracil, 1 mM His, Leu, Trp were used. 
 
Vitamin mix. A 1:1000 stock was used to supplement minimal media.  The final 
concentrations of 0.1 nM biotin and 1 nM pantothenate were used. 
 
 
5.3 Results and Discussion 
YPDE propagation.  A. aceti 1023 was shown to exhibit biphasic growth [11, 12] in rich 
medium.  A. aceti propagation in YPDE was monitored up to the first log phase to 




Figure 5.1  Propagation of A. aceti 1023 in YPDE. 
 
The growth curve for A. aceti 1023 was similar to that of previous studies [11, 12].  The 
first log phase was determined to end ~36-40 hrs post-inoculation with an O.D.600 ~0.75-1.   
 
A. aceti minimal media propagation. 
 Multiple attempts at growing A. aceti 1023 on Ohmori medium [7] yielded 
unreproducible and unpredictable results.  Some cultures grew after 72 hrs as previously 




supplemented with 0.2% peptone however, cultures in both Ohmori and AMM media 
showed some growth, even though O.D.600 did not surpass 0.4 (data not shown). 
 
 Aeration was important as cultures grown in baffled flasks reached a higher O.D.  
Ohmori medium supplemented with peptone in a baffled flask, followed by plain Ohmori 
medium in a baffled flask, seemed to work well for A. aceti growth.  AMM, which was 
designed for Acetobacter xylinus [9], was not as good of a medium for A. aceti, therefore 
it will not be used for subsequent studies.  Ohmori et. al did not mention the addition of 
micronutrients [7]; however sterilized tap water, which would contain metals, may have 
been used.  Tap or deionized water have not been tested for A. aceti growth using the 
Ohmori medium salts. 
 
Propagation of A. aceti in the modified Ohmori medium (Ohmori + AMM micronutrients) 
is shown in Figure 5.2. 
 
 
Figure 5.3  A. aceti 1023 propagation in supplemented Ohmori medium. 
Supplementation with AMM micronutrients (O mod, ☐) or with AMM micronutrients 






Cultures with or without peptone in Figure 5.3 were inoculated at a lower starting O.D.600, 
0.005 rather than 0.1, since there was ambiguity about the complete depletion of nutrients 
and if cultures had reached the end of the log phase.  Growth was observed in the 
presence of peptone where the stationary phase was reached in ~ 100 hrs, compared to > 
200 hrs for the media lacking peptone.  Peptone may contain some nutrient that A. aceti 
requires for growth in minimal medium. 
 
Thiamin dependence of A. aceti.  The de novo purine and thiamin biosynthetic pathway 
share the same first five steps.  The necessity of thiamin supplementation in minimal 
medium for A. aceti was unknown and always added to minimal media.  The thiamin 
dependence of A. aceti is shown in Figure 5.3.  
 
 
Figure 5.3 Thiamin requirement of A. aceti in modified Ohmori medium.   
NB - addition of thiamin may have been omitted in the 1 uM curve. 
 
 
Previous studies in the lab utilized 10 uM thiamin, but it seems that 0.5 uM is sufficient, 
although the culture containing 1 uM thiamin grew the most poorly (addition of thiamin 
in that flask might have been omitted).  Thiamin seems to be required in order for A. aceti 
to grow since the culture without any thiamin grew to O.D.600 ~0.1.  No peptone was 




after 10 days.  A. aceti may need some other nutritional requirement that is in peptone.  
An amino acid mix designed from the results of a JGI/DOE search for A. aceti amino 
acid requirements is listed in the Methods and Materials and was tested below with 
supplementation with the vitamin mix. 
 
 S. cerevisiae was used as a positive control to ensure that the media tested could 
sustain growth since A. aceti did not yield reliable results thus far.  S. cerevisiae W1588-
4C is a purine auxotroph and contains the ade2 (PurE-PurK fusion) mutation.  ade2 
colonies appear red due to the accumulation and conversion of aminoimidazole 
ribonucleotide (AIR) to the red compound.  W1588-4C, when streaked on YPD, had the 
expected red pigmentation.  Growth of pink colonies was observed on modified Ohmori 
plates supplemented with peptone (data not shown) and those results were also seen in 
liquid media (Figure 5.4). 
 
 
Figure 5.4  Growth curves of A. aceti and S. cerevisiae on modified Ohmori medium.   
Legend:  Sc, S. cerevisiae; Aa, A. aceti; O, Ohmori unsupplemented; H, +hypoxanthine; 






In liquid medium, S. cerevisiae grew well in the presence of peptone, and although A. 
aceti did not grow as well, there was some observable growth in the peptone-
supplemented medium.  These results indicate that the use of peptone will not yield 
purine starvation conditions since S. cerevisiae W1588-4C, a purine auxotroph, grew, 
indicating that peptone contains purines (and potentially pyrimidines).  No growth was 
observed for either organism in modified Ohmori medium, modified Ohmori medium 
supplemented with hypoxanthine, or modified Ohmori medium supplemented with the 
amino acid/vitamin mixes. 
 
 Additional modified Ohmori plates were poured where a mix containing uracil, 
tryptophan, histidine, leucine, and adenine were included to ensure growth of S. 
cerevisiae as a positive control.  Hypoxanthine was also tested since it had been used in 
the past as the go-to purine; however A. aceti’s preference of hypoxanthine over adenine 
(or vice versa) was unknown. 
 
Table 5.3 Ohmori Plate results. 
 S. cerevisiae A. aceti 
Ohmori (water) - + 
Ohmori (peptone) +++ +++ 
Ohmori (UWLH) + + 
Ohmori (UWLH ade) +++ +++ 
Ohmori (UWLH hyp) +++ ++ 
Ohmori (aa) +++ +++ 
Ohmori (aa ade ura) +++ +++ 
Ohmori (aa hyp ura) +++ ++ 
Legend:   +++  growth observed after 96 hrs 
  ++    growth observed after 144 hrs 
  + growth observed after 2 weeks 
  -    no growth after 2 weeks 
 
 
Although colonies were very small, a lawn was observed.  The amino acid/vitamin and 
the uracil/trp/leu/his mixes seem to also have contaminating purines as S. cerevisiae was 
able to grow, albeit not well, on both.  Although the dry amino acid stocks may have been 
contaminated with purines (obtained from old labs), another possibility is the conversion 




dioxide.  A denser lawn of A. aceti was observed on the Ohmori+peptone plate when 
compared to the Ohmori+amino acid/vitamin mix and the UWLH mix plates.  
Additionally, A. aceti seems to prefer adenine as a source of purines over hypoxanthine 
as growth was observed on adenine 2 days before that on hypoxanthine-supplemented 
plates.  Another option to try next is yeast nitrogen base (YNB), used in complete 
synthetic medium (CSM) or synthetic complete (SC) medium, for S. cerevisiae.  Yeast 
nitrogen base contains defined salts, vitamins, and micronutrients; SC medium 
supplements YNB with amino acids, adenine, and/or uracil, and a carbon source.  No 
growth was observed for either A. aceti or S. cerevisiae at the first attempt using solid 
CSM medium, possibly due to too large of a dilution when plating cells and the short 
amount of time (72 hrs) the plates were left at 30°C.  CSM and SC differ in the amount of 




 Growth of A. aceti in Ohmori medium could not be reproducibly observed, even 
when micronutrients were added (modified Ohmori).  Some growth was observed when 
peptone was present, but an unknown key nutrient maybe found in tap water (not yet 
tested) is required by A. aceti.  S. cerevisiae was used as a positive control in order to 
ensure that any manipulations would not yield toxic effects.  A. aceti was found to require 
proper aeration (baffled flasks), thiamin supplementation, and a preference for adenine 
over hypoxanthine.  Further work needs to be done in finding a defined minimal medium 
for A. aceti 1023 as peptone contains purines and has the disadvantage of batch-to-batch 
variability.  CSM and SC media, which both utilize YNB, have been developed as 
defined minimal media for yeast.  Since A. aceti and S. cerevisiae have similar culturing 
conditions (growth at 30°C; propagation in YPD for yeast, YPDE for the acidophile), 
CSM and SC could be explored as potential culture media for A. aceti even though 
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CHAPTER 6. MISCELLANEOUS WORK 
6.1 Materials and Methods 
All materials and chemicals were from Sigma Aldrich or Fisher Scientific and of the 
highest purity unless otherwise noted.  Oligodeoxynucleotides (ODNs, Table 1) were 
obtained from IDT.  OneTaq and Vent polymerases were obtained from NEB.  
FlexiGoTaq polymerase was purchased from Promega.  Chapple Taq polymerase was 
isolated in the Chapple laboratory by Joann Cusumano (Purdue University). 
 
Table 6.1 Oligodeoxynucleotides used in this chapter. 










Table 6.2 Plasmids used in this chapter. 
pJK Vector Description Source 
358 pET23a uctD [3] 
551 pET28a H6uctD This study 






Construction of H6uctD construct plasmid pJK551.  pJK358 was digested with NdeI and 
EcoRI and ligated into the NdeI and EcoRI restriction sites of the destination vector 
pET28a to yield pJK551.  The plasmid encodes for A. aceti H6UctD. 
 
Construction of evgA R153W construct plasmid pJK634.  A Taq PCR product obtained 
by K. Nyffeler using ODNs 2283 and 2284 was purified using a Qiagen PCR purification 
kit and ligated into pDrive with the Qiagen QIAexpress UA cloning kit following the 
manufacturer’s instructions.  The plasmid contains the endogenous promoter region of 
EvgA and encodes for A. aceti EvgA R153W. 
 
Colony PCR protocol.  Protocol adapted from [1].  In short, PCR reactions were set up as 
delineated in Tables 6.3, 6.5 and 6.7 and amplified according to the conditions in Table 
6.4, 6.6, and 6.8, respectively.  Colonies were first picked from transformation plates, 
patched onto a fresh LB-antibiotic plate, and the remainder of the colony on the pipette 
tip was transferred into the PCR reaction by pipetting up and down 5-6 times while 
avoiding the introduction of air bubbles.  Occasionally, to obtain more material, colonies 
were patched on fresh LB-antibiotic plates first and left to grow for 4-6 hrs at 37°C prior 
to colony PCR.  Antibiotics were ampicillin at 100 ug/mL, streptomycin at 50 ug/mL, or 
kanamycin at 70 ug/ml final concentrations.  PCR products were analyzed on 0.7%-1.5% 
agarose depending on the size of the amplification products.  Controls usually consisted 
of a PCR reaction using colonies carrying the parent vector (pET23a, pET23d, pET28a, 
pET-Duet, or pCDF-Duet) or the actual plasmid as template. 
 
Table 6.3 Cocktail for Vent.  Table 6.4 PCR conditions for Vent. 
Vent polymerase    Conditions Vent   
Mix [Final] Volume (uL)  Step Temp (C) Time  
10X ThermoPol buffer 1X 3  Hot start 98 5 min  
MgSO4 5 mM 1.5  Init. Den. 98 30 sec  
Primer 1 (5 uM) 0.25 uM 1.5  Den. 98 20 sec 
Primer 2 (5 uM) 0.25 uM 1.5  Anneal 55 (varies!) 20 sec 
dNTPs (2.5 mM) 200 uM 2.4  Extension 72 1 min/kb 
repeat 
25X 
Template   Final Ext. 72 7 min  
Vent 0.3 U 0.3 Hold 4 infinity  
Water  19.5 
 
    





ESI-MS of A. aceti proteins.  OrfYH6 from prep 1 (Chapter 1) and previously isolated A. 
aceti proteins were analyzed on a Thermo Scientific LTQ (Parker laboratory) with S. 
Ouellette’s assistance.  Samples were diluted in 50:50:01 water: acetonitrile: formic acid.  




6.2 Results and Discussion 
Colony PCR.   Figure 6.1 shows the annealing sites for the ODNs (listed in Table 6.1) 
used for screening construct candidates.  It is important to note that gene specific primers 
can also be used in this protocol. 
Table 6.5 Cocktail for OneTaq.  Table 6.6 PCR conditions for OneTaq. 
OneTaq polymerase    Conditions OneTaq   
Mix [Final] Volume (uL)  Step Temp (C) Time  
5X OneTaq Buffer 1X 6  Hot start 94 5 min  
Primer 1 (5 uM) 0.25 uM 1.5  Init. Den. 94 30 sec  
Primer 2 (5 uM) 0.25 uM 1.5  Den. 94 20 sec 
dNTPs (2.5 mM) 200 uM 2.4  Anneal 55 (varies!) 20 sec 
Template    Extension 68 1 min/kb 
repeat 
25X 
OneTaq  0.5 Final Ext. 68 7 min  
Water  18.1 Hold 4 infinity  
 total: 30 uL 
 
    
 
        
Table 6.7 Cocktail for Taq.  Table 6.8 PCR conditions for Taq. 
Taq (Chapple or Promega)   Conditions Taq   
Mix [Final] Volume (uL)  Step Temp (C) Time  
5X Flexi GoTaq Buffer 1X 6  Hot start 95 5 min  
Primer 1 (5 uM) 5 uM 1.5  Init. Den. 95 30 sec  
Primer 2 (5 uM) 5 uM 1.5  Den. 95 20 sec 
MgCl2 (25 mM) 1.25 mM 1.5  Anneal 55 (varies!) 20 sec 
dNTPs (2.5 mM) 200 uM 2.4  Extension 72 1 min/kb 
repeat 
25X 
Template    Final Ext. 72 7 min  
OneTaq  0.5 Hold 4 infinity  
Chapple Taq (1:50 dil)  1.5     
Water  18.1     
 total: 30 uL 
 





Figure 6.1  Colony PCR annealing sites.   
Plasmids not to scale. 
 
Colony PCR was used as a method to screen for candidates as an alternative to restriction 
mapping, the latter which requires isolating the plasmid first and digesting the DNA prior 
to running a gel.  If colony PCR failed, restriction mapping was used to screen constructs.  
Use of the empty vector as a control ensured that the PCR reaction worked and 
determined a baseline where successful ligation of inserts would yield an amplification 
product larger than ~250 bp (size of the T7 promoter-terminator region). 
 
Cloning.  H6UctD (pJK551) was obtained for comparison with the untagged protein 
(Benjamin Carter and Funmi Adebesin rotations).  EvgA R153W (pJK634) was obtained 
for UctB and acid adaptation of A. aceti studies (Kayleigh Nyffeler). 
 
ESI-MS.  Steven Ouellette (Parker Lab) ran some samples on their LTQ.  A minimum of 
the top 3 peaks from each spectrum were analyzed by ESIprot 1.0 [2] and the 





















Table 6.9 ESI-MS results as analyzed by ESIprot 1.0 [2]. 




Std Dev. Difference 
(Da) 
% Diff. 
PurE H59Q* 1:100 18856.8 18859.95 1.77 -3.15 -0.02 
E. coli PurE 
(500) 
1:100 17741.94 17677.03 19.24 64.91 0.37 
E. coli PurE 
(501) 
1:100 17741.94 17697.95 37.28 43.99 0.25 
507* 1:50 18788.37 18788.99 1.66 -0.62 0 
508* 1:100 18765.34 18765.2 0.44 0.14 0 
509* 1:100 18804.37 18801.85 0.92 2.52 0.01 
510* 1:100 18804.37 18804.72 1.11 -0.35 0 
526* 1:20 18804.37 18809.82 18.62 -5.45 -0.03 
527* 1:100 18804.37 18809.82 1.53 -5.45 -0.03 
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